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resumo 
 
 
Gαo é a subunidade Gα mais abundante no cérebro, no entanto, as suas funções 
especificas ainda estão longe de serem claras. Estudos das vias de sinalização 
moduladas pela Gαo têm exposto potenciais papéis para a Gαo no 
desenvolvimento do sistema nervoso, especialmente em neuritogénese. A 
caracterização do interactoma da Gαo também tem sido crucial para uma melhor 
compreensão das funções desta proteína. Uma das proteínas interatoras da Gαo 
é a proteina precursora de amiloide (APP), uma proteina que se encontra 
envolvida em várias funções fisiológicas, como sobrevivência celular, migração 
neuronal, e diferenciação neuronal. APP também é mais conhecida pelo seu 
envolvimento da Doença de Alzheimer (AD). APP liga-se e ativa a Gαo, uma 
interação que tem sido associada com migração neuronal e AD. No entanto, até 
agora, não existem estudos publicados que investiguem a interação APP-Gαo na 
neuritogénese. O principal objetivo deste trabalho foi então caracterizar o papel 
da Gαo na neuritogénese através do foco na investigação dos efeitos 
neuritogénico do complexo Gαo-APP. 
Primeiro, através do uso de células de neuroblastoma SH-SY5Y, estudámos o 
impacto da fosforilação da serina 655 (S655) da APP na interação APP-Gαo. 
Através do uso de dois mutantes da APP que mimetizam o estado fosforilado e 
desfosforilado da S655, SE e SA APP respetivamente, demonstrámos que a 
fosforilação da S655 aumenta a eficiência da APP em ligar e ativar a Gαo. Além 
disso, apresentamos provas de que a APP modula os efeitos neuritogénicos da 
Gαo num mecanismo fosfo-dependente. Neste mecanismo neuritogénico, a 
sinalização da STAT3 e ERK1/2 exibiram uma ativação sequencial, com a STAT3 
participando na formação de novos processos e a ERK1/2 na elongação dos 
mesmos. Apresentamos ainda dados que suportam um papel da APP-Gαo na 
dendritogénese em culturas neuronais primárias. 
A segunda parte deste trabalho focou-se na investigação de mecanismos 
envolvidos no controlo dos níveis proteicos celulares da APP e Gαo. Identificámos 
o lisossoma como um novo processo pelo qual a Gαo é degradada em 
consequência da sobre expressão da SA APP. Também mostramos provas de 
que este mecanismo pode fazer parte de autofagia mediada por chaperonas, 
através do qual a sinalização da APP-Gαo poderá estar a ser regulada. 
Finalmente, devido ao nosso interesse em estudar diferenciação neuronal e à 
falta de ferramentas para este estudo em imagens de contraste de fase, criámos 
o NeuronRead, uma macro do ImageJ capaz de analisar de forma 
semiautomática imagens neuronais de contraste de fase e fluorescência. 
NeuronRead foi extensivamente validado, e usado para monitorizar a 
diferenciação de células SH-SY5Y após modulação da atividade da Gαo.  
Com este trabalho contribuímos com novos dados que ajudam na compreensão 
da função e regulação do complexo Gαo-APP, e disponibilizamos para a 
comunidade cientifica uma nova ferramenta para o estudo da diferenciação 
neuronal 
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abstract 
 
Gαo is the most abundant Gα subunit present in the brain, however, its specific 
functions are still far from clear. Studies of the signaling pathways modulated by 
Gαo have uncovered potential roles for Gαo in the development of the nervous 
system, especially in neuritogenesis. The characterization of Gαo interactome has 
also been crucial for the better understanding of this protein’s functions. One of 
the Gαo interacting proteins is the amyloid precursor protein (APP), a protein that 
is involved in several physiological functions, such as cell survival, neuronal 
migration, and neuronal differentiation. APP is also best known for its involvement 
in Alzheimer’s Disease (AD). APP binds and activates Gαo, an interplay that was 
associated with neuronal migration and AD. However, so far, no published study 
has investigated the effects of the APP-Gαo interaction on neuritogenesis. The 
main goal of this work was thus to characterize Gαo role on neuritogenesis by 
focusing the research on the neuritogenic effects of the Gαo-APP complex.  
First, by using SH-SY5Y neuroblastoma cells, we studied the impact of APP 
serine 655 (S655) phosphorylation on the APP-Gαo interaction. Through the use 
of two APP mutants mimicking the phosphorylated and dephosphorylated state of 
S655, SE and SA APP respectively, we have demonstrated that S655 
phosphorylation increases APP efficiency to bind and activate Gαo. Moreover, we 
present evidence that APP modulates Gαo neuritogenic effects in a phospho-
dependent mechanism. STAT3 and ERK1/2 signaling displayed a sequential 
activation on this neuritogenic mechanism, with STAT3 being mainly involved in 
the formation of new processes, while ERK1/2 was more involved in neuritic 
elongation. We also present data supporting a role for the APP-Gαo complex on 
dendritogenesis in rat primary neuronal cultures. 
The second part of this work focused on unraveling the mechanisms involved in 
the control of APP and Gαo cellular protein levels. We identified the lysosome as a 
new pathway by which Gαo is degraded, as an effect of SA APP overexpression. 
We also provide evidence that this degradation mechanism might be part of 
chaperone-mediated autophagy, through which APP-Gαo signaling might be 
regulated.   
Finally, due to our interest in studying neuronal differentiation and a lack of reliable 
tools to analyze phase contrast images, we developed NeuronRead, an ImageJ 
macro capable of semi-automated analysis of both phase contrast and 
fluorescence neuronal images. NeuronRead was extensively validated and used 
to monitor SH-SY5Y differentiation upon modulation of Gαo activity.   
With this work, we delivered new data that advances knowledge on the function 
and regulation of the Gαo-APP complex in a neuronal context, and provided the 
scientific community with a new tool for the study of neuronal differentiation. 
 
 
University of Aveiro  1 
Table of contents 
 
Table of Figures .................................................................................................................................. 5 
Table of Supplementary Material ...................................................................................................... 7 
Abbreviations ..................................................................................................................................... 9 
A. General Introduction and Aims .................................................................................................... 13 
A1. Neuronal Differentiation ........................................................................................................ 15 
A1.1. Neuritogenesis and Acquisition of Neuronal Polarity ..................................................... 15 
A1.2. Cytoskeleton remodeling during neuronal differentiation ............................................. 17 
A1.3. Axon specification ........................................................................................................... 19 
A1.4. Dendritic vs Axonal structure .......................................................................................... 20 
A1.5. Synaptogenesis ............................................................................................................... 21 
A1.6. Signaling during neuronal differentiation ....................................................................... 21 
A2. The Other G protein (Go) ....................................................................................................... 26 
A2.1. Gαo genetics ................................................................................................................... 27 
A2.2. Gαo expression and distribution ..................................................................................... 27 
A2.3. Gαo signaling in the brain ............................................................................................... 30 
A3. The Amyloid Precursor Protein .............................................................................................. 41 
A3.1. APP processing ................................................................................................................ 42 
A3.2. APP trafficking ................................................................................................................. 44 
A3.3. APP phosphorylation ....................................................................................................... 45 
A3.4. APP as a neuritogenic protein ......................................................................................... 47 
A4. The APP‐Gαo complex ........................................................................................................... 50 
A4.1. APP‐Gαo interaction ....................................................................................................... 50 
A4.2. APP‐Gαo physiological function ...................................................................................... 52 
A4.3. APP‐Gαo pathological function ....................................................................................... 54 
2  University of Aveiro 
References .................................................................................................................................... 57 
Aims .............................................................................................................................................. 83 
B. Results .......................................................................................................................................... 85 
B1. The APP‐Gαo interaction is modulated by APP S655 phosphorylation and impacts 
neuritogenesis via STAT3 and ERK activation............................................................................... 87 
B1.1. Abstract ........................................................................................................................... 88 
B1.2. Introduction .................................................................................................................... 89 
B1.3. Materials and Methods ................................................................................................... 91 
B1.4. Results ............................................................................................................................. 95 
B1.5. Discussion ...................................................................................................................... 107 
B1.6. References ..................................................................................................................... 112 
B1.7. Supplementary Material ............................................................................................... 121 
B2. Regulation of Gαo and APP protein levels ........................................................................... 125 
B2.1. Abstract ......................................................................................................................... 126 
B2.2. Introduction .................................................................................................................. 127 
B2.3. Materials and Methods ................................................................................................. 130 
B2.4. Results ........................................................................................................................... 133 
B2.5. Discussion ...................................................................................................................... 144 
B2.6. References ..................................................................................................................... 148 
B2.7. Supplementary Material ............................................................................................... 156 
B3. NeuronRead, a semi‐automated tool for morphometric analysis of phase contrast and 
fluorescence neuronal images ................................................................................................... 157 
B3.1. Abstract ......................................................................................................................... 158 
B3.2. Introduction .................................................................................................................. 159 
B3.3. Materials and Methods ................................................................................................. 161 
B3.4. Results ........................................................................................................................... 168 
B3.5. Discussion ...................................................................................................................... 177 
University of Aveiro  3 
B3.6. References ..................................................................................................................... 181 
B3.7. Supplementary Material ............................................................................................... 187 
C. General Discussion ..................................................................................................................... 197 
C1. Main findings and future work ............................................................................................. 199 
C2. Potential role of APP‐Gαo signaling during brain development .......................................... 205 
C3. Conclusion ............................................................................................................................ 208 
References .................................................................................................................................. 209 
 

University of Aveiro  5 
Table of Figures 
 
Figure A1.1. Stages of Neuronal Differentiation .............................................................................. 16 
Figure A1.2. Growth cone structure ................................................................................................. 18 
Figure A1.3. Different factors that influence axon specification in vivo .......................................... 20 
Figure A1.4. Signaling in neuronal differentiation ........................................................................... 25 
Figure A2.1. Gαo expression in the different regions of the human nervous system ..................... 28 
Figure A2.2. CB1R‐Gαo‐STAT3 signaling in neurite outgrowth ........................................................ 31 
Figure A2.3. Wnt‐Gαo signaling in synaptogenesis .......................................................................... 38 
Figure A3.1. Different isoforms of APP ............................................................................................ 41 
Figure A3.2. APP processing ............................................................................................................. 42 
Figure A3.3. APP trafficking .............................................................................................................. 45 
Figure B1.1. APP‐Gαo interaction and Gαo activation are potentiated by APP S655 
phosphorylation ............................................................................................................................... 96 
Figure B1.2. Gαo:APP functionally cooperate in neuritogenesis ..................................................... 97 
Figure B1.3. APP and Gαo modulation of the STAT3 signaling pathway ....................................... 100 
Figure B1.4. Gαo:APP morphological and signaling effects after 24h of transfection ................... 102 
Figure B1.5. Gαo:APP neuritogenic effects in primary neurons .................................................... 104 
Figure B1.6. STAT3 and ERK1/2 signaling on APP‐Gαo effects in primary neurons. ...................... 106 
Figure B2.1. APP and Gαo distribution in SH‐SY5Y cells ................................................................. 133 
Figure B2.2. Effects of APP and Gαo on each other’s protein levels ............................................. 134 
Figure B2.3. Effects of proteasome inhibition on Gαo protein levels ............................................ 135 
Figure B2.4. Gαo and APP colocalization in SH‐SY5Y cells ............................................................. 136 
Figure B2.5. APP and Gαo degradation in lysosomes .................................................................... 137 
Figure B2.6. Presence of lysosomal‐targeting motifs in the Gαo sequence .................................. 138 
Figure B2.7. Gαo and Hsc70 co‐localize in SH‐SY5Y cells ............................................................... 139 
Figure B2.8. Impact of PTX treatment on Gαo and APP protein levels .......................................... 141 
Figure B2.9. Effect of proteasome inhibition on PTX treatment .................................................... 143 
Figure B3.1. Processing workflow of the NeuronRead macro ....................................................... 163 
Figure B3. 2. Details of the NeuronRead workflow, applied to Phase Contrast Images ................ 164 
Figure B3.3.NeuronRead versus manual detection of neuronal cell bodies areas ........................ 169 
Figure B3.4. NeuronRead validation in PhC and fluorescence neuronal images ........................... 170 
6  University of Aveiro 
Figure B3.5. Neuritic length analysis of neuronal cultures treated with the EGFR inhibitor ......... 172 
Figure B3.6. Differentiation of SH‐SY5Y cells with RA and BDNF ................................................... 174 
Figure B3.7. Treatment of differentiating SH‐SY5Y cells with Pertussis Toxin (PTX) ...................... 176 
 
 
University of Aveiro  7 
Table of Supplementary Material 
 
Supplementary Figure B1.1. Morphometric analysis of SH‐SY5Y cells transfected with the different 
APP‐GFPs for 6h ............................................................................................................................. 121 
Supplementary Figure B1.2. JAK2‐STAT3 inhibition ....................................................................... 121 
Supplementary Figure B1. 3. EGFR inhibition in SH‐SY5Y cells ...................................................... 122 
Supplementary Figure B1.4. Confirmation of the neuritic nature in 4 DIV neurons ..................... 122 
Supplementary Figure B1.5. Impact of EGFR inhibition on APP‐Gαo effects in primary neurons . 123 
Supplementary Figure B2.1. Effect of proteasome inhibition on PTX treatment .......................... 156 
Supplementary Figure B3.1. Comparison between NeuronRead analyses of phase contrast images 
and fluorescence images ................................................................................................................ 187 
Supplementary Figure B3.2. Analysis of rat cortical primary neuronal cultures ........................... 187 
Supplementary Figure B3.3. Testing NeuronRead robustness and sensitivity to noises ............... 188 
Supplementary Figure B3.4. Differentiated SH‐SY5Y cells analyzed with NeuronRead ................ 189 
NeuronRead Tutorial ...................................................................................................................... 190 
 

University of Aveiro  9 
Abbreviations  
 
5‐HT Serotonin 
AD Alzheimer's disease 
ADF Actin depolymerizing factor 
ADP Adenosine diphosphate 
AICD APP intracellular C‐terminal domain 
ANOVA Analysis of variance 
AP Adaptor protein 
APLP Amyloid precursor‐like protein 
APP Amyloid precursor protein 
APPL β‐amyloid‐like protein 
Arp Actin‐related protein 
Aβ Amyloid β‐peptide 
BACE β‐site APP‐cleaving enzyme 
BCA Bicinchoninic acid 
BDNF Brain‐derived neurotrophic factor 
BSA Bovine serum albumin 
CA  Constitutively active 
CaMKII calcium‐calmodulin‐dependent protein kinase II 
cAMP cyclic adenosine monophosphate 
CB1R Type 1 cannabinoid receptor 
cdc42 Cell division control protein 42 
CMA Chaperone‐mediated autophagy 
CQ Chloroquine 
CREB cAMP response element binding protein 
CTF C‐terminal fragment 
DAPI 4',6‐diamidino‐2‐phenylindole 
DIV Days in vitro 
DN Dominant negative 
DoG Difference of Gaussians 
ECL Enhanced chemiluminescence 
10  University of Aveiro 
EGF Epidermal growth factor 
EGFR Epidermal growth factor receptor 
ERK Extracellular signal‐regulated kinase 
FAD Familial Alzheimer's Disease 
FBS Fetal bovine serum 
FC Fold change 
FGF Fibroblast growth factor 
Fluor Fluorescence  
GAP GTPase‐accelerating protein 
GAP43 Growth‐associated protein 43 
GDI Guanosine dissociation inhibitor 
GDP Guanosine diphosphate 
GEF Guanine nucleotide exchange factor 
GFP Green fluorescent protein 
GNAO1 Gαo gene 
GPCR G protein‐coupled receptor 
GR Golgi region 
GRIN G protein‐regulated inducer of neurite outgrowth 
GSK3 Glycogen Synthase Kinase 3 
GTP Guanosine triphosphate 
holoAPP Full length APP 
Hsc70 Heat shock cognate protein 70 
Hsp90 Heat shock protein 90 
ICC Immunocytochemistry 
IGF Insulin‐like growth factor 
IL‐6 interleukin‐6 
JAK Janus kinase 
JNK c‐Jun N‐terminal kinase 
KO Knockout 
KPI Kunitz‐type protease inhibitor 
Lac Lactacystin 
LAMP2 Lysosome‐associated membrane protein 2  
LTD Long‐term depression 
University of Aveiro  11 
LTP Long‐term potentiation 
M1AChR Muscarinic acetylcholine receptor M1 
MAP Microtubule‐associated protein 
MAPK Mitogen‐activated protein kinase 
MCH Melanin‐concentrating hormone 
MEK MAPK/ERK kinase 
MIS Müllerian inhibiting substance 
NGF Nerve growth factor 
NMJ Neuromuscular junction 
NT Neurotrophin 
O/N Overnight  
ORL Opioid receptor‐like 
p75NTR Neurotrophic receptor p75 
PACAP Pituitary adenylate cyclase‐activating peptide 
PAGE Polyacrylamide gel electrophoresis 
pAPP Phosphorylated APP 
PAR Protease‐activated receptor 
PBS Phosphate buffered saline 
PDBu Phorbol 12,13‐dibutyrate 
PDK1 phosphoinositide‐dependent kinase 1 
PhC Phase contrast 
PI3K Phosphatidylinositol 3‐kinase  
PIP3 phosphatidylinositol (3,4,5)‐tri‐phosphate 
PKA Protein kinase A 
PKC Protein kinase C 
PM Plasma membrane 
PSD‐95 Postsynaptic density protein 95 
PSI Proteasome inhibitor I 
PTX  Pertussis toxin 
RA  Retinoic acid 
RGS Regulator of G‐protein signaling 
ROI Region of interest 
S&P Salt and pepper  
12  University of Aveiro 
S655 Serine 655 
sAPP secreted or soluble APP 
SDS Sodium dodecyl sulfate 
SE Structuring element 
SEM Standard error of the mean 
STAT Signal transducer and activator of transcription 
TAG Transient axonal glycoprotein 
TBS‐T Tris‐buffered saline with Tween 20 
Tf Transfection 
TGFβ Transforming growth factor β 
TGN Trans‐Golgi network 
Trk Tyrosine receptor kinase 
WB Western blot 
Wt Wild‐type 
 
 
University of Aveiro  13 
 
 
 
 
 
 
 
 
 
A. General Introduction 
and Aims 
 

A1. Neuronal Differentiation 
University of Aveiro  15 
A1. Neuronal Differentiation 
 
The brain is a complex organ made of different types of highly specialized cells. The main “unit” of 
the brain is the neuron, a cell with a very characteristic morphology. The neuron is composed of a 
long process called the axon, that can grow for longer than 1 meter, and several shorter but highly 
branched processes called dendrites. The mechanism by which neurons acquire this morphology 
has been the subject of intense study in neurosciences. From the initial morphological changes that 
undifferentiated cells suffer when they start to form new processes to the formation of synapses 
between mature neurons, and all the signaling pathways underlying these different steps in 
neuronal differentiation, these are mechanisms that researchers have explored to better 
understand how neurons work. Understanding neuronal differentiation has also shed light on other 
mechanisms, such as neuronal regeneration, that can prove essential to the understanding and 
treatment of several neuropathologies. 
 
A1.1. Neuritogenesis and Acquisition of Neuronal Polarity 
Early embryonic neurons are spherical cells, so the first step of neuronal differentiation involves 
the formation of membrane extensions that will become neurites. This step is designated by 
neuritogenesis, but is also usually called neurite outgrowth or neurite initiation/extension, and is 
accompanied by an extensive reorganization of the cytoskeleton [1, 2]. After the initial formation 
of neurites, these have to differentiate into axons and dendrites, in a phenomenon called neuronal 
polarization [3, 4]. Both neuritogenesis and neuronal polarization are highly dynamic mechanisms 
and must occur in tandem so that neuronal differentiation is properly developed. Earlier research 
has established the different developmental stages that cultured hippocampal neurons go through 
(Figure A1.1) [5]. In stage 1, which in vitro occurs during the first hours after plating, cells extend 
their membranes around them, creating the lamellipodium. This is a filamentous actin (F‐actin) 
structure that makes cells strongly adhere to the cell plates. Several small finger‐like F‐actin 
processes start to appear at the edge of the membrane, named filopodia. In stage 2, that occurs 
throughout the first day of differentiation, the filopodia start to enlarge, giving rise to several 
neurites. At this point, all neurites are virtually indistinguishable, with each one having the potential 
to further elongate and develop into the axon. These two first stages encompass the bulk of 
neuritogenesis. Stage 3 sees the beginning of neuronal polarity, with one neurite starting to grow 
A1. Neuronal Differentiation 
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significantly faster than the rest (5‐10x faster), eventually becoming the axon. Stage 4 occurs 2‐3 
days after the initial axon growth, usually around 4 days after cells plating, and it is characterized 
by the growth and branching of the remaining neurites that will make the dendritic tree. At this 
time, the axon continues to elongate, although to a slightly lower rate (but still at least 5x faster 
than dendrites). Stage 5 is the maturation of the neuron, characterized by the formation dendritic 
spines, where cell‐to‐cell contacts are made in the form of synapses [6]. Several other studies have 
been published describing neuronal differentiation both in vitro and in vivo, and looking at different 
types of neurons. Neuritogenesis and neuronal polarization occur roughly the same in cortical 
neurons in vivo, with a few differences [4, 7, 8]. For example, excitatory cortical neurons start their 
differentiation in the cortical ventricular zone of the developing embryo by forming several 
neurites, thus becoming a multipolar cell. One of these neurites suffers elongation and becomes a 
trailing process, that further develops into the axon, while another neurite becomes the leading 
process, defining the neuron’s first dendrite. The remaining neurites suffer a retraction, thus 
turning the cell into a bipolar neuron. At this stage these neurons migrate through the cortical plate 
into the marginal zone. That is why the future dendrite is called the leading process (the process 
that “guides” the migration) whereas the future axon is called the trailing process (the process that 
follows behind the migratory neuron) [9–11]. Upon reaching the marginal zone of the cortical plane, 
the neuron matures, with the leading process suffering further elongation and ramification to 
become the dendritic tree. 
Figure A1.1. Stages of Neuronal Differentiation. Stage 1: Formation of Lamellipodia; Stage 2: Neurite outgrowth; 
Stage 3: Axon specification and elongation; Stage 4: Dendritic growth; Stage 5: Neuronal maturation and 
synaptogenesis. Image adapted from [2]. 
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A1.2. Cytoskeleton remodeling during neuronal differentiation 
A1.2.1. Lamellipodia and Filopodia formation 
Neuritogenesis starts with the assembly of actin filaments on the edge of the differentiating neuron 
(Stage 1). These actin filaments, a result of actin polymerization, form two distinct structures: the 
lamellipodium, a sheet‐like extension of the plasma membrane all around the cell; and the 
filopodia, several thin protrusions, comprising bundles of actin filaments, that arise from the 
lamellipodium [12, 13]. The exact mechanism that leads to the formation of filopodia it is still not 
completely clear. Some studies describe the formation of branches of actin filaments within the 
lamellipodium by association of proteins to the filaments barbed end (the fast‐growing end, or plus‐
end). Subsequent recruitment of fascin to the barbed ends culminates in the bundling of different 
actin filaments and the filopodia formation [1, 14, 15].  This is called the convergent model. The de 
novo nucleation model, or tip nucleation model, describes filopodia formation as actin filaments 
present in the lamellipodium that are nucleated by formin proteins, thus growing and protruding 
out and that are later crosslinked together by fascin [16, 17]. The presence of common players (e.g. 
fascin) between both models indicates that the real formation of filopodia might comprise a mix of 
both mechanisms [1, 17]. As evidenced by both models, actin dynamics are the main force behind 
neurite initiation and elongation. Continuous polymerization/depolymerization of actin filaments 
is required for the elongation of the filopodia, in a “treadmilling” mechanism [14]. In this 
mechanism, there is an exchange of actin subunits (globular actin, G‐actin) between the pointed 
end (minus end) and the barber end (plus end) of the actin filament. Polymerization occurs at the 
barber end (addition of G‐actin), while depolymerization occurs at the pointed end (removal of G‐
actin) [2, 14]. This mechanism allows the actin filament to “push” against the plasma membrane 
and thus elongate the filopodia [18].  
 
A1.2.2. Neurite stabilization and maturation 
Filopodia are highly dynamic structures, suffering continuous formation and retraction. To stabilize 
these processes and form neurites (Stage 2), it is required the involvement of another component 
of the cell cytoskeleton, the microtubules [1, 19]. The microtubule subunit is a heterodimer of two 
types of tubulin, α and β. Of the several known α and β subunits, β‐III tubulin is the only isoform 
specific to neurons and its expression is increased during neurite outgrowth [1, 20, 21]. After the 
formation of the filopodia, microtubules formed at the centrosome start to extend into the 
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filopodia. This extension occurs either by re‐distribution of stable microtubules into the actin 
filopodia or through polymerization of new microtubules [1, 19, 22]. The stabilization of the 
microtubules and maturation of the first neurite normally results in the commitment of this neurite 
to axon specification [23, 24].  
Lamellipodia and filopodia remain present at the extremity of the growing neurite, in a structure 
called growth cone. This structure is present in all neurites, but it is especially dynamic and active 
in the first neurite, contributing to its faster extension and eventual differentiation into the 
neuronal axon (Figure A1.2) [4, 25]. Filopodia are also formed during dendritic and axonal growth, 
and, if matured, give rise to dendritic and axonal branches, an essential step in neuronal 
differentiation that allows a single neuron to make contact with thousands of other cells [26]. 
 
 
 
 
 
 
 
 
 
 
A1.2.3. Control of Actin and Microtubules Dynamics 
Several proteins are involved in the control of actin polymerization/depolymerization, and in the 
control of microtubules transport and stabilization. The Arp2/3 complex is one of the main factors 
involved in actin nucleation (assembly of actin monomers) [15], being essential in the formation of 
actin filaments, and plays a role in the formation of the lamellipodia [1, 3, 12]. Its exact role on 
neurite outgrowth it is still not completely clear, though, with different studies pointing to either a 
role of Arp2/3 in neurite formation [27, 28], or Arp2/3 inhibition having no impact on the formation 
of filopodia [29]. Cofilin I and ADF (actin depolymerizing factor) are two members of the cofilin 
Figure A1.2. Growth cone structure. Actin (Green) forms lamellipodia and filopodia at the extremity of the growth 
cone, while microtubules (red) extend through the neurite into the growth cone to stabilize it. Adapted from [3]. 
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family abundantly present in the growth cone. They act by binding to the pointed end of the actin 
filaments and thus promoting the depolymerization of actin, driving neurite elongation [3, 30]. 
Other proteins that influence actin dynamics include WAVE, Ena/VASP, and profilin [1, 3].  
The main regulators of microtubules dynamics are the MAPs (microtubule‐associated proteins). 
MAP1b promotes microtubule nucleation, polymerization and stabilization, and is believed to be a 
bridge between actin and microtubules, regulating both neurite elongation and branching [1, 26, 
31]. MAP2 also stabilizes microtubules but has the additional function of binding to actin and 
participate in the formation of the actin bundles [22, 26]. MAP2 and MAP tau are also specially 
interesting because of their differentially localization in mature neurons, with MAP2 being specific 
to the dendrites, and MAP tau being enriched in the axon, highlighting possible specific functions 
for the different MAPs during neuronal polarization [22, 32].   
 
A1.3. Axon specification 
As previously mentioned, an early neuron starts its differentiation by protruding several equivalent 
neurites (Stage 1‐2). However, one of these neurites at one point starts to elongate much faster 
than the remaining ones, and eventual becomes the axon (Stage 3‐4) [5]. The extensive 
reorganization the cytoskeleton suffers during neuronal differentiation is especially evident in the 
growth cone of the future axon, with a high degree of actin instability and the stabilization of 
microtubules being key in this mechanism [24, 33, 34], however there is still little information about 
what triggers one neurite to elongate in detriment of the rest. One model explaining the beginning 
of neuronal polarization is the “Touch & Go” model. In this model, cell‐to‐cell interactions between 
the pioneering axon of a pyramidal neuron and the neurite of a multipolar cell triggers the 
cytoskeleton remodeling in the neurite of the latter that leads to its elongation into an axon, a 
mechanism dependent on the cell‐adhesion molecule transient axonal glycoprotein 1 (TAG1) (the 
signaling pathways underling this mechanism will be discussed further ahead) [4, 8, 35]. Cell‐cell 
interactions mediated by N‐cadherin are also important to trigger axonal specification, since 
knockdown of this protein disrupts the efficient transformation of a multipolar cell into a bipolar 
cell [4, 36].  
Several extracellular cues are also involved in axon specification and growth, such as the brain‐
derived neurotrophic factor (BDNF), neurotrophin 3 (NT3), Reelin, transforming growth factor 
(TGFβ), insulin‐like growth factor 1 (IGF1), semaphorins and Wnts [4, 6, 8]. Prevailing theories 
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suggest that these factors might act in an autocrine or paracrine way not only to trigger axon 
specification but to also maintain its elongation (Figure A1.3) [6, 8]. Differential distribution of these 
factors in vivo, such is the case of TGFβ, could also help explain the axon specification on different 
areas of the developing brain [4]. The gradient of neurotrophic factors existing in the medium could 
also explain why only one neurite develops into an axon. Accumulation of these factors on the 
growing axon location could mean a lack of stimuli on the other neurites, resulting in an inhibition 
of their growth [37]. 
The activation of different intracellular signaling pathways also regulates axon initiation and 
extension, but these will be discussed in a later section.  
 
A1.4. Dendritic vs Axonal structure 
Though at first glance dendrites are just shorter and more ramified versions of the axon, there are 
key structural differences between both type of neuronal processes. As mentioned above, after 
filopodia elongation through actin remodeling, microtubules invade the filopodia to mature it into 
a neurite. While in the axon the microtubules are densely packed and are uniaxially orientated 
(their minus end is always facing the cell body and their plus end is always facing the growth cone, 
Figure A1.2), in the dendrites microtubules have both orientations [23]. While is not completely 
clear why these differences arise, MAP2 and tau different localizations to the dendrites and axon, 
respectively, could play a role in the microtubule orientation [24].  
Figure A1.3. Different factors that influence axon specification in vivo. Neurotrophins released by neuronal cells act in 
a paracrine and autocrine to activate intracellular signaling pathways (Blue). Similar signaling pathways are activated 
by cell‐to‐cell contacts (purple). Gradients of extracellular molecules drive both axonal polarization as well as neuronal 
migration. Adapted from [8]. 
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A1.5. Synaptogenesis 
Neuronal differentiation culminates with the formation of cell‐cell contacts defined as synapses 
(Stage 5). Synapses are the main place of data transmission between neurons and are one of the 
most dynamic structures of the adult brain [38]. A synapse consists of a presynaptic terminal (axonal 
side), a postsynaptic terminal (dendritic side) and a synaptic cleft separating both [39] (this defines 
the chemical synapses, electrical synapses will not be explored here). There are reports of two ways 
neurons establish synapses[40]. In the postsynaptic spine hypothesis, filopodia developed in the 
dendrites establish contact with presynaptic neurons, which triggers the filopodia maturation into 
dendritic spines and consequently the formation of the synapse [26, 40]. In the presynaptic 
hypothesis, it is the axon who initiates the synapse formation. The axon continues to grow until it 
reaches near a postsynaptic terminal. At this point, a signal terminates the axonal growth cone 
elongation and starts its maturation into a presynaptic terminal[40]. This signal might be mediated 
by collapsins [41], with the activation of the Wnt‐7a signaling playing a part in the maturation of 
the presynaptic terminal[42].  The differences in both models could relate to the synaptogenesis in 
different types of neurons. Moreover, synaptogenesis in the adult brain seems to be regulated by 
different mechanisms, related to neuronal activity [43]. 
 
A1.6. Signaling during neuronal differentiation 
While neuronal differentiation is ultimately a result of an extreme reorganization of the cell 
cytoskeleton, there are several signaling pathways that control this remodeling. From extracellular 
cues, like BDNF, to intracellular proteins, such as the Rho family or the MAPK/ERK pathway, there 
are a lot of factors that intervene in the different steps, from the initial filopodia formation to the 
acquisition of the neuronal polarity and formation of synapses.  
 
A1.6.1. Brain Derived Neurotrophic Factor (BDNF) 
BDNF is a neurotrophin produced and secreted by neurons that has been for a long time implicated 
in the promotion of several aspects of neuronal differentiation [44]. Upon secretion, it can bind to 
the Tyrosine receptor kinase B (TrkB), as well as to the neurotrophic receptor p75 (p75NTR). Recent 
experiments show that BDNF induces axonal growth in in vitro conditions, while in vivo its role 
seems to be more on promoting the branching of the elongating axon [45]. Studies with Xenopus 
showed that expressing a dominant negative TrkB on retinal ganglion cells did not affect the ability 
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of the axons to reach their target, but significantly altered the growth cone morphology and 
impaired the formation of axonal branches [45, 46]. The axonal branching promoted by BDNF relies 
upon the activation of the ERK1/2 signaling pathway [47]. BDNF is able to influence correct wiring 
of the brain not only by extending new axonal branches, but also by pruning unnecessary ones 
through the activation of the p75NTR [47, 48]. BDNF also modulates the dendritic tree morphology, 
especially in aiding the formation of dendritic spines, and consequently synapses. BDNF activation 
of TrkB promotes dendritic filopodia motility in a PI3K‐dependent way [45, 47]. BDNF also 
stimulates the increase of PSD‐95 in dendritic filopodia [26, 45], thus promoting the maturation of 
the postsynaptic terminal.  
BDNF role in neuronal differentiation is also highlighted by its common use as a neurotrophic factor 
in the differention of SH‐SY5Y neuroblastoma cells [49–52]. Pre‐incubation of these cells with 
retinoic acid leads to the expression of TrkB, with follow‐up treatment with BDNF resulting in the 
differentiation of SH‐SY5Y cells into neuron‐like cells, expressing neuronal markers such as MAP2 
and tau [49]. BNDF effects on these cells are mediated by activation of both the ERK1/2 and PI3K 
signaling pathways [51], which will be discussed ahead. 
 
A1.6.2. Rho small GTPases 
The three main members of the Rho protein family are RhoA, Cdc42 and Rac1. These are small 
GTPases that act as molecular switches in several signaling pathways. All three have been 
associated with neuronal differentiation: Cdc42 and Rac1 have mainly a positive role in neurite 
outgrowth, while RhoA has negative role [53]. Cdc42 knockout in mice leads to the development of 
smaller brains, with a reduced number of axons, that results in death at birth, thus highlighting a 
fundamental role of Cdc42 in axon specification [54, 55]. Cdc42 modulates the actin cytoskeleton, 
promoting the formation and elongation of filopodia [56]. Rac1 activation promotes axonal 
branching and formation of dendrites, while its inactivation leads to a decrease in the number of 
primary dendrites, and also affects axon growth and guidance [54]. Interestingly, Rac1 activation 
has to be tightly controlled during neuronal differentiation, since some experiments showed that 
expressing a constitutively active (CA) form of Rac1 or a dominant negative Rac1 both resulted in a 
decrease in neurite outgrowth [54, 57]. Similarly, a cyclic activation of Cdc42 is required for it to 
promote neuronal polarization [58]. RhoA seems to act as a limiting factor in neuronal 
differentiation [54]. Activating RhoA in hippocampal neurons and neuronal models, such as PC12, 
inhibits the growth of small processes or even promotes the retraction of neurites, respectively, 
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while its inactivation greatly enhances neurite outgrowth [4, 53]. It has been hypothesized that 
RhoA role in vivo is to control axon elongation and neuronal polarization by inhibiting the formation 
of extra axons [4]. This is supported by the evidence that RhoA activity is higher in growth cones of 
smaller neurites when compared to the axonal growth cone [59].    
While these opposing roles between Cdc42/Rac1 and RhoA have been well established, normal 
neuronal differentiation is a result of a coordinated interplay between the three proteins, with 
defects in any of them seriously affecting the proper formation of axons and dendrites [53].  
 
A1.6.3. PI3K / Akt pathway 
The phosphatidylinositol 3‐kinase (PI3K) and Akt signaling can be activated by different membrane 
receptors during neuronal differentiation, including TrkA and TrkB, as well as G‐protein coupled 
receptors [1, 60, 61]. Activation of PI3K leads to the increase of PIP3 (phosphatidylinositol (3,4,5)‐
tri‐phosphate), which in turn promotes Akt phosphorylation via phosphoinositide‐dependent 
kinase (PDK1). For instance, BDNF signaling through TrkB increases filopodia motility and its number 
in hippocampal dendrites through the activation of PI3K signaling [1], while the neuritogenic effects 
of the Nerve Growth Factor (NGF) in dorsal root ganglion neurons involves the activation of a TrkA‐
PI3K‐Akt signaling [60]. In both cases, PI3K/Akt translates its effects to the cell cytoskeleton by 
mediating the activation of the Rho GTPases proteins. Indeed, a possible positive signaling 
mechanism mediating neuronal polarization has been described involving PI3K, Cdc42 and Rac1 [8]. 
Signaling of BDNF through PI3K‐Akt has also been shown to be involved in regulating the complexity 
of the dendritic tree as well as the formation of dendritic spines, with chronic inhibition of PI3K 
resulting in a decrease in the formation of dendritic spines and filopodia [62]. Interestingly, this 
study also showed a cooperation between PI3K‐Akt and MAPK signaling in regulating dendritic 
morphology.  
Besides directly inducing neurite formation, the PI3K/Akt signaling also promotes differentiation by 
inhibiting the GSK3 signaling [63]. Activation of PI3K/Akt in NGF signaling results in the 
phosphorylation of GSK3β, thus inactivating it, and this inactivation is essential in the promotion of 
NGF neuritogenic effects [64]. Moreover, activation of the 5‐HT1A GPCR potentiates NGF 
neuritogenic output in a signaling dependent on PI3K and Akt activation [61]. Taking together, these 
different reports indicate that PI3K/Akt seems to be one of the main signaling pathways where 
several extracellular cues converge to induce neuronal differentiation.  
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A1.6.4. ERK1/2 pathway 
The extracellular regulated kinases 1 and 2 (ERK1/2) are part of the main pathway of the MAPK 
(mitogen‐activated protein kinase) signaling. Different receptors translate their intracellular 
signaling through the activation of small GTPases of the Ras family. These activate a kinase signaling 
cascade that starts with the Raf kinases, which in turn activate the MAPK kinases (MEK1/2) and 
culminates in the activation of ERK1/2. Several reports have put ERK1/2 has a main player in 
neuronal development [65]. Treatment with different neurotrophic factors, usually NGF and BDNF, 
lead to neuritic outgrowth in vitro as a result of increased ERK1/2 activity [51, 66–68]. In PC12 cells, 
ERK1/2 is especially important, being able to induce different outcomes depending on the duration 
of its signaling. Sustained activation, as the one induced by NGF, results in neurite outgrowth, while 
temporary activation leads to cell proliferation, normally as a result of EGF incubation [68]. ERK1/2 
seems to be especially involved in the axon specification mechanism. Studies involving the Rit 
GTPase showed that its activation led to axonal elongation in detriment of dendritic growth, and 
inhibition of ERK activation blocked Rit effects [69]. Another study also showed that ERK2 
phosphorylation of Par3 modulated neuronal polarization[70]. 
In vivo, knockout studies have been essential not only to identify potential ERK functions, but also 
to differentiate between ERK1 and ERK2. ERK2 deletion results in a 50% reduction in axonal length, 
as well as a reduction in dendritic branching on mice cortex [71]. ERK2 deletion also led to 
embryonic cell death, contrary to ERK1 knockout, revealing a crucial role for this isoform on normal 
development[72].  
 
A1.6.5. STAT3 pathway 
The signal transducer and activator of transcription 3 (STAT3) is a transcriptional factor involved in 
innumerous cellular functions, as well as a key factor in the genesis of different cancer types. STAT3 
is activated by phosphorylation by tyrosine kinase signals, with its canonical activator being the 
Janus kinase 2 (JAK2), but being also activated by the Src kinase or directly phosphorylated by 
tyrosine kinase receptors such as the Epidermal Growth Factor Receptor (EGFR) [73–75]. Although 
STAT3 function has been mainly studied in a context of carcinogenesis, a possible role in neuronal 
differentiation has been unveiled through the last years. Treatment of PC12‐E2 cells with 
interleukin‐6 (IL‐6) induces neuronal‐like morphological changes similar to the incubation of these 
cells with NGF. However, while NGF treatment is accompanied by a substantial increase in ERK1/2 
activation, IL‐6 leads to STAT3 activation[76]. Moreover, blocking STAT3 activity, but not blocking 
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of ERK1/2, significantly decreased IL‐6 induced neurite outgrowth, showing that STAT3 activation 
in these cells is sufficient to induce neuronal‐like differentiation [77]. Notwithstanding these results, 
the STAT3 role on neuronal differentiation in vivo is still not clear. In the adult nervous system, 
STAT3 has been implicated in the organism response to neuronal injury, being activated in cases of 
brain ischemia and spinal cord injury [78, 79]. STAT3 is also important in synaptic plasticity, for its 
activation in the postsynaptic terminal is required for long‐term depression (LTD) to take place [80]. 
Interestingly, activation of STAT3 by the Src kinase also leads to neurite outgrowth in Neuro‐2A 
cells, in a signaling mechanism mediated by Gαo [81]. This pathway will be explored in more detail 
in the following section. 
Over the years, several other players in neuronal differentiation have been uncovered. A detailed 
scheme of the main signaling pathways involved in neuritogenesis and neuronal polarization is 
displayed on figure A1.4, adapted from [8]. 
 
 
 
Figure A1.4. Signaling in neuronal differentiation. The different signaling pathways described here have to cross‐
talk with each other to successfully induce neuronal differentiation. Adapted from [8]. 
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A2. The Other G protein (Go) 
 
Heterotrimeric G proteins are one of the main components of intracellular signal transduction. They 
consist of three subunits, the α, β, and γ, with the latter two usually tightly bound together into the 
βγ complex. G proteins are divided according to their alpha subunit into 4 major families: Gs, Gi/o, 
G12/13, and Gq/11 [82]. One of the most intriguing G proteins is one of the members of the Gi/o 
family, the Go protein. Its alpha (α) subunit, Gαo, got its name due to being discovered after both 
Gs and Gi: Gs was named for being able to stimulate the adenylate cyclase activity, while Gi inhibits 
it. Since the new G protein had no specific function or attribute, it was named the “other” G protein 
[83, 84].  
Similar to the small G proteins, heterotrimeric G proteins work as molecular switches of intracellular 
signal transduction. When inactive, Gαo is bound to GDP (guanosine diphosphate), and forms a 
trimeric complex with the βγ subunit. To be activated, Gαo must release the GDP and bind GTP 
(guanosine triphosphate). This is promoted by the binding of Guanine Nucleotide Exchange Factors 
(GEFs) to the G protein, with the most common GEFs being the G protein‐coupled receptors 
(GPCRs). The activation of a GPCR by an extracellular ligand results in a conformational change that 
allows the binding of the receptor to the G protein. This in turn causes a second conformational 
change on the α subunit that results in the exchange of GDP for GTP, and the separation of the α 
and βγ subunits. At this point the G protein is active, and both the α and βγ subunits interact with 
downstream effectors to modulate different signaling pathways. What characterizes the G proteins 
as molecular switches is the intrinsic GTPase activity that the α subunits possess (as well as the 
small G proteins). Thus, G proteins only stay active for short periods of time, after which the GTP is 
hydrolyzed to GDP, the α and βγ subunits reconnect, and Go returns to its inactive state. Members 
of the Regulators of G‐protein Signaling (RGS) family can bind to the α subunit and drastically 
increase the rate of GTP hydrolysis, thus terminating the G protein signaling faster. RGS proteins 
are also known as GTPase‐accelerating proteins (GAPs), however this term is more commonly used 
to proteins that interact and regulate small monomeric G proteins, such as Ras and Rho family 
proteins [85–87]. As a member of the Gi/o family, Gαo is also inhibited by the Pertussis Toxin (PTX). 
PTX ADP‐ribosylates the cysteine located four residues from the carboxyl terminus of Gαo, thus 
blocking Gαo interaction with its activators [88]. 
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Although it has been intensively studied for the last 3 decades, Gαo specific function in the human 
organism is still not completely clear. Some data regarding Gαo physiological function has come out 
from a few published knockout reports. General knockout of Gαo in mice results in viable animals 
but that have a lifespan of only 7 weeks. The animals are small, hyperactive, hyperalgesic and have 
severe motor control impairments, exhibiting a turning behavior that result in the mice going 
around in circles for long periods of time. At a cellular level, there was a decrease in the ability of 
opioid receptors to inhibit Ca2+ channel currents in dorsal root ganglion cells, indicating a role for 
Gαo in translating the intracellular signaling of these receptors [89]. 
 Since Gαo is the most expressed Gα subunit in the brain, accounting for around 1% of the total 
membrane protein [90], most of the studies have been devoted to try uncover the Gαo role in the 
brain physiology.  
 
A2.1. Gαo genetics 
The Gαo protein is highly conserved across several species, including human, rat, bovine, fly, 
nematode, among others, sharing over 80% identity between proteins of the different species [90]. 
In humans, the Gαo gene (GNAO1) is located on chromosome 16, comprising over 100 kb and 
containing 11 exons [91]. Analysis of the GNAO1 gene detected that exon 7 and exon 8 are 
duplicated, and mechanisms of alternative splicing give rise to two different isoforms, Gαo1 (aka 
GαoB) containing the exons 7A and 8A, and Gαo2 (aka GαoB) containing the exons 7B and 8B [91–
93]. These isoforms are almost identical, with differences appearing only in 20 amino acids of the 
last portion of the protein (C‐terminal), and since this region is essential to receptor and effector 
binding, Gαo1 and Gαo2 could have different functions in the brain [91, 94]. 
A third isoform, Gαo3, has been identified as a result of a posttranslational modification, where an 
asparagine at residue 346 of Gαo1 is converted through deamidation into an aspartate [95, 96]. 
However, there is still no description of this modification occurring in human Gαo. 
 
A2.2. Gαo expression and distribution  
Although Gαo can be found a little all over the human body, it is greatly enriched in the brain [97]. 
Initial immunohistochemical studies in rat brain showed that Gαo is mainly present in neuropil 
(regions with abundance of dendrites and axons, and consequently rich in synapses) and absent 
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from cell bodies [98]. The study also detected a differential distribution of Gαo along the rat central 
nervous system: Gαo is enriched in cerebral cortex, especially in the molecular layer (layer 1), in 
neuropil of the hippocampal formation, striatum, subtstantia nigra pars reticulate, molecular layer 
of the cerebellum, substantia gelatinosa of the spinal cord, and posterior pituitary [98]. Current 
data retrieved from the database Expression Atlas shows that Gαo also has a differential expression 
in the human nervous system, being enriched in the cerebral cortex and the basal ganglia (putamen, 
nucleus accumbens, caudate nucleus, globus pallidus and substantia nigra) (Figure A2.1) [97, 99–
102]. 
At a cellular level, mouse Gαo is located in striatal neurons, cortical neurons, cerebellar granular 
cells, as well as striatal glial cells, cerebral cortex and colliculi glial cells. At a subcellular level, 
neuronal Gαo is present on the plasma membrane, mainly at cell‐cell contacts, and in neurite 
arborization. It is also present at low levels in the cytoplasm and is absent from the nucleus [103]. 
During neuronal development, Gαo is especially present on the growth cones of elongating neurites 
[104]. In glial cells, Go is present throughout the cell in low levels, with specially strong staining 
around the nucleus [103]. 
 
Gαo expression in the human Nervous System
anterior cingulate cortex frontal cortex
occipital cortex putamen
nucleus accumbens caudate nucleus
globus pallidus substantia nigra
cerebellum amygdala
hypothalamus hippocampus
dorsal thalamus brain meninx
pituitary gland medulla oblongata
spinal cord pineal body
Figure A2.1. Gαo expression in the different regions of the human nervous system. Data was retrieved from four studies 
present in the Expression Atlas database, and the values were normalized to each study. The studies analyzed were The 
FANTOM5 project, The Human Protein Atlas and two studies from the Genotype‐Tissue Expression (GTEx) Project [97, 
99–102].  
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Gαo expression suffers distinct variations during neuronal development. Initial studies showed that 
differentiation of neuroblastoma cells (NG 108‐15 and N1E‐115 cells) induced different expression 
profiles on both Gαo isoforms: Gαo1 expression was either absent (N1E‐115) or very low (NG108‐
15) in undifferentiated cells, with differentiation greatly increasing its protein levels; Gαo2 was 
already present in undifferentiated cells and its protein levels did not change substantially during 
differentiation [105, 106]. However, analysis of primary cultures of matured neurons showed that 
Gαo2 was almost absent [106], indicating that neuronal differentiation is accompanied by an 
increase in Gαo1 and a decrease in Gαo2 protein levels. Moreover, analysis of Gαo metabolism 
showed a significant increase in the protein half‐life with differentiation, being around 28h in 
undifferentiated neuroblastoma cells, 58h in differentiated cells, and 154h in primary culture of 
cerebellar granule cells [107]. Adding the results that showed that mRNA levels on cerebellar cortex 
of mice did not suffer significant alterations during cerebellum development [108], the increase in 
Gαo levels with differentiation could be a result of a decrease in Gαo degradation rather than an 
increase in Gαo gene expression.  
Interestingly, while differentiation of PC12 cell also correlates with an increase of Gαo levels [109], 
differentiation of the neuroblastoma cell line SH‐SY5Y with retinoic acid (RA) gave opposing results, 
with Gαo levels suffering a slight decrease, although not significant [110]. Of note, the study did 
not distinguish between Gαo1 and Gαo2. Nevertheless, this could indicate that distinct 
differentiation mechanisms on different cell types affect Gαo expression differently. 
Rat primary neuronal cultures have also evidenced an increase in Gαo expression during the 
differentiation of mesencephalon and hypothalamus neurons, with Gαo levels being barely 
detectable for the first 2 days in vitro, but rapidly increasing after 4 days and stabilizing 2‐3 weeks 
after plating [111]. This increase in Gαo levels was associated with a significant increase of Gαo 
presence in neuronal processes, dendrites and axons. Also, in the case of mesencephalon neurons, 
increasing the cell density also resulted in an increase in Gαo levels, which could be an effect of the 
increase in cell‐cell contacts [111]. A study using rat brain extracts also showed that Gαo protein 
levels not only increases during development, but continues to increase for several days after birth 
[112].  
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A2.3. Gαo signaling in the brain 
As mentioned before, although intensively studied, Gαo role in the brain is still not completely clear. 
The discovery of the receptors that activate intracellular signaling through Gαo, as well as its 
downstream effectors have helped to establish Gαo signaling pathways, as well as deciphering 
potential functions of Gαo, particularly in neuritogenesis [90, 113, 114].   
 
A2.3.1. Necdin 
Necdin is a neuronal protein highly expressed on post‐mitotic neurons, where it functions by 
blocking cell cycle progression, thus maintaining the neurons in the G0 phase of cell cycle [115]. It 
is also expressed during brain development, opening a potential role in regulating neuronal 
differentiation. A recent study by Ghil’s group as identified Necdin has an interactor of Gαo [116]. 
Using co‐immunoprecipitation assays followed by quantitative western‐blot, the authors showed 
that Necdin interacted preferentially with the activated Gαo, thus putting Necdin as a downstream 
effector of Gαo. Overexpression of a constitutively active (CA) form of Gαo with Necdin enhanced 
the Necdin‐induced blocking of cell proliferation, while co‐transfection of Necdin with either wild‐
type or Gαo CA increased of the number of cells with neurites (this work stablishes a neurite as 
being a process longer than the cell body length). Furthermore, Gαo activation of Necdin signaling 
was promoted by activation of the type 1 Cannabinoid Receptor (CB1R), and culminated on the 
inhibition of the transcription factor E2F1.  
 
A2.3.2. Src-STAT3 pathway 
As mentioned above, the STAT3 pathway is a prominent player in brain development and function 
[77, 80], and while JAK2 is known as STAT3’s canonical activator, some signaling pathways involve 
STAT3 activation by the Src kinase [73]. Initial studies using NIH‐3T3 fibroblasts showed that 
overexpressing a Gαo CA resulted in proliferation and neoplastic transformation of these cells [117, 
118]. This transformation was accompanied by an increase in STAT3 activity, with no alterations in 
ERK1/2 activity. Moreover, the Gαo‐induced transformation was a result of STAT3 phosphorylation 
by the Src kinase rather than by JAK2.  The authors had already hypothesized a possible role for the 
Gαo‐Src‐STAT3 pathway in differentiation by stating that mechanisms that induce NIH‐3T3 
transformation sometimes translate to other cell types as differentiation mechanisms, with their 
follow‐up work supporting this statement. Using Neuro2A cells as a model, the research shows that 
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stimulating the CB1R significantly increases the number of cells with neurites (this work stablishes 
a neurite as being a process at least 2x longer than the cell body diameter), a mechanism mediated 
by the activation of the Gαo‐Src‐STAT3 pathway [81, 119]. CB1R activation causes Gαo to bind to 
Rap1GAP, a Rap1 negative regulator protein. This binding results in the targeting of Rap1GAP to 
proteasomal degradation, thus eliminating the blockage upon Rap1 activity [119, 120]. Rap1 
activates Ral, which in turn activates the Src kinase, culminating in STAT3 phosphorylation. Besides 
phosphorylating STAT3 directly, the study also showed that Src kinase can activate STAT3 via an 
alternate pathway, where it activates Rac1‐c‐Jun N‐terminal kinase (JNK) signaling. Activation of 
both signaling pathways by CB1R‐Gαo are essential in inducing neurite outgrowth (Figure A2.2). 
Interestingly, although G protein effectors tend to bind with 
more affinity to the activated forms of the Gα subunits, 
Rap1GAP binds preferentially to the wild‐type form of Gαo 
when compared to the Gαo CA. Since stimulation of the 
CB1R leads to the activation of Gαo, it is unexpected that 
this mechanism would lead to the binding of Gαo to 
Rap1GAP. The authors try to explain these events as a 
possible sequential mechanism [119]. Go activation by 
CB1R leads to the separation of the Gα and Gβγ subunits. 
This separation allows Rap1GAP to bind to Gαo, since 
Rap1GAP binds to the same region as the βγ subunit, 
through the GoLoco motif. The binding of Gαo to Rap1GAP 
is initially weak, but it is strengthened when GTP is 
hydrolyzed to GDP. At this point, Rap1GAP would act as a 
guanosine nucleotide dissociation inhibitor (GDI), 
maintaining Gαo in its inactivation state until Rap1GAP 
could be targeted to degradation. Although no direct 
evidences are shown to support this theory, the idea that 
Gαo proper function relies on an activation/deactivation 
cycle is supported by similar mechanisms described in small 
G proteins, as the aforementioned Cdc42 [58].  
An interplay between Gαo and the Src kinase has also been described downstream of Reelin [121]. 
As mentioned before, Reelin is an extracellular factor known to participate in neuronal polarization, 
as well as in the control of neuronal migration [8, 122]. Treatment of primary cultures of 
Figure A2.2. CB1R-Gαo-STAT3 signaling in 
neurite outgrowth. Image reproduced from 
[81]. 
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hippocampal neurons with Reelin increased both the total neuritic length as well as neuritic 
branching. Treatment with PTX blocked Reelin neuritogenic effects on hippocampal neurons, while 
knockdown of Gαo did the same in F11 cells [121], thus demonstrating that Reelin activates an 
intracellular pathway dependent on Gαo. By trying to fully comprehend the complete signaling 
pathway involved in Reelin effects, the authors identified the Src kinase as a player in this signaling. 
Co‐immunoprecipitation assays showed that Src and Gαo interact with each other, and that this 
interaction is strengthened by treatment with Reelin. Gαo activation in this pathway was 
accompanied by an increased activation of JNK, while Akt and GSK3β (other common players in 
Reelin signaling) were unaffected. Interestingly, activation of Src and JNK was also seen in the 
cannabinoid‐induced signaling [81], which could implicate some cross talk between both pathways. 
However, the authors did not check for STAT3 activity, so is not certain that the interaction of Gαo‐
Src in Reelin‐treated cells leads to same outcome that in cannabinoid‐treated cells. Also, 
surprisingly, in this study Src seems to be acting upstream Gαo in the Reelin signaling pathway, 
rather than downstream as seen before. This was demonstrated by showing that inhibiting Gαo 
with PTX did not significantly inhibited Src kinase. Combining both studies [81, 121], one could 
hypothesize that Gαo and Src kinase could be involved in a positive loop, where Src activates Gαo, 
which in turn activates a signaling pathway (Rap1‐Ral) that further activates Src. Such positive loop 
has already been described as an important mechanism of neuronal polarization, where activation 
of PI3K by Trk receptors leads to the activation of a cascade involving Cdc42Par‐complexRac1 
that feedbacks into further activation of PI3K (Figure A1.4) [8], opening the possibility for Gαo‐Src 
also participating in a similar process. Nevertheless, further research is required to better 
understand the inner works of Gαo‐Src signaling 
 
A2.3.3. GAP-43 
Although G proteins are mostly known to be activated by GPCRs, one of the first known activators 
of Gαo was the growth associated protein 43 (GAP‐43 aka neuromodulin) [104]. GAP‐43 is protein 
highly enriched in neurite growth cones and is commonly used as marker for neuronal 
differentiation [123, 124]. The presence of both GAP‐43 and Gαo in growth cones raised the 
question if these proteins could functionally interact in the regulation of the growth cone dynamics. 
Indeed, GAP‐43 can bind to Gαo and stimulate the exchange of GDP for GTP, thus acting as a GPCR‐
like protein [104, 125]. The Gαo‐activating sequence of GAP‐43 was then shown to be able to induce 
neurite outgrowth in N1E‐115 cells, an effect that was mimicked by mastoparan (an activator of 
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Gi/o) and inhibited by PTX, thus showing that Gαo plays a role in mediating GAP‐43 neuritogenic 
function. The effect of GAP‐43 interaction with Gαo is not always the same, however, since in dorsal 
root ganglia neurons this interaction leads to the collapse of the growth cones [126], indicating that 
the outcome of GAP‐43‐Gαo interaction might depend upon the cellular environment in which it 
occurs, and also that a tight control is required to achieve successful neurite outgrowth.  
There are some contradictory reports regarding the mechanism by which GAP‐43 interacts with and 
activates Gαo. The initial report showed that treatment with PTX did not alter the ability for GAP‐
43 to activate Gαo [125], contrary to what happens normally to GPCRs, which could mean that GAP‐
43 binds to a different region of Gαo. However, later studies showed that effects mediated by GAP‐
43 are sensible to PTX treatment [126]. The authors explain these differences as a possible result 
of GAP‐43 being overabundant in the initial experiments, thus somehow being able to bypass PTX 
inhibition, or that the GAP‐43 peptides used in the later experiments are more susceptible to PTX 
action than the full‐length protein [126]. The interaction between GAP‐43 and Gαo is also affected 
by palmitoylation of Gαo, a reversible post‐translational modification that facilitates the 
attachment of Gαo to the cell membrane [127]. GAP‐43 ability to activate Gαo is greatly increased 
when Gαo is depalmitoylated [128]. The authors point to the fact that activation of G proteins by 
GPCRs results in the increase of Gαo depalmitoylation, indicating that GAP‐43 could function as an 
intracellular potentiator of GPCR signaling. Indeed, some studies have already showed that GAP‐43 
is able to modulate GPCR‐Gαo signaling. GAP‐43 and the muscarinic M2 receptor can synergistically 
activate Gαo in vitro, while injection of GAP‐43 in Xenopus laevis oocytes significantly increased 
GPCR response to agonist stimulation [129]. More recently, a study showed that an α7 nicotinic 
receptor could modulate neurite outgrowth by interaction with a protein complex containing Gαo, 
GAP‐43 and GRIN1 (another Gαo interactor that will be discussed further ahead) [130], not only 
adding evidence that GAP‐43 is a potential intracellular positive modulator of GPCR‐Gαo signaling, 
but also that this signaling is important in regulating neuritogenesis.  
 
A2.3.4. ERK1/2 pathway 
One of the main signaling pathways at the center of Gαo activity is the ERK1/2 signaling. Gαo was 
first described to activate ERK1/2 in CHO cells [131]. In these cells, stimulation of the muscarinic 
acetylcholine receptor M1 (M1AChR) and the platelet‐activating factor receptor (PAFR) resulted in 
activation of ERK (note that this work only checked for the activation of p44 MAPK aka ERK1). This 
effect was blocked by treatment with PTX and rescued by the expression of a PTX‐insensitive Gαo, 
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thus demonstrating that Gαo activity was required for ERK activation. Gαo activation of ERK was 
done by a non‐canonical pathway, since Ras was not involved but the protein kinase C (PKC) was 
required [131]. Further work confirmed this, with PKC inactivation blocking ERK activation by Gαo 
[132]. The pathway by which Gαo activates ERK was further resolved, with PI3K and B‐Raf linking 
Gαo‐PKC to ERK1/2. It was also shown that Gαo activation by GPCRs could lead to the modulation 
of signaling activated by other receptors, such as the Epidermal growth factor receptor (EGFR), 
since expressing Gαo CA was not enough to activate ERK, but significantly potentiated ERK 
activation by EGFR [132]. The Gαo‐PKC‐ERK pathway has still not been seen in a neuronal setting, 
however, PKC‐ERK signaling has already been strongly associated with neurite outgrowth [133, 
134], so Gαo participation on the mediation of these effects should not be excluded.  
Neuronal activation of ERK1/2 by Gαo seems to be associated with a variety of functions. In 
Neuro2A cells, expression of Gαo CA significantly increases the number of cells with neurites, 
accompanied by an increase in ERK1/2 activation [135]. This activation of ERK1/2 was mediated by 
a small GTPase, Rit, with transfection of a dominant negative form of Rit blocking Gαo neuritogenic 
effects and decreasing ERK1/2 phosphorylation. Another study also showed that Gαo neuritogenic 
roles in Neuro2A are possibly translated via ERK1/2 activation [136]. Focusing on the study of RGS8, 
the authors showed that this protein inhibits Gαo, producing several effects: it blocked the ability 
to Gαo activate Necdin, reduced the formation of neurites induced by Gαo transfection, and 
blocked ERK1/2 activation induced by a protease‐activated receptor (PAR1)/Gαo signal. Of note, 
while these results show that Gαo has a neuritogenic effect, and it is able to activate ERK1/2, these 
events were evaluated in separated, so it is not clear if ERK1/2 activation induced by the PAR1/Gαo 
signaling can produce neuritogenic effects.  
In SH‐SY5Y cells, Gαo might also potentially induce neurite outgrowth via ERK1/2 [137]. Treatment 
of cells with melanin‐concentrating hormone (MCH) led to an increase in the number of neurites 
per cell, as well as an increase in their length. This effect was accompanied by an increase in ERK1/2 
phosphorylation, and was significantly decreased when cells were treated with PD98059, an 
inhibitor of MEK. MCH induction of ERK1/2 activation was blocked by treatment with PTX, indicating 
that the MCH receptor is coupled to either Go or Gi. Since no specific experiments were performed 
to differentiate between Gαo and Gαi, further studies are required to confirm the potential MCH‐
Gαo‐ERK1/2 pathway in neurite outgrowth.  
One of Gαo functions in the brain seems to be in the modulation of nociception[89], with ERK1/2 
potentially playing a role in this function. Knockouts of Gαo in mice resulted in animals that suffered 
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from hyperalgesia when subjected to hot‐plate tests [89]. The opioid receptor‐like (ORL1) receptor, 
a potential target for pain medication, has been shown to translate intracellular signaling through 
Gαo. Moreover, the activation of Gαo by ORL1 leads to the phosphorylation of ERK1/2, confirmed 
by treating cells with PTX or overexpressing a PTX‐insensitive form of Gαo [138].  Stimulation of µ‐
opioid receptor with morphine also activates an intracellular pathway that involves Gαo and ERK1/2 
activation [139]. The involvement of Gαo in ERK1/2 activation was demonstrated by expressing Gαo 
mutants that were insensitive to PTX and RGSs. Further work has helped establish a critical role for 
Gαo in pain control, particularly in mediating supraspinal anti‐nociception effects of morphine, 
methadone and nalbuphine, although ERK1/2 activity was not monitored in these studies [140, 
141]. 
Finally, a Gαo‐ERK1/2 pathway has been described in cell survival. Overexpressing the YWK‐II 
transmembrane protein in CHO cells results in an increased activation of ERK1/2 induced by the 
Müllerian inhibiting substance (MIS). This increased ERK1/2 activation was blocked by incubation 
with PTX and by transfection of cDNAs encoding the C‐terminal of Gαo1 and Gαo2 (with Gαoi c‐
terminal having no effect), thus demonstrating that MIS‐YWK‐II signal was translated specifically 
via Gαo. MIS is able to promote cell survival, and indeed in this study it was able to do so by 
activating the YWK‐II‐Gαo‐ERK1/2 signaling pathway [142]. This pathway could be important in 
brain function since YWK‐II is widely distributed throughout the human organism, including the 
brain, and has a high homology with the amyloid precursor‐like protein 2 (APLP2), being sometimes 
even referred as APLP2 in rat [142–144]. 
 
A2.3.5. GRIN1 
The G protein‐regulated inducer of neurite outgrowth (GRIN or GPRIN) is a highly enriched protein 
of the human central nervous system that has two isoforms, GRIN1 and GRIN2 [145]. While it was 
first discovered as an interactor of Gαz, its potential biological function was brought to light by its 
interaction with Gαo. GRIN1 is highly enriched in neuronal growth cones, together with GAP‐43 and 
Gαo, and initial experiments showed that GRIN1 interacts preferentially with the active form of 
Gαo, indicating it is as a potential effector of Gαo. Further characterization of this interaction 
identified the C‐terminal region of GRIN1 (aa 716‐746 and 797‐827) as the binding point of Gαo 
[146]. This interaction has no effect in GTPase activity, supporting the hypothesis that GRIN1 is an 
effector of Gαo rather than its regulator. The outcome of this interaction is an interesting one. 
Expression of Gαo CA with GRIN1 in Neuro2A and MA104 cells significantly increases the formation 
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of neurites [145], while transfection of a mutant GRIN1 lacking the Gαo binding region, with or 
without Gαo present, also resulted in increased neurite extension [146]. The authors concluded 
that the Gαo binding region acts as a self‐inhibitory domain upon GRIN1. Binding of Gαo to this 
domain causes a change that lifts GRIN1’s inhibition, thus resulting in its ability to induce neurite 
extension. The interaction between Gαo and GRIN1 is also essential for the translocation of the 
latter from the cytosol to the plasma membrane. This work also identified Cdc42 as a possible 
downstream effector for this interaction, since co‐expression of a dominant negative (DN) Cdc42 
with Gαo and GRIN1 blocked neurite extension in Swiss3T3. Interestingly, in Neuro2a cells, 
expressing a DN Rac1 also blocked neurite extension induced by Gαo‐GRIN1 [146], which means 
that this interaction can modulate different signaling pathways according to the environment in 
which it occurs. 
A previously mentioned study has identified GRIN1 and Gαo as part of neuritogenic complex with 
GAP‐43 [130]. This complex was co‐immunoprecipitated with the α7 acetylcholine nicotinic 
receptor, with GRIN1 acting as the link between the receptor and Gαo and GAP‐43, since 
downregulation of GRIN1 using siRNAs significantly decreased the α7 receptor interaction with the 
G protein complex. From this and the follow‐up work [147] it is not completely clear if the α7 
receptor is a downstream effector of a potential GAP‐43‐Gαo‐GRIN1 pathway, or if it is a negative 
regulator of this pathway. Both works show that inactivation of the α7 receptor leads to an increase 
in neurite outgrowth, while its activation reduces the number of growth cones present in 
hippocampal neurons. Moreover, inactivation of the α7 receptor increases its interaction with GAP‐
43 and Gαo, while its activation decreases the interactions, with GRIN1 interaction being unaffected 
in either conditions. Also, the study detected an increase in GAP‐43 phosphorylation, which is 
correlated with an increase in neurite outgrowth, when the receptor was inactivated, while Gαo 
modulation (through treatment with either PTX or Mastoparan) had a significant impact on α7 
receptor effects [130]. Taking these results all together, a hypothesis emerges of a convergence of 
the two signaling pathways, one starting with the α7 receptor and the other with GAP‐43, on GRIN1, 
however, further research is required to fully comprehend the inner works of this new potential 
signaling.  
Analysis of the expression and colocalization of GRIN1 and Gαo during the development of the 
mouse’s nervous system highlighted a possible role for this complex in the migration and 
differentiation of neurons during development, as well as in the maintenance of the neuronal wiring 
on mature brains, although future functional experiments are required to test these hypotheses 
[148]. 
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The interaction between Gαo and GRIN2 has also been subjected to investigation, with some 
surprising results. Although previous reports have established the ability for Gαo to activate the 
ERK1/2 pathway [131, 135], its interaction with GRIN2 negatively regulates ERK1/2 activity [149]. 
The study showed that without activation of Gαo, GRIN2 is bound to Sprouty2, an inhibitor of MAPK 
signaling. Upon activation of Gαo through CB1R, Gαo binds to GRIN2, thus freeing Sprouty2, which 
in turn blocks ERK1/2 activity induced by FGF treatment. It is not clear what are the effects of this 
signaling, since the work thus not show any morphological output. Since ERK1/2 has already been 
associated with neuronal differentiation, either activated by Gαo or other pathways, its inhibition 
could mean a decrease in neuritic outgrowth. However, ERK1/2 output can be significantly different 
depending on the source of its activation [150, 151], meaning that the interference of Gαo‐GRIN2 
with FGF‐ERK1/2 pathway could have an effect in cellular functions other than neuritogenesis. 
 
A2.3.6. Dopamine receptors 
Several dopamine receptors are coupled to Gαo. In SH‐SY5Y cells, D3 receptors regulate cyclic AMP 
(cAMP) production and Ca2+ channel currents through activation of Gαo [152]. Studies on Gαo 
knockout mice showed that most of the dopamine D2 receptors in the central nervous system 
preferentially translate their signals through Gαo instead of Gαi, which could explain some of the 
motor control defects exhibited by these mice [89, 153]. A more recent study, besides also showing 
that D2 receptors activate preferentially Gαo, it advanced the hypothesis that this signaling could 
be important in stimulating synaptic plasticity, due to the positive effect Gαo has in neurite 
outgrowth [154].  
 
A2.3.7. Wnt pathway 
The Wnt signaling plays several roles in the nervous system, from participating in the neuronal 
differentiation to the regulation of synaptic plasticity [155]. Experiments in both Drosophila and 
mammalian cells have shown that Gαo is coupled to Frizzled receptors and is able to translate Wnt 
extracellular signals to a pathway that involves Dishevelled proteins, small Rho GTPases and JNK 
[156, 157]. Wnt‐Gαo seems to be important in forming and maintaining the synaptic structure. Gαo 
is activated by Frizzled2 in Drosophila, and disturbances in this pathway leads to a reduction in the 
number of synaptic boutons present in the neuromuscular junction [158]. Gαo role in this signaling 
seems to be to bind to Ankyrin2, a protein that participates in regulating the stability of the 
microtubule cytoskeleton. The study also showed that the interaction between Gαo and Ankyrin is 
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also necessary for the neuritogenic effects of Gαo, since downregulation of Ankyrin in Neuro2a cells 
significantly decreased the formation of neurites induced by Gαo transfection [158]. Gαo also 
couples to Frizzled9 in rat hippocampal neurons [159]. Wnt‐5a binding to Frizzled9 results in the 
activation of Gαo, which in turns activates a non‐canonical pathway of Wnt signaling, involving the 
calcium‐calmodulin‐dependent protein kinase IIα, PKC, and JNK, culminating in an increase in the 
formation of dendritic spines, as well as the clustering of PSD‐95 in the post‐synaptic region (Figure 
A2.3). These effects were mimicked by treatment with Mastoparan‐7, an activator of Gαo and Gαi, 
strengthening the potential role of Gαo in synaptogenesis [160]. 
 
 
A2.3.8. Gαo2 functions 
Almost every study dedicated to Gαo either focus on the Gαo1 isoform or does not distinguish 
between both isoforms. However, there have been a few studies that highlight specific Gαo2 
functions.  One of these seems to be the regulation of vesicles. Activation of Gαo2, but not of Gαo1 
or Gαi, induced a significant reduction of vesicular catecholamine uptake in PC12 cells by inhibiting 
the catecholamine transporters [161, 162]. By using specific knockouts of Gαo2, researchers 
showed that Gαo2 also controls the vesicular uptake of glutamate, thus putting Gαo2 as a potential 
player in the control of neurotransmitter storage and release, as well as in mechanisms of synaptic 
plasticity [163]. 
Figure A2.3. Wnt-Gαo signaling in synaptogenesis. Image reproduced from [159]. 
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Interestingly, Gαo2 seems to have opposite effects to Gαo1 on neuronal differentiation. While 
several reports show that Gαo activation is associated with neurite outgrowth, one study showed 
that deleting Gαo2 gives rise to longer axons, and with more branches, in hippocampal neurons 
[164]. Gαo2, like Gαo1, also binds to Rap1GAP, but while this binding in the case of Gαo1 leads to 
the increase in Rap1 activity through the degradation of Rap1GAP [81, 120], the deletion of Gαo2 
increases Rap1 activity, which could mean that Gαo2 is redirecting Rap1GAP to inactivate Rap1, 
rather than targeting it for degradation. The study also showed that Gαo2 effects were mainly in 
axon morphology, with the dendritic outgrowth not suffering major changes with Gαo2 deletion 
[164]. Combining these results with the differential expression pattern of both Gαo1 and Gαo2, 
where Gαo2 is expressed mainly in undifferentiated cells while Gαo1 protein levels increase with 
differentiation, one could speculate that Gαo2 is important in maintaining cells in an 
undifferentiated state, with Gαo1 increase leading to the overcome of Gαo2 blockade, and thus 
helping promote neuronal differentiation. However, there is still a lot of research required to assess 
this potential mechanism. 
  
A2.3.9. Other Gαo signaling 
The continuous discovery of new Gαo interactors has been essential in the understanding of the 
potential Gαo roles in the brain. RGS14 is one of those interactors, a regulator of G protein signaling 
that binds preferentially to Gαo in comparison to Gαi, terminating its activity [165]. RGS14 has been 
shown to negatively regulate synaptic plasticity, and since it is highly enriched in hippocampal 
neurons, this could be an important function in learning and memory mechanisms [166, 167]. 
Moreover, this regulation is thought to be mediated by RGS14‐induced inhibition of ERK1/2 
signaling [166, 168]. There is still no evidence connecting these RGS14 effects to its interaction with 
Gαo, and ERK1/2 inhibition by RGS14 seems to be dependent on a direct interaction between 
RGS14 and H‐Ras. Nonetheless, since both proteins have been associated with synaptic plasticity 
mechanisms, there could be an interplay happening between Gαo and RGS14 and controlling each 
other functions. 
The serotonin type‐1D (5‐HT1D) receptor is another GPCR that acts through Gαo. As mentioned 
above, Gαo seems to have a key role in the control of nociception, and data suggests that this could 
also be through its interaction with the 5‐HT1D receptor. Activation of this receptor leads to the 
increase in A‐type potassium currents (IA) in mouse trigeminal ganglion neurons, and if IA is blocked 
it induces neuronal hyperexcitability and can lead to pain generation [169]. The IA elevation was 
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mediated by the activation of protein kinase A (PKA) and the p38 MAPK, and was blocked by 
treatment with antibodies against Gαo and Gβ. Interestingly, no activation was seen of JNK and 
ERK, two signaling pathways modulated by Gαo, whereas blocking PKC (another Gαo signaling 
partner) did not affect IA [170]. These results, coupled with the fact that antibodies against the Gβ 
subunit affected the 5‐HT1D receptor effects, could mean that Go mediates serotonin signaling 
mainly through its Gβγ subunit rather than through Gαo.  
Interestingly, stimulation of the serotonin receptor 5‐HT1A can also induce neurite outgrowth 
through activation of a Gα‐Rap1‐Src‐STAT3 pathway, much like CB1R [171]. The study describes Gαi 
as being the G protein involved in this signaling. However, they only tested this by treatment with 
PTX, which blocks both Gαi and Gαo, which means that Gαo could also play a role in 5‐HT1A‐induced 
neurite outgrowth.  
Gαo has been reported to modulate neurite outgrowth by repressing cAMP‐CREB activation. While 
the exact mechanism that results in CREB inhibition is not known, overexpression of Gαo and Gαo 
CA in F11 cells resulted in a significant decrease in neurite elongation induced by cAMP activation, 
while increasing the number of new neurites formed [172]. 
Most of the studies presented here seem to indicate that Gαo is largely involved in mechanisms of 
neuritogenesis and synaptic plasticity, with some of the signaling mechanisms activated by Gαo 
being uncovered. One crucial Gαo signaling partner that was still not described here is the amyloid 
precursor protein (APP). APP not only interacts with Gαo but it is also involved in regulating some 
of the same pathways than Gαo, highlighting potential functions that could be shared by both 
proteins. The interaction between Gαo and APP will be the main focus of this thesis so the following 
introductory sections will be dedicated to APP and the published data regarding this interaction. 
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A3. The Amyloid Precursor Protein 
 
The amyloid precursor protein (APP) is a Type I transmembrane protein ubiquitously expressed 
throughout the organism, that is best known for giving rise to the β‐amyloid peptide (Aβ), one of 
the hallmarks of the Alzheimer’s Disease. The APP gene is expressed as several isoforms, with the 
3 main ones being APP695, APP751 and APP770 (the numbering represents the number of amino 
acids present in the protein sequence), which are a result of alternative splicing of exons 7 and 8 
[173]. These 3 isoforms are all characterized by a long N‐terminal extracellular domain and a short 
C‐terminal intracellular domain, with their main structural differences being the presence of a 
Kunitz‐type protease inhibitor (KPI) domain on APP751 and APP770, and the presence of an OX‐2 
domain on APP770 (Figure A3.1) [173]. APP is part of a protein family composed of two other APP‐
like proteins, APLP1 and APLP2. These two proteins differ from APP due to their lack of the Aβ 
region [174], and they seem to share essential functions with APP. Evidence for this comes from 
knockout studies in mice, where single knockouts of any member of the APP protein family results 
in viable animals, while double knockout of either APP/APLP2 or APLP1/APLP2 (but not APP/APLP1) 
resulted in early post‐natal lethality [175, 176]. These studies show that while crucial for a normal 
development, APP functions can to a certain extent be compensated by the other members of its 
family.   
 
 
 
Figure A3.1. Different isoforms of APP. EC, Extracellular space; IC, Intracellular space. Adapted from [173]. 
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The three APP isoforms have distinct expression profiles. While all three proteins are expressed in 
the brain, APP695 is the most abundant isoform on this tissue [177]. In the brain, APP role has been 
highly studied, being implicated in mechanisms of cell adhesion, neuronal migration and neuronal 
differentiation [173, 176, 178]. APP functions, as well as its role in the pathogenesis of Alzheimer’s 
Disease, are strictly linked to the extremely dynamic “life” that APP takes inside the cell. This life 
involves posttranslational modifications, from phosphorylation to glycosylation, an intense traffic 
across several cell compartments, and proteolytic processing that originates different peptides (e.g. 
Aβ) with diverse functions. 
 
A3.1. APP processing 
A main feature of APP is its proteolytic processing into Aβ. However, Aβ is only one of the different 
peptides that result from APP processing. The canonic processing pathways that APP suffers are the 
amyloidogenic pathway and the nonamyloidogenic pathway, depending on if Aβ is produced or not 
(Figure A3.2) [179–182]. In the amyloidogenic pathway, APP is first cut on the β‐cleavage site of its 
extracellular domain by a β‐secretase, resulting in the shedding of sAPPβ (secreted or soluble 
APPβ), with the remaining c‐terminal fragment (C99 or β‐CTF) remaining membrane‐bound. The 
βCTF is then cleaved by γ‐secretase to originate Aβ and the APP intracellular domain (AICD). The 
nonamyloidogenic pathway starts with APP being cut by a α‐secretase, resulting in the release of 
Figure A3.2. APP processing. Amyloidogenic (left) and nonamyloidogenic (right) pathways. Adapted from [182]. 
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sAPPα and the c‐terminal fragment (C83 or α‐CTF), with the latter being then cut by γ‐secretase to 
originate the p3 fragment and the AICD. 
Each protein fragment originated during APP processing has been the focus of research to try to 
understand their potential physiological functions. Aβ interest is mainly due to its role in AD, where 
it accumulates and forms aggregates in the form of senile plaques in  extracellular space [182, 183]. 
The formation of these plaques seems to be one of the main causes of neuronal death in 
Alzheimer’s, with the amyloid cascade hypothesis still being one the most accepted theories 
regarding Alzheimer’s pathogenesis, however the complete mechanism is still not completely clear 
[184]. Besides its pathological part, low levels of Aβ seem to be a positive regulator of synaptic 
plasticity and memory, by modulating presynaptic nicotine receptors and increasing Ca2+ levels 
[185–187]. 
The sAPP fragments are mostly released into the extracellular space where they are thought to act 
as ligands to stimulate different cellular functions, many of them through binding to the full  length 
APP [178]. Most of the physiological roles of the soluble APP have been attributed to sAPPα. sAPPα 
participates in mechanisms of long term‐potentiation (LTP) by regulating NMDA receptor function 
[188, 189]. The positive effects of sAPPα on memory formation are also dependent on its role in 
the formation of dendritic spines [187, 190, 191]. sAPPα is strongly involved in neuroprotection by 
modulating full‐length APP‐dependent and independent mechanisms. In the APP‐dependent 
mechanism, sAPPα binds to APP and blocks the formation of APP dimers, leading to the protection 
of neuroblastoma cells against starvation [192]. In the APP‐independent mechanism, the ability of 
mice to recover after neuronal injury is significantly impaired in APP knockout animals, but the 
addition of sAPPα to these animals reverts the negative effects even in the absence of full‐length 
APP [193]. sAPPα has also been implicated on cell proliferation, with inhibition of α‐secretase 
reducing proliferation of different types of stem cells, which could be recovered by the addition of 
exogenous sAPPα. Additionally, this trophic effect was associated with ERK activation [194]. A 
strong role of sAPPα on neurite outgrowth has also been strongly implied, and it will be discussed 
further ahead. sAPPβ physiological effects are more unclear, with a potential function in regulating 
axonal pruning and neuronal death during development, but that could also be a mechanism by 
which this fragment could be involved in neuronal death during Alzheimer’s pathogenesis [181, 
195]. 
The APP C‐terminal fragments have different functions regarding their length. While α‐CTF has still 
no clear role, β‐CTF has been implicated in mechanisms of memory impairment and neuronal 
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degeneration [187]. AICD, on the other hand, has some important physiological functions, mainly 
in regulating transcription [187]. One of the main characteristic of AICD is the presence of the 
YENPTY domain, which is thought to regulate its interaction with different proteins and thus 
influence AICD functions. Indeed, AICD capability of gene transactivation is thought to be 
modulated by its interaction with the adaptor protein FE65 [196, 197]. One of the genes 
upregulated by AICD/FE65 is GSK3β, an effect that is thought to be important in the control of the 
cell cytoskeleton and cell trafficking [197]. Interestingly, AICD can also upregulate the expression of 
APP itself [198].  AICD can also be involved in cell death mechanisms by increasing the expression 
of the pro‐apoptotic factor p53 [197, 199]. Regardless of these different reports showing AICD 
transcriptional activity, there is still some controversy over the significance of this function in vivo 
[187]. 
Lastly, to this day the P3 fragment has still not been implicated in any physiological or pathological 
mechanisms [187].  
 
A3.2. APP trafficking 
The APP processing is closely related to its intracellular trafficking (Figure A3.3) [178, 200]. APP is 
produced in the endoplasmic reticulum (ER) and from there it is transported by secretory pathway 
through the Golgi apparatus into the plasma membrane (PM) (Step 1). It is during this transport 
that APP suffers maturation through several post‐translational modifications, mainly N‐ and O‐
linked glycosylation, phosphorylation, and tyrosine sulphation. Even though most of the nascent 
APP takes this secretory pathway to the PM, there is only a small portion of APP localized in the PM 
(≈ 10%). Most of it remains in the Golgi apparatus or in the Trans‐Golgi network (TGN). Some of the 
APP that reaches the PM goes through the nonamyloidogenic pathway, due to the presence of α‐
secretases in this region, resulting in the shedding of sAPPα into the extracellular space. The 
remaining APP can either remain in the PM where it can act as a receptor‐like protein [201], or take 
the endocytic pathway (Step 2). Endocytosis is triggered by the presence of the YENPTY domain, 
and APP is then compartmentalized into endosomes, from where it can be recycled back to the 
membrane (Step 3) or targeted to lysosomal degradation. It is during the endocytic pathway that 
APP comes into contact with β‐secretases, specially β‐site APP‐cleaving enzyme 1 (BACE‐1), either 
in the endosomes or in the TGN. This leads to the amyloidogenic pathway and thus the production 
of Aβ. There is in fact several evidence that interfering with the YENPTY domain, or with some of 
the proteins that interact with APP through the YENPTY domain, such as FE65 or Mint1, leads to 
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the reduction of Aβ production. The resulting CTFs from both amyloidogenic and nonamyloidogenic 
processing are cut by γ‐secretases in either the endosomes or in the lysosomes [178, 200]. 
APP trafficking in neurons follow the pathway described above within the soma, however trafficking 
along dendrites and axons have a few peculiarities that are still under study. It is known that APP 
travels in vesicle‐like structures along the axon, but is not clear at which point to they fuse with the 
membrane, or what signals regulate this process. The same is true to the retrograde traffic that APP 
goes through the axon, while the specific signals that mediate APP trafficking to either dendrites or 
axons are still under study [200]. Nonetheless, it is clear that APP is present in both the pre‐ and 
postsynaptic terminals [202]. 
 
A3.3. APP phosphorylation 
APP can be subjected to phosphorylation in several of its residues, two of which are present in the 
ectodomain, and 8 potential sites present in the intracellular domain. The phosphorylation of the 
two ectodomain residues, Ser198 and Ser206, is still a matter of debate, with no specific function 
being attributed to these modifications so far [203, 204]. Phosphorylation of APP’s intracellular 
domain, on the other hand, has been extensively studied, and it has potential roles in APP’s 
trafficking, processing, and mediating interactions with other proteins. The 682YENPTY687 domain 
Figure A3.3. APP trafficking. Reproduced from [200]. 
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can be modulated by phosphorylation of its tyrosine residue, Tyr682, or phosphorylation of the 
upstream residue Thr668 [201]. Tyr682 can be phosphorylated by different kinases, such as TrkA, 
Abl, and Src, and its phosphorylation is required for APP interaction with adaptor proteins SchA and 
Grb2, which in turn leads to the activation of the MAPK pathway [201, 205]. Thr668 can be 
phosphorylated by JNK3, Cdk5, and GSK3, leading to a conformational change in the YENPTY 
domain. This causes an interference with the APP‐Fe65 interaction, while also increasing the APP 
processing by BACE1 and γ‐secretase, thus favoring the amyloidogenic pathway [200, 206]. 
However, these results are controversial, with different reports showing that Thr668 
phosphorylation inhibits γ‐secretase action and decreases Aβ formation [207], while it is also 
required for AICD interaction with Fe65 and its translocation into the nucleus [208, 209]. 
Phosphorylation of both YENPTY tyrosine, Tyr682 and Tyr687, also have an impact on Aβ production 
by directing APP to different cellular compartments, and thus promoting either α or β‐secretase 
cleavage [209].  
Ser655 is another phosphorylatable residue, which is located on the 653YTSI656 sorting motif, and its 
phosphorylation, which can occur via PKC and CaMKII, has a significant impact in APP trafficking. A 
study using APP phosphomutants that mimic Ser655 phosphorylation (S655E) or dephosphorylation 
(S655A) showed that Ser655 phosphorylation increased APP secretory trafficking through the Golgi 
and into the plasma membrane, while also increasing sAPP production [210]. A follow‐up study 
showed that Ser655 phosphorylation also enhanced APP recycling back to the TGN, in a process 
mediated by the retromer complex. Moreover, Ser655 dephosphorylation resulted in an increased 
targeting of APP to the lysosomes, thus showing that Ser655 phosphorylation is also important for 
regulating APP half‐life [211]. A more recent study corroborates these results by showing that the 
Ser655 residue is required for the interaction between APP and AP‐3 (adaptor protein 3), and that 
phosphorylation of Ser655 disrupts this interaction and decreases APP trafficking to the lysosome 
[212]. The authors also showed that Ser655 phosphorylation resulted in a decreased production of 
Aβ, which could be tied to the decreased targeting of phosphorylated APP to the late endosome‐
lysosome compartments. Of note, this study was conducted using APP phosphomutants constructs 
in the APP751 isoform. Ser655 phosphorylation could also be important in regulating APP 
interactions with other proteins, since it has been shown that it induces significant conformational 
changes in the intracellular domain of APP, specifically in the hydrophobic pocket downstream of 
Ser655, 656IHHGVV661, which could affect the binding of proteins to this region [213]. 
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A3.4. APP as a neuritogenic protein 
Although APP is best known for giving rise to Aβ, research has highlighted several potential roles 
that APP has in the normal brain, from cell adhesion to synaptogenesis, and of especially interest 
for this work, its role on neurite outgrowth [178, 187, 201]. Early evidence show that APP is highly 
enriched in developing neurites of rat neocortex and hippocampal neurons [214]. In fact, APP seems 
to be involved in the elongation of neurites, since increasing APP levels in PC12 cells leads to a 
significant increase in neuritic length and branching without affecting the number of primary 
neurites [215]. This effect of APP in neuritic elongation was also seen in SH‐SY5Y neuroblastoma 
cells differentiated with RA, where a significant increase in APP levels was detected during a second 
phase of differentiation (4‐8 days of differentiation), which is characterized by neurite elongation 
and stabilization [216]. The APP role on this mechanism was further confirmed by overexpressing 
full‐length APP695 during the second phase of RA‐induced differentiation, which led to a significant 
increase in neurites longer that 50 µm. Besides RA, APP also mediates differentiation induced by 
NGF. Using specific antibodies to block APP significantly reduces NGF neuritic effects on PC12 cells 
[215]. Moreover, APP phosphorylation seems to play a significant role on NGF effects, since APP 
phosphorylation of Thr668 is detected during NGF differentiation, mainly in the growth cones of 
PC12 cells [217]. Interestingly, NGF treatment of PC12 cells expressing an APP phosphomutant 
mimicking Thr668 phosphorylation resulted in the decrease of neurite extension. While this could 
at first indicate that phosphorylation of APP blocks its neuritogenic effects, the authors advance a 
model by which the phosphomutant could be competing with the endogenously phosphorylated 
APP for the binding to a neuritogenic molecule present in the growth cone, thus acting as a 
dominant negative form of APP [217]. APP effect on neuronal differentiation has also been reported 
on rat cortical neurons, with the decrease in APP expression leading to a decrease in both dendritic 
and axonal growth [218]. APP neuritogenic function could also be important in neuroregeneration 
mechanisms, with APP expression being significantly increased in axons after neuronal injury [176]. 
The mechanisms by which APP induces neurite outgrowth remain elusive; however, the study of its 
interacting proteins have been helpful in uncover potential signaling pathways. APP acts as an 
adhesion molecule through its interaction with several extracellular components, such as laminin, 
collagen I, and heparin, with these interactions being important to neurite outgrowth and axonal 
guidance [176, 219].  APP also regulates axonal guidance through interaction with netrin‐1 and its 
receptor, DCC, and consequent activation of the ERK1/2 pathway [220]. APP interaction with Reelin, 
another extracellular protein involved in neuronal differentiation (see above), results in changes to 
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both APP trafficking and processing [221, 222]. Reelin treatment causes an increase in cell surface 
APP, which correlates with an increase in sAPPα shedding and a reduction in Aβ production. 
Moreover, Reelin neuritogenic effects seem to be dependent on its interaction with APP, since 
downregulation of APP blocks Reelin‐induced neurite outgrowth in vitro. Also, knockdown of APP 
or Reelin significantly decreased dendritic outgrowth in vivo [222]. Taken together, these reports 
strengthen the idea that APP role in cell physiology is by acting as a receptor‐like protein.  
APP neuritogenic effects are not restricted to is full‐length form (aka holoAPP), with several reports 
indicating sAPPα as a key potentiator of neuritogenesis. After secretion to the extracellular space, 
sAPPα can induce neurite outgrowth through the interaction with different membrane proteins, 
including holoAPP. sAPPα interacts directly with p75NTR, and while sAPPα induces neurite 
outgrowth in mouse cortical neurons, this effect is abolished when p75NTR is knockdown. This 
effect was mediated by activation of the PKA signaling [223]. sAPPα also induces neurite outgrowth 
by modulating both holoAPP and β1‐integrin, with knockout of APP, or blockage of β1‐integrin with 
antibodies, resulting in the loss of sAPPα effects. Also, this study showed that knockout of APP also 
induces neurite elongation, with the addition of sAPPα in this condition not having any additional 
effect. The model proposed indicate that holoAPP blocks neurite elongation by interacting with β1‐
integrin, while sAPPα acts by disrupting this interaction and thus promotes neuritogenesis [224]. 
sAPPα signaling is also required for activity‐induced neurite outgrowth, in a mechanism mediated 
by activation of the ERK signaling[225]. ERK1/2 activation also occurs during axonal elongation 
induced by sAPPα. Interestingly, in this study, sAPPβ also induced axonal growth, although it 
required higher concentrations to do it significantly [226]. Besides neuronal differentiation, sAPPα 
can also induce glial differentiation. Treatment of human neural progenitor cells with sAPPα led to 
an increase in cells expressing the glial fibrillary acidic protein (GFAP, a glial marker), which 
correlated with an increase in the activation of STAT3. The authors show that sAPPα activates STAT3 
by either increasing the levels of the gp130 receptor by an indirect mechanism, or by activating 
gp130 directly, thus functioning as a novel ligand for this receptor [227]. Neurite outgrowth has 
also been associated with other peptides originated from APP processing, such as Aβ and AICD [228, 
229]. Of especial interest to this work, an interaction between a membrane‐bound AICD and Gαs 
was found to mediate neurite outgrowth, and it will be discussed further ahead [230].  
Finally, APP knockouts have shed some contradictory evidence regarding its neuritogenic function, 
with some showing an impact of APP knockout in dendritic extension and branching [231], while 
others showed that APP absence has no significant effect on neuronal differentiation [232], or even 
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reporting an increased elongation of neurites [224]. These contradictory results highlight the need 
to further investigate APP signaling to fully comprehend its function in the normal brain.                  
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A4. The APP-Gαo complex 
 
A4.1. APP-Gαo interaction 
The interaction between the amyloid precursor protein (APP) and Gαo was first described in 1993 
[233, 234]. On a first approach, the researchers identified the sequence His657‐Lys676 of the 
cytoplasmic region of APP695 as a possible interaction point with G proteins. This is due to the 
presence of two basic residues on the N‐terminal side of this sequence (His657‐His658) and a BBXXB 
motif on the C‐terminal side of the sequence (B represents a basic residue and X represents a non‐
basic residue; 672RHLSK676), a pattern present in Gα‐activating domains of several GPCRs [235–238]. 
Using in vitro assays, the researchers were able to confirm that a peptide with this 20 amino acid 
sequence increased the rate of GTP binding to Gαo, while having little to no effect on other Gα 
subunits. Also, this effect was blocked by incubation of Gαo with Pertussis Toxin (PTX). 
Immunoprecipitation assays performed in bovine brain membranes with the antibody 22C11 
(antibody which recognizes the N‐terminal of APP) revealed that APP interacted with Gαo but not 
with other G proteins, and that the His657‐Lys676 sequence was essential for this interaction. 
Furthermore, by pre‐incubating Gαo with GTPγS prior to the immunoprecipitation assays it was 
demonstrated that APP does not interact with the active form of Gαo [233].  
APP has also been characterized as an atypical GPCR, activating Gαo in a ligand‐dependent manner 
[239]. Phospholipid vesicles containing APP695 and Gαo were incubated with 22C11, which led to 
the increase of GTPγS binding and its turnover without altering the intrinsic GTPase activity of Gαo. 
This mechanism is similar to the one promoted by GPCRs, which act by increasing the rate of 
GTP/GDP exchange [240]. The authors hypothesize that 22C11 is acting as a possible extracellular 
ligand of APP, not yet identified, and it “activates” APP by promoting its dimerization, which is the 
mechanism present in other single membrane‐spanning receptors [241–244]. Another study also 
showed that incubation of 22C11 had an effect in APP‐Gαo interaction [245]. However, contrary to 
the previous results, they detected a reduction in Gαo GTPase activity. An explanation advanced by 
the authors for this difference was the fact that they used full membrane preparations extracted 
from rat brain, while the previous study was conducted in phospholipid vesicles [239]. The presence 
of other proteins (and potential APP/Gαo interactors) in the membranes could interfere with the 
APP‐Gαo complex, thus resulting in a different outcome. The authors also point out that 22C11 
might be acting by inducing a conformational change in the C‐terminal domain of APP, or by 
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releasing other interactor proteins, although the latter effect could be a direct consequence of the 
former. Nevertheless, this study also offered more evidence for the specificity of APP‐Gαo binding 
by showing that Gαi2 was not able to bind APP. Also, the mutation of two histidines present in the 
APP His657‐Lys676 sequence resulted in a loss of APP‐Gαo interaction, further confirming this 
sequence as the Gαo binding domain. 
Other regions of APP have also been associated with its interaction with Gαo. Mutations in the 
residue Valine642 of APP, associated with Familial Alzheimer’s Disease (FAD) [246, 247], have been 
described to influence Go activity. Mutation of this residue to isoleucine (V642I), phenylalanine 
(V642F) or glycine (V642G) all lead to an increased activation of Gαo when compared to wild‐type 
APP (Wt APP) [248]. The ability of these mutated APPs (FAD‐APPs) to activate Gαo depend on the 
presence of the Go binding domain, and are sensible to the action of PTX. The authors hypothesize 
that the mutation of V642 into other amino acids causes a shift in APP conformation, in what they 
call a change between an inactive conformation (as in Wt APP) and an active conformation (as in 
FAD‐APPs). The role of the C‐terminal sequence downstream of the Gαo binding domain, specially 
the 682YENPTY687 domain, on the APP‐Gαo interaction is still not completely clear. Most of the initial 
studies show that deletion of the sequence encompassing this domain, or its targeting with specific 
antibodies, do not affect APP‐Gαo interaction, nor does it affect the outcome of this interaction 
[233, 248–250]. However, a more recent study showed that the YENPTY domain can modulate APP‐
Gαo interaction. While full‐length APP shows a decreased interaction with Gαo when Aβ is present, 
Aβ incubation with APP lacking the YENPTY domain blocks Aβ effect [251]. While this highlight a 
possible role for the YENPTY domain on APP‐Gαo interaction, the exact mechanism behind this role 
still needs to be further explored.  
The C‐terminal domain of Gαo, more specifically the 5 C‐terminal residues, has been identified has 
the APP binding point [252]. Using Gα chimeras with the 5 C‐terminal residues from different G 
proteins showed that APP could only activate the Gα chimera presenting the Gαo C‐terminal. This 
is consistent with classical binding of GPCRs to heterotrimeric G‐proteins [253]. It also explains why 
treatment of Gαo with PTX affects Gαo activation by APP [233, 248], since PTX acts by APD‐
ribosylating the cysteine residue present in that 5‐residue C‐terminal of Gαo [254, 255].  
Most of the studies done so far have not only  showed that APP interacts with Gαo, but also that 
this interaction is specific, with other G proteins being excluded as APP interactors [233, 239, 245]. 
However, this specificity has been challenged by a report showing an interaction between APP and 
Gαs [230]. This study focused on the capability of the APP intracellular domain (AICD) to activate 
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signaling mechanisms that regulate neurite outgrowth. They expressed a construct of a membrane‐
bound AICD (mAICD) that led to an adenylate‐cyclase dependent activation of PKA and inhibition 
of GSK3β signaling. These results raised the question of a possible involvement of the Gs 
heterotrimeric protein, and indeed, mAICD was co‐immunoprecipitated with Gαs in N2a cells 
overexpressing both mAICD and wild‐type Gαs. Mutation of the APP BBXXB motif blocked both the 
mAICD‐Gαs interaction and the neuritogenic effects elicited by mAICD, thus highlighting a new 
potential signaling pathway involving APP and Gαs. Interestingly, besides not showing if mAICD can 
interact with Gαo beside Gαs, the authors did not address the fact that previous studies had 
excluded Gαs as an APP interactor. Also, the interaction here described was only verified for mAICD 
and not for the full‐length APP, while previous studies of APP‐Gα interaction have used mainly the 
full‐length APP695. The mAICD peptide could possibly have a different conformation that enables 
the binding of Gαs, a hypothesis similar to the one advanced by other authors who stated that 
cleavage of APP into AICD could trigger a switch in the interaction with the different G proteins. 
[234]. Nevertheless, further work is still required to fully comprehend the extension of the 
interactions between APP and G‐proteins.  
 
A4.2. APP-Gαo physiological function 
Although APP interaction with Gαo as been a subject of study for over 20 years, the outcome of this 
interaction is still not clear. There is published data pointing to a role of this complex in both a 
pathological setting, such as the progress of the Alzheimer’s Disease, as well as in a physiological 
setting, like the development and function of the human brain. APP and Gαo have been individually 
implicated in controlling neuronal migration [256–258], with a possible cooperation between both 
in this mechanism emerging recently [259]. An initial study conducted by the Copenhaver research 
group focused on a possible interaction between APPL, an ortholog of APP from Manduca sexta, 
and Gαo in migrating neurons [260]. Using a highly motile type of neurons, EP cells, as a model, the 
study showed that both APPL and Gαo colocalized in these cells in immunohistochemical 
preparations of Manduca sexta embryos. Immunoprecipitation assays further confirmed that APPL 
and Gαo interacted in these migrating neurons. A follow up study showed that inhibiting either 
APPL (by knocking down its expression) or Gαo (by incubation with PTX) resulted in very similar 
effects on neuronal migration, specifically a pattern of ectopic growth and migration of EP cells 
[261]. Although this indicates that APPL and Gαo might have similar functions and act upon the 
same signaling pathways, the research does not present data showing a direct effect of APPL‐Gαo 
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binding on neuronal migration. Also, further research is required to check if these results are 
maintained in a mammalian model.   
This study also showed that consistent with the interaction of Gαo with mammal APP695 [233], there 
is a significantly decrease of active Gαo co‐immunoprecipitation with APPL. However, treatment 
with PTX, a toxin that inhibits Gαo and Gαi activity by blocking their activation by GPCRs, increased 
the interaction of APPL with Gαo. This is an unexpected result since ADP‐ribosylation of G proteins 
by PTX is supposed to result in the uncoupling of the G protein from the GPCR [88, 262]. As 
previously stated, PTX treatment affects  APP activation of Gαo, however, there is no published 
data about its impact on the direct interaction between APP‐Gαo [233, 245, 248]. So, it is not clear 
if the increase in APPL binding to Gαo is specific to this insect ortholog or if it also occurs in 
mammalian cells. In APPL case, it could be that ADP‐ribosylation of Gαo still allows APPL binding 
but somehow blocks the conformational change that APPL (and GPCRs in general) needs to elicit 
on Gαo to activate it, and thus APPL‐Gαo remain in a complexed state.  
The APP‐Gαo complex also seems to play a potential role in mediating sAPPα signaling. sAPPα has 
already been implicated in several neuronal functions, from cell survival/protection to cell 
differentiation [192, 193, 223, 225]. New data shows that activation of the Akt pathway by sAPPα 
requires both full length APP and G protein activity [263]. Treatment with sAPPα significantly 
decreased cell death in both SH‐SY5Y cells and mouse hippocampal neurons that were under 
trophic factor deprivation, an effect that was lost when APP gene was knockdown in these cells. 
This neuroprotective effect of sAPPα was translated inside the cell by the activation of the Akt 
signaling pathway, and it was blocked by treatment with PTX. Expression of an APP mutant lacking 
the G‐protein interaction domain also blocked sAPPα and Akt signaling [263]. Taken together, these 
results describe a possible neuroprotective signaling pathway with sAPPα as an extracellular ligand, 
APP as its membrane receptor and Gαo as an intracellular signaling transducer that activates PI3K‐
Akt.  
Notwithstanding the research presented above, the physiological significance of the APP‐Gαo 
complex it is still not clear [234]. While potential roles in neuronal migration and neuroprotection 
seem promising, further research is still required to confirm these functions. There are also other 
potential processes where the APP‐Gαo complex can participate that remain unexplored. One of 
those is their potential cooperation in neuritogenesis. As previously mentioned, Gαo and APP have 
both been strongly associated with neuritogenesis. Briefly, Gαo has been seen to activate different 
signaling pathways that lead to neurite outgrowth, such as the Src‐STAT3 pathway [81, 113] and 
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the ERK1/2 pathway[135]. Also, some of Gαo interactors have neuritogenic functions, with some 
being attributed to their interaction with Gαo, such as Rit [135], Necdin [116], GAP‐43 [126, 130] 
and GRIN1 [130, 146]. Likewise, full length APP interaction with Reelin also plays a part in the 
induction in neurite outgrowth [222], with APP also participating in the mediation of the NGF effects 
[215]. Moreover, APP’s proteolytic fragment sAPPα induces neurite outgrowth through the Egr1 
[226] and MAPK/ERK signaling [225]. Both APP and sAPPα participate in the regulation of neurite 
outgrowth via interactions with Integrin β1 [224], with our lab also showing a relationship between 
sAPP/APP expression and neuronal differentiation, in SH‐SY5Y neuroblastoma cells differentiated 
with RA treatment [216]. There is some contradictory data showing that APP might instead have a 
negative impact in neurite outgrowth [264], or that it is not essential for proper neuronal 
differentiation [232]. 
Still, there is enough evidence supporting a role for both APP and Gαo in neuritogenesis that raises 
the possibility of these two proteins interacting and cooperating in this function. Supporting this 
potential role is the aforementioned study showing that AICD interacts with another G protein, Gαs, 
in the promotion of neurite outgrowth [230]. The authors showed that not only AICD interacted 
with Gαs, but that mutating the Gαs binding‐motif (672RHLSK676) present in AICD blocked its 
neuritogenic effects. Since the mutated motif is also required for the APP‐Gαo binding [233], this 
gives strength to the possibility of APP and Gαo playing a role in neuronal differentiation. 
 
A4.3. APP-Gαo pathological function 
Far more data has been published about the role of the APP‐Gαo interaction in cell death and 
disease than its physiological function [234]. This is mainly due to the prominent part that APP plays 
in the pathogenesis of the Alzheimer’s Disease (AD). Mutations of the residue Valine642 of APP are 
present in Familial Alzheimer’s Disease (FAD). In vitro studies showed that cells expressing mutated 
APPs undergo apoptosis associated with DNA fragmentation, in a Go‐dependent mechanism [248, 
265, 266]. These APP mutants (FAD‐APP) show an increased capability to activate Gαo, and FAD‐
APP apoptotic effects were blocked by either incubation with PTX, overexpression of a FAD‐APP 
lacking the G‐protein binding sequence, or by incubation with antibodies targeting the G‐protein‐
binding sequence (thus blocking APP‐Gαo interaction). Gαi involvement in this mechanism was 
excluded by co‐expression of FAD‐APPs with a dominant negative Gαi (G204A), which had no effect 
on APP‐induced apoptosis. As expected, co‐expression of FAD‐APP with a dominant negative Gαo 
(G204A) blocked DNA fragmentation, further confirming Go involvement in FAD‐APP apoptotic 
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effects. Interestingly, one study showed that Gαo activation by FAD‐APP resulted in suppression of 
the transcriptional activity of the cAMP response element (CRE) [252]. Since activation of the cAMP‐
CREB signaling has been associated with synaptic plasticity and memory formation [267, 268], the 
authors hypothesize that CRE inhibition by FAD‐APP could be a molecular event behind the memory 
loss that occurs during AD. Although APP interacts directly with Gαo, the βγ subunit of the 
heterotrimeric G‐protein also seems to be important for the apoptosis induced by FAD‐APP. FAD‐
APP co‐transfection with βγ subunits induced DNA fragmentation in NK1 cells, while overexpression 
of Gαo alone did not have significant effects [269]. Taken together, these results show two possible 
roles for the APP‐Gαo interaction in FAD: 1) direct activation of Gαo that leads to the blocking of 
the cAMP‐CREB signaling and thus disrupting memory formation; or 2) releasing and activating the 
βγ subunit, inducing DNA fragmentation, and culminating in neuronal death [234]. Not all FAD‐APP 
mutations lead to cell death through Gαo activation, though. For example, the Swedish mutation 
(K595N/M596L) induces cell death via Go activation when it is expressed at low levels, however, 
when expressed at high levels it leads to cell death in a way that is resistant to PTX [250].  
Cell death was also detected in F11 cells and mouse primary neuronal cultures expressing Wt APP 
and incubated with antibodies targeting the extracellular domain of APP, an effect blocked by 
incubation with PTX and deletion of the His657‐Lys676 sequence [249, 270]. This correlates with 
previous results that showed that incubation of APP with the 22C11 antibody increased Gαo 
activation [239]. Further studies trying to identify the signaling downstream of the APP‐induced 
neuronal death showed that not only was Gαo potentially involved, but that the Src kinase could 
also play a role, since treatment with either PTX or the Src inhibitor PP2 blocked APP effects [271]. 
These results are of particular interest since previous work had stablished a neuritogenic signaling 
pathway involving both Gαo and the Src‐STAT3 [81], thus opening the possibility that APP could 
also participate in this pathway, and that a tight regulation is required to balance between neuronal 
differentiation and neuronal death.  
Finally, there is still some mixed information about the role of Aβ in neuronal death induced by the 
APP‐Gαo complex. While some reports show that Aβ does not participate in APP‐Gαo neuronal 
death [249], others demonstrated that Aβ toxicity in neuronal cells was dependent on APP binding 
to Gαo (deletion of Gαo binding sequence) and Gαo activity (incubation with PTX) [251, 272]. These 
differences might be due the different types of studies being conducted. Sudo study tried to check 
if Aβ mediated the neurotoxic effect of APP upon its “activation” with specific antibodies, thus 
placing Aβ downstream of APP‐GαO interaction, while Sola Vigo and Shaked researches placed Aβ 
upstream of the APP‐Gαo interaction. Still, more work needs to be developed to fully understand 
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the interplay between Aβ and the APP‐Gαo complex, and if these results have a real impact in our 
understandment of the AD pathology. 
Analyzing the published data, one must ask how can the APP‐Gαo complex have so different effects, 
from neuronal death to neuronal protection. There are several ways researchers can try to answer 
this question. One possible way is to further characterize the nature of the APP‐Gαo interaction. 
The constitutively activation of Gαo induced by a mutant APP, such as the one occurring in FAD, in 
contrast with a cyclic activation of Gαo induced by Wt APP, the mechanism most likely present in 
healthy neurons, could be one possible explanation why so different outcomes are described. 
Another untapped area of APP physiology that could answer this question is the modifications that 
APP suffers during its cellular life. While the role of the APP proteolytic fragments have been 
explored (e.g. AICD), few is known about the impact of phosphorylation on APP‐Gαo interaction. 
APP phosphorylation has several important functions, from modulation of its transport and 
processing, to the regulation of its protein interactome, thus it is reasonable to speculate that it 
might also influence APP‐Gαo interaction and function.  
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Aims 
 
The major goal of this work was to perform a systematic research of the role of Gαo on 
neuritogenesis. We approached this goal by studying the effects of Gαo interaction with the 
Amyloid Precursor Protein (APP) on the mechanisms behind neurite formation and elongation. To 
this end, we defined the following specific aims: 
 Study the impact of APP Serine 655 phosphorylation on the ability to APP bind and activate 
Gαo.  
 Characterize the neuritogenic effects of Gαo and determine how APP modulates these 
effects. 
 Identify potential mechanisms by which APP and Gαo regulate each other protein levels. 
Additionally, our interest in studying the mechanisms of neuronal differentiation led us to the 
development of a new tool that would assist us in this research. To achieve this goal, we defined 
the following aim: 
 Develop and validate an ImageJ macro for morphological analysis of Phase Contrast and 
Fluorescence images of neuronal cells. 
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B1.1. Abstract 
 
Neuritogenesis comprises the generation, elongation, and maturation of neurites, the pillars of 
neural networks. Various neuritogenic molecules have been discovered through the last couple of 
decades, including the main cerebral G‐alpha subunit Gαo, and the amyloid precursor protein 
(APP), central to the Alzheimer’s disease (AD) pathogenesis. APP binding to Gαo increase its 
activation but, despite their high relevance in neurophysiology and pathophysiology, the functions 
of the APP‐Gαo complex are still unclear. We here demonstrate that the APP ability to bind and 
activate Gαo is dependent on the phosphorylation state of the APP Serine 655 residue, and that 
this interaction plays a role on neurite outgrowth. APP phosphorylation influences the formation of 
new processes and their elongation. Evaluation of the STAT3 and ERK1/2 pathways provided 
evidence that these pathways are sequential activated during Gαo‐APP driven neuritogenesis. 
While STAT3 mainly mediates the generation of new processes, ERK1/2 is more involved in neuritic 
elongation. Unraveling APP‐Gαo neuritogenic functions not only adds knowledge to the 
mechanisms of neuronal differentiation and neuritic plasticity but may also spur future therapeutic 
strategies on neuroregeneration, and on AD itself. 
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B1.2. Introduction  
 
Neuronal differentiation is a key embryonic event that is recalled during neuroregeneration in 
adulthood. Early neuronal differentiation comprises neuritogenesis, the formation of processes 
that will elongate into neurites. These arise from the neuronal body, elongate and specialize into 
dendrites and axon [1]. Neuritogenesis initiates from the contact between adhesion molecules on 
the neuron’s membrane and the extracellular matrix, which triggers cytoskeleton remodeling [2–
4]. Various signaling pathways are subsequently activated in neurons and neuronal‐like cells such 
as PC12 and SH‐SY5Y, including the extracellular signal‐regulated kinase (ERK) and the signal‐
transducer‐and‐activator‐of‐transcription 3 (STAT3) cascades [5–8].  
The complete mechanism underlying neuritogenesis is not yet fully understood and, as the list of 
key neuritogenic players increases [9], new promising molecules with potential therapeutic value 
emerge, namely the amyloid precursor protein (APP) and the alpha subunit of the heterotrimeric G 
Protein Go, Gαo. Albeit best known for its role in Alzheimer’s disease (AD) [10], APP’s biological 
functions are a current focus of interest. APP is a type‐I transmembrane glycoprotein, and its 
secreted form (sAPP), which results from APP processing by α‐secretases such as ADAM10 [11], has 
growth factor‐like neurotrophic functions and induces neuritic elongation in cultured neurons [12, 
13]. Both full‐length and secreted APP have been associated with neuritogenesis, potentially via 
Integrin beta1 [13, 14]. APP and its cleavage into sAPP also have been linked to neuronal 
differentiation induced by neurotrophins such as NGF and BDNF [14–16], with APP being shown to 
increase NGF‐induced neuritic length and branching in PC12 cells [17]. sAPP is also required for 
activity‐induced neuritogenesis that occurs in differentiating neurons, via ERK pathway activation 
[18]. Although it is clear that APP behaves as a neurotrophic signal transducer, its mode of action 
has not been fully elucidated. APP neurotrophic functions rely not only on its sAPP extracellular 
domain but also in its short intracellular domain (AICD), responsible for APP binding to several 
proteins. Gαo, the most abundant alpha subunit of G proteins in the central nervous system [19], 
is such an APP binding protein [20, 21].  
Although the object of extensive study, due to the major role that G‐protein‐coupled receptors 
(GPCRs) play in human physiology, it was the discovery of some Gαo interactors that shed light on 
its neuritogenic functions. Activated Gαo binds to and activates G protein‐regulated inducer of 
neurite outgrowth 1 (GRIN1), inducing neuritic elongation in Neuro2a cells [22]. Gαo can also induce 
neuritic outgrowth through the STAT3 pathway. In Neuro2a cells, ligand binding to the CB1 
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cannabinoid receptor (CB1R) activates Gαo, which binds Rap1GAPII thus activating Rap1. This 
culminates in Src kinase activation and STAT3 phosphorylation [23–25]. Although mainly associated 
with cellular proliferation, the STAT3 cascade mediates neuronal differentiation induced by ligands 
such as IL‐6 and PACAP in PC12 cells [26, 27]. Gαo has also been shown to modulate neurite 
outgrowth by interfering with the cAMP pathway [28] and by interacting with Rit , leading to ERK1/2 
activation [29].  
The group of Nishimoto and Ogata first described an APP/Gαo physical interaction and reported 
that APP increased Gαo activation [20, 21, 30]. APP binding to Gαo increases the Gαo activation 
state, either by activating it (increased Gαo‐binding to GTP) or by decreasing the Gαo GTPase 
activity [21, 31]. A potential role for APP‐Gαo interaction in the AD pathogenesis has also been 
investigated [32, 33] and an effect of the APP insect‐homologue in Gαo‐mediated neuronal motility 
was described in Manduca sexta´s developing enteric nervous system [34, 35]. Notwithstanding 
these results, the physiological role of this interaction is still not clear. 
In the work here presented we advance knowledge on the physical and functional interaction 
between Gαo and APP, including the effects of APP phosphorylation at Serine 655 (S655) on APP‐
Gαo binding. PKC‐mediated APP S655 phosphorylation alters the conformation of the 653YTSI656 
sorting motif and of a hydrophobic pocket immediately downstream [36–39]. This hydrophobic 
pocket is a part of the APP’s 657His‐Lys676 C‐terminal domain to which Gαo binds [20, 37, 38]. APP 
S655 phosphomutants were used to demonstrate that APP interaction with Gαo can be modulated 
by phosphorylation of APP Serine 655 residue, with also having an impact in the ability of APP to 
activate Gαo. Moreover, we demonstrate that APP and Gαo cooperate in the sequential activation 
of the STAT3 and ERK pathways, with S655 phosphorylation influencing the outcome of this 
interaction, and presenting different neuritogenic outcomes.  
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B1.3. Materials and Methods  
 
B1.3.1. Antibodies  
Primary antibodies used in Western Blot (WB) and Immunocytochemistry (ICC) assays: mouse 
22C11 monoclonal anti‐APP N‐terminus (Chemicon; WB‐1:250; ICC‐1:50); rabbit anti‐Gαo/GNAO1 
polyclonal (Upstate; WB‐1:5000; ICC‐1:250; Thermo; WB‐1:2000; ICC‐1:200); rabbit anti‐
phosphoTyr705‐STAT3 (monoclonal (Millipore; WB‐1:3000); mouse anti‐STAT3 monoclonal (Cell 
Signaling Technology; WB‐1:2000); rabbit anti‐phosphoThr185/Tyr187‐ERK1/2 monoclonal 
(Millipore; WB‐1:1000); rabbit anti‐ERK1/2 polyclonal (Millipore; WB‐1:1000); mouse anti‐βIII‐
tubulin C‐terminus (Millipore; ICC‐1:250); mouse anti‐MAP2 (Sigma‐Aldrich; ICC‐1:200). Secondary 
antibodies used: horseradish peroxidase‐labeled goat antibodies (GE Healthcare) for enhanced 
chemiluminescence (ECL) detection; Alexa Fluor 405, 488 or 594‐conjugated goat antibodies 
(Molecular Probes) for ICC analysis. Antibodies were prepared in 3% BSA in phosphate buffer saline 
(PBS) for ICC, and in either 3‐5% milk or BSA for WB, per the manufacturers’ instructions.  
 
B1.3.2. Chemicals 
The JAK2 inhibitor AG490 (Tyrphostin B42; Selleck Chemicals), the Src kinase inhibitor PP1 (1‐(1,1‐
dimethylethyl)‐3‐(4‐methylphenyl)‐1H‐pyrazolo[3,4‐d]pyrimidin‐4‐amine) (Enzo Life Sciences), and 
the EGFR inhibitor PD168393 (Santa Cruz Biotechnology) were used at 10 μM [40–42]. SH‐SY5Y cells 
were incubated for 6h with each inhibitor before being harvested in 1% SDS. Neurons were 
incubated for 18h before being subject to ICC or collected for WB. To stimulate PKC and thus 
increase APP S655 phosphorylation [43], SH‐SY5Y cells were incubated with 1 µM phorbol‐12,‐14‐
di‐butyrate (PDBu) for 2h prior harvesting [38]. 
 
B1.3.3. Gαo and APP cDNA constructs 
Wild‐type and constitutively active cDNAs of human G‐protein alpha o, isoform A, (Gαo and GαoCA, 
respectively), cloned into a pcDNA3.1+ vector, were from Missouri S&T cDNA Resource Center. The 
GαoCA cDNA has a Q205L mutation that hinders its GTPase activity [44]. The empty pcDNA3 vector 
(‘V1’; Invitrogen) was used to control Gαo transfections. APP cDNAs (human isoform 695), Wild‐
type (Wt) and Serine 655 (S655) point mutated to Alanine (‘SA’) or to Glutamate (‘SE’), already N‐
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terminally fused to GFP (Green Fluorescent Protein) were previously constructed. Due to the amino 
acids characteristics, the SE and SA APP mutants mimic a constitutively phosphorylated and 
dephosphorylated S655 state, respectively. The pEGFP‐N1 empty vector (‘V2’; Clontech) was used 
to control the APP‐GFP cDNAs transfections [38, 45]. 
 
B1.3.4. SH-SY5Y cells and primary neuronal cultures 
Human neuroblastoma SH‐SY5Y cells (ATCC CRL‐2266) were grown in Minimal Essential Medium 
(MEM) supplemented with F‐12, 10% FBS, 0.5 mM L‐glutamine, 100 U/ml penicillin and 100 mg/ml 
streptomycin (Gibco, Invitrogen). Cells were maintained at 37°C/5% CO2. APP‐GFP (Wt, SA, and SE) 
and Gαo (Wt, CA) cDNAs were transiently transfected using TurboFect (Fermentas), according to 
the manufacturer. After 6 or 24h of transfection, cells were either harvested with 1% SDS for WB, 
or fixed with 4% paraformaldehyde for ICC.  
Rat cortical primary neuronal cultures were established from E18 Wistar rat embryos as previously 
described [46]. Briefly, following dissociation with trypsin and deoxyribonuclease I, cells were 
plated onto poly‐D‐lysine coated 6‐well plates (0.75x106 cells/well) in Neurobasal medium (Gibco, 
Invitrogen) supplemented with B27, 0.5 mM glutamine and 60 μg/ml gentamicin. Neuronal 
cultures, maintained at 37ºC/5% CO2 for 3 days, were transfected with Gαo and APP‐GFP cDNAs 
using Lipofectamine® 2000 (Invitrogen Life Technologies). 18 hours before cell fixation, neurons 
were incubated with 10 μM of the EGFR inhibitor PD168393 or the Src inhibitor PP1. Upon 24h of 
transfection, cells were harvested with 4% paraformaldehyde or 1% SDS for ICC and WB analyses, 
respectively. A minimum number of pregnant female Wistar rats (9‐12 weeks; Harlan Interfaune 
Ibérica, SL) was used, and all steps were taken to ameliorate animal suffering. All experimental 
procedures complied the ARRIVE guidelines, observed the European legislation for animal 
experimentation (EU Directive 2010/63/EU) and were approved and supervised by our Institutional 
Animal Care and Use Committee: Comissão Responsável pela Experimentação e Bem‐Estar Animal, 
CREBEA).  
 
B1.3.5. Immunocytochemistry, microscopy and image software 
Fixed cells were permeabilized (0.2% Triton), washed with PBS, blocked (3% BSA/PBS), and 
incubated with primary antibodies for 2h. Following 3 washes with PBS, cells were incubated with 
secondary antibodies for 1h, washed with PBS and deionised water, and mounted onto glass slides 
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(Vectashield mounting medium with or without DAPI; Vector Labs). Microphotographs were 
acquired on a LSM 510 META confocal microscope (Zeiss), as before [38], and image analysis was 
carried out using ImageJ Fiji [47]. The JaCoP plugin [48] was used to obtain the percentage of 
proteins co‐localization, using the Manders’ method. The number of processes/cell was determined 
by counting any membrane projection arising from the cell body. The length of the processes was 
determined with the NeuronJ plugin; processes with lengths between 20‐35 μm were categorized 
as ‘pre‐neurites’; if longer than 35 μm, as ‘neurites’ [14, 49].  
 
B1.3.6. SDS-PAGE and Western Blot  
Total protein mass‐normalized (BCA protein assay; Pierce) cell aliquots were subjected to SDS‐PAGE 
and WB. Ponceau‐S staining of the transferred proteins was used as loading control, as an 
alternative to actin or tubulin, since these proteins vary with our experimental conditions [14, 50]. 
For this, nitrocellulose membranes were immersed in Ponceau‐S solution (Sigma‐Aldrich; 0.1 % 
[w/v] in 5% acetic acid), further washed with distilled water, and scanned (GS‐800 calibrated 
densitometer, Bio‐Rad). Following their wash with TBS‐T, membranes were subject to WB analysis. 
Briefly, membranes were blocked with 5% milk or BSA in TBS‐T, incubated with primary antibodies 
for 2h or overnight (O/N), and with horseradish peroxidase‐linked secondary antibodies for 2h, and 
subject to ECL detection. X‐ray films (Amersham) were scanned and protein bands quantified with 
the Quantity One 1‐D Analysis Software (Bio‐Rad).  
 
B1.3.7. APP/Gαo co-Immunoprecipitation and pull-down assays  
APP/Gαo were co‐immunoprecipitated with Protein‐G Dynabeads (Novex, Life Technologies) pre‐
complexed with the 22C11 antibody. Briefly, rat neurons were collected in lysis buffer (50 mM Tris‐
HCl pH 8.0, 120 mM NaCl, 4% CHAPS) containing a protease inhibitors cocktail (Sigma‐Aldrich). 
Lysates were precleared for 1h with dynabeads and further incubated O/N  at 4°C with the 22C11‐
dynabeads complexes. The immunoprecipitate was washed 3x with PBS, and the protein complexes 
eluted with Laemli buffer. Samples were boiled and subjected to WB [38]. 
APP‐GFP proteins were pulled‐down with GFP‐Trap® (Chromotek) following the manufacturer’s 
protocol with adaptations: SH‐SY5Y cells, co‐transfected with the APP‐GFPs and Gαo/GαoCA cDNAs 
for 12 h, were incubated for 45 min/RT in‐plate with the cross‐linker DSP [Dithiobis(succinimidyl 
propionate); Sigma‐Aldrich]. Cells were washed with PBS, harvested in cold 1 mM PMSF/PBS, 
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centrifuged for 5 min/4ºC, and resuspended in 200 μl Lysis buffer [10 mM Tris/Cl pH 7.5, 150 mM 
NaCl, 0.5 mM EDTA, 0.5% NP‐40, 1 mM PMSF, protease inhibitor cocktail (Sigma‐Aldrich)]. Samples 
were lysed on ice for 30 min, with extensively pipetting every 10 min. Following centrifugation (5 
min at 10,000 g/4ºC), a 25 μl supernatant aliquot was taken (‘Lysates’), and 300 µl Wash buffer (NP‐
40‐free Lysis buffer) was added to the remaining supernatant. Mass‐normalized samples were 
incubated with 20 µl GFP‐TRAP® beads (pre‐washed in Wash buffer) with orbital shaking O/N at 
4ºC. Samples were subsequently centrifuged (5 min at 10,000 g/4ºC) and the pellet washed 3x with 
1 ml Wash buffer. Pulled‐down proteins were recovered in 50 μl Laemmli’s buffer, boiled and 
sonicated, and subjected to WB. 
 
B1.3.8. Gαo activation assay 
The Gαo activation assay (NewEast Biosciences) was performed according to the manufacturer’s 
instructions. Briefly, SH‐SY5Y cells were transfected for 6h with the APP‐GFPs cDNAs (or V2 as 
control), and lysed. In the last 2h before lysis, a set of Wt APP‐GFP transfected cells was incubated 
with 1 μM PDBu to activate PKC and induce APP S655 phosphorylation [37, 39]. Cellular lysates 
were incubated for 1h with an anti‐active Gαo monoclonal antibody and 20 µl protein A/G‐agarose 
beads; the primary antibody/active Gαo complexes were recovered by centrifugation. Following 3 
washes with lysis buffer, pulled‐down active Gαo proteins were extracted with Laemli buffer and 
subjected to WB. For positive and negative controls, non‐transfected cellular lysates were pre‐
incubated for 90 min with GTPγS and GDP, respectively.  
 
B1.3.9. Statistical analysis 
Data is expressed as mean ± SEM (standard error of the mean) of at least three different 
experiments. Statistical analysis was conducted by one‐way ANOVA followed by the Tukey test, or 
by one‐sample t‐test, using the GraphPad Prism® software. Three levels of significance were used, 
depending if the p‐value was under 0.05, 0.01 or 0.001.  
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B1.4. Results 
 
B1.4.1. PhosphoS655 APP preferentially interacts with and activates Gαo  
Gαo is known to interact and be activated by APP [20, 21, 30, 31]. This interaction was here verified 
in rat cortex lysates by immunoprecipitating APP using the anti‐APP N‐terminus 22C11 antibody. 
Cortical Gαo co‐immunoprecipitated with APP, as expected (Figure B1.1A). Although the APP‐Gαo 
interaction has been well established, with the specific region of APP known to interact with Gαo 
already identified, the influence of APP phosphorylation in said interaction is still unknown. We 
thus investigated if APP phosphorylation at Serine 655 (S655) could modulate the APP‐Gαo 
interaction, since phosphorylation of this residue affects the conformation of the APP’s 
hydrophobic pocket that binds Gαo [20, 36]. SH‐SY5Y neuroblastoma cells were transfected with 
APP‐GFP cDNAs (human isoform 695) expressing the Wild type form of APP (Wt APP), and two 
phosphomutants mimicking the unphosphorylated S655 (SA) and the phosphorylated S655 (SE) APP 
[38, 45]. APP‐GFP proteins were then pulled‐down using a GFP‐trap® assay (Figure B1.1B). Albeit 
the three APP‐GFP forms pulled‐down Gαo, their binding efficiencies were quite different. Gαo was 
pulled‐down in similar amounts with Wt and SE APP‐GFP, although slightly higher with the 
phosphomimicking mutant (Figure B1.1B‐C). Conversely, SA APP‐GFP showed a 50% decrease in its 
ability to pull‐down Gαo (p<0.01) (Figure B1.1B‐C).  
Following, the effect of APP S655 phosphorylation in the reported ability of APP to activate Gαo 
was analyzed. For that, active Gαo levels were monitored in APP‐overexpressing SH‐SY5Y cells (‘Gαo 
activation assay’, Figure B1.1D). Taking APP‐GFP transfection levels into account, the SE APP‐GFP 
mutant activated Gαo at the highest level, followed by the Wt form, while SA poorly activated Gαo 
(Figure B1.1D, left panel). This assay was also performed in Wt APP‐overexpressing cells pre‐
exposed for 2h to PDBu, a PKC activator that increases APP S655 phosphorylation [43]. In the cells 
incubated with PDBu, the levels of active Gαo also increased over control (Figure B1.1D, right 
panel), supporting the model that APP phosphorylation modulates Gαo interaction and activation.  
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B1.4.2. APP modulation of early Gαo-induced neuritogenesis 
Gαo role in neural differentiation has been a focus of research for quite some time [22–24, 29, 51–
54]. After establishing that APP phosphorylation modulates Gαo activity, we analyzed if this could 
translate into altered Gαo‐induced neuritogenesis.  
A morphological analysis of SH‐SY5Y cells overexpressing wild‐type Gαo or a constitutively active 
Gαo (Gαo CA) during 6h (a time‐point at which protein overexpression was already significant) 
detected neuritogenic alterations in transfected cells (Figure B1.2A). Gαo overexpression 
significantly increased the number of cellular processes (2.2‐fold change over the empty vector; 
p<0.01), with Gαo CA also increasing the number of processes, slightly higher than Gαo (4.9±0.5 
and 5.6±0.5 processes/cell, respectively) (Figure B1.2C). Gαo overexpression also had an effect on 
the processes’ length by  increasing  the  percentage  of  cells  presenting  at  least  one  pre‐neurite 
(process longer than 20 μm) (1.45‐fold change over the empty vector, p<0.05). Interestingly, GαoCA 
also increased the percentage of cells with pre‐neurites, but to a lower extent than Gαo (Figure 
B1.2D). A similar result had already been described in F11 cells [28], where transfection with Gαo 
Figure B1.1. APP-Gαo interaction and Gαo activation are potentiated by APP S655 phosphorylation. A. Gαo was co‐
immunoprecipitated with APP from rat neuronal cortex, using the anti‐APP 22C11 antibody; ‘C’, control (without 22C11). 
B. Gαo was co‐pulled down with the APP‐GFP proteins (Wt, SA and SE) by GFP‐Trap®, in SH‐SY5Y cells co‐transfected 
with APP‐GFPs and Gαo. C. The levels of co‐precipitated Gαo were quantified and expressed as fold changes over the Wt 
APP‐GFP condition (taken as 1). These values were corrected to the amount of APP‐GFP pulled‐down in each assay. D.
Gαo activation assay: active Gαo (‘actGαo’) was immunoprecipitated in SH‐SY5Y cells transfected with the APP‐GFPs 
proteins. ‘GDP’ and ‘GTP’: negative and positive controls, respectively. Right panel: Gαo activation assay of Wt APP‐GFP 
expressing cells pre‐incubated in the last 2h with 1 µM PDBu to increase the levels of APP S655 phosphorylation. 
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and Gαo CA led to a decrease in average neurite length when compared to control, but had a 
significant increase in the number of processes. Taken together, these results indicate that Gαo 
activation has mainly an immediate effect in the formation of new processes rather than in the 
elongation of pre‐existing ones.   
Figure B1.2. Gαo:APP functionally cooperate in neuritogenesis.  A. Microphotographs of SH‐SY5Y cells transfected with 
the empty vector pcDNA3 (‘Vector’), Gαo, and Gαo CA cDNAs. Endogenous and transfected Gαo proteins were detected 
by immunofluorescence (red). Scale bar: 10 μm. B. Microphotographs of SH‐SY5Y cells co‐transfected with either Wt, SA 
or SE APP‐GFPS (green) and Gαo (red). ‘GR’ – Golgi region; ‘Cyt’ – cytoplasm. Scale bar: 10 μm. Morphometric analyses 
were performed on these cells: C. Number of processes arising from the cell body; D. Percentage of cells presenting at 
least one pre‐neurite or neurite, termed ‘(pre‐)neurite’, and representing processes longer than 20 μm. Symbols ‘*’ and 
‘#’ represent a statistical significance relative to the empty vector and to the Gαo single transfection condition, 
respectively. */#, p<0.05; **/##, p<0.01; ***/###, p<0.001. 
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To investigate the effects of APP and its phosphorylation on Gαo‐induced neuritogenesis, the 
different cDNA forms of APP (Wt, SA, SE) were co‐transfected with wild‐type Gαo (Figure B1.2B). 
Gαo:Wt APP‐GFP co‐expression had a strong effect on the formation of new processes, higher than 
Gαo alone (Figure B1.2C; 7.6±0.5 vs 4.9±0.5 processes/cell respectively, p<0.01). Neither Gαo:SA 
(4.1±0.4) nor Gαo:SE (5.7±0.1) combinations were able to significantly alter the number of Gαo‐
induced processes. Nevertheless, SE tended to increase this number to a level similar to Gαo CA 
alone (5.7±0.1 vs 5.6±0.5 for Gαo CA), while SA tended to decrease it (4.1±0.4). Comparatively, at 
6h of transfection, none of the APP‐GFP proteins alone increased the number of processes 
(Supplementary Figure B1.1).  
Regarding the capacity to elongate processes (Figure B1.2D), Gαo:SE APP significantly increased the 
percentage of cells with at least one pre‐neurite or neurite over Gαo alone (60±3% vs 48±2%, 
p<0.01), while no significant variations occurred for both Gαo:Wt APP and Gαo:SA APP co‐
transfections. Therefore, combined Gαo overexpression with sustained APP S655 phosphorylation 
results in processes’ elongation (in detriment to their generation). Of note, 6h of sole SE APP 
expression did not promote neuritic elongation (Supplementary Figure B1.1).  
Our results show that APP indeed modulates Gαo‐induced neuritogenesis, and that APP’s S655 
phosphorylation has an impact on the outcome of this interaction.  
 
B1.4.3. APP enhances the Gαo-induced STAT3 activation involved in neuritogenesis  
As aforementioned, Gαo is able to induce neurite outgrowth by activation of the STAT3 signaling 
pathway [23, 24]. So, to evaluate the potential role of the STAT3 pathway in APP‐Gαo induced 
neuritogenesis, we examined STAT3 phosphorylation at Tyr705 (pSTAT3) in cells overexpressing the 
different forms of Gαo and APP (Figure B1.3).   
Upon 6h of transfection (Figure B1.3A), both Gαo forms increased pSTAT3 (2.4±0.7‐fold change for 
Gαo and 1.9±0.5‐fold change for GαoCA). Regarding Gαo:APP co‐transfections, co‐transfection of 
Gαo with Wt APP, the condition where the highest number of processes was observed, was the 
only one where an increase in pSTAT3/STAT3 was detected, though to slightly lower levels than 
Gαo and Gαo CA (1.7±0.7‐fold change). It has already been reported that activated STAT3 remains 
phosphorylated for only short time periods, followed by a negative feedback mechanism of 
dephosphorylation [55]. Our data indicates that this might be occurring earlier/faster for GαoCA 
and Gαo:Wt APP co‐transfection. Moreover, there was a high degree of variability between 
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experiments, evidenced by the high standard errors. This gives strength to the idea that in these 
conditions a fast cycle of STAT3 phosphorylation/dephosphorylation was occurring. To test this 
hypothesis, a time‐course analysis of STAT3 phosphorylation was performed at 3, 4, 5 and 6 hours 
of transfection (Figure B1.3B). The levels of pSTAT3 and STAT3 were compared to control levels 
(transfection of empty vectors) and the pSTAT3/STAT3 ratio plotted as fold changes over control 
levels with time. Figure B1.3B shows that both Gαo and Gαo:Wt APP transfections activate STAT3 
and are indeed associated with a phosphorylation/dephosphorylation cycle of STAT3. These cycles, 
however, seem to be slightly out of phase with each other. Gαo alone shows an increase from 3 to 
4h followed by a decrease at 5h (1.24, 1.44, 1.05‐fold changes), while its co‐transfection with Wt 
APP shows an already higher STAT3 phosphorylation status at 3h, which decreases at 4h, followed 
by an increase at 5h (1.40, 1.10, 1.30‐fold changes). These results corroborate our initial idea that 
STAT3 signaling is occurring faster when both Gαo and Wt APP are overexpressed. Comparatively, 
Gαo CA overexpression also led to an initial increased STAT3 phosphorylation, but this decrease for 
the next 2 hours, only increasing back at 6h of transfection. This seems to indicate that a constant 
activation of GαoCA activates STAT3 but elicits a stronger feedback mechanism, while a cyclic Gαo 
activation, such as the one occurring when Wt APP and Gαo are expressed, leads to a faster cycle 
of STAT3 activity with less/shorter inhibition periods.  
The time‐course experiment showed again that there is a highly dynamic modulation of the STAT3 
pathway during transfection of Gαo and APP, evidenced by the variability between experiments. 
This data is strong evidence that the STAT3 pathway is activated by APP‐Gαo and that this pathway 
could be the main drive for the formation of new processes. To further confirm this, STAT3 
phosphorylation was pharmacologically inhibited with either 10 μM of AG490 or PP1, drug 
inhibitors of Janus Kinase‐2 (JAK2) and Src kinase, respectively (Figure B1.3C). Morphometric 
analyses proved that STAT3 activation is indeed a main pathway mediating Gαo:Wt APP‐induced 
neuritic outgrowth. While the incubation with either of the inhibitors significantly impacted the 
number of cell processes, Src inhibition led to a steeper reduction of this score (Figure B1.3C, left 
graph). This indicates that Gαo:Wt APP, as Gαo [23], induces the formation of cellular processes 
mainly via the Src‐STAT3 pathway. Regarding elongation in Gαo‐overexpressing cells, while the Src 
PP1 inhibitor decreased it to 34±4% (p<0.05), JAK2 inhibition markedly increased the percentage of 
(pre‐)neurites from 48±2% in control to 69±3% (p<0.01). Indeed, JAK2 inhibition led to a dose‐
dependent neuritic elongation in a Gαo‐overexpression background (Supplementary Figure B1.2A‐
C). This suggests that Src‐STAT3 also participates in the mild Gαo‐induced neuritic elongation, with 
the JAK2‐STAT3 pathway competing for this role, probably by deviating STAT3 for other functions. 
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Remarkably, pSTAT3 inhibitors had no effects on processes’ elongation in an APP overexpression 
background (Figure B1.3C, right graph). Hence, APP‐Gαo seem to be elongating processes by 
mechanisms that use signaling molecules other than STAT3. Concordantly, SE APP is the APP form 
that more strongly activates Gαo (Figure B1.1) and that leads to the greatest percentage of cells 
with pre‐neurites (Figure B1.2), but does not seem to have an impact in STAT3 activity (Figure 
B1.3A).  
Figure B1.3. APP and Gαo modulation of the STAT3 signaling pathway. A. WB analysis of STAT3 phosphorylation 
(pSTAT3) at 6h of transfection of the different Gαo and APP‐GFP cDNAs. The fold changes (FC) of the pSTAT3/STAT3 ratios 
were calculated, taking the ratios of the respective controls (V1 and V1:V2) as 1. B. Time‐course analysis of STAT3 
phosphorylation after 3, 4, 5 and 6h of transfection with Gαo, GαoCA and Gαo:Wt APP. STAT3 phosphorylation was 
compared to the transfection of the empty vector at each time‐point. N=4 C. Morphometric analyses in conditions of 
STAT3 inhibition with 10 μM of JAK2 inhibitor (AG490) and Src inhibitor (PP1), for 6h. ‘(pre‐)neurites’, pre‐neurites and 
neurites (processes longer than 20 μm). The ‘*’ symbol represents statistical significance relative to control. *, p<0,05; 
**, p<0,01; ***, p<0,001. 
 
The MAPK/ERK pathway could be a possible signaling pathway modulated by APP‐Gαo, since Gαo 
is able to activate ERK1/2 [29, 56–58], and activation of this pathway has also been associated with 
sAPP [18]. Further, JAK2 inhibition resulted in a dose‐dependent increase in ERK1/2 
phosphorylation (pERK1/2), supporting the role of this pathway (together with the STAT3 one) in 
Gαo‐mediated neurite elongation (Supplementary Figure B1.3D). However, after 6h of transfection 
we could not observe increases in pERK1/2 in any of the conditions analyzed (data not shown). APP‐
Gαo might be mediating early elongation via other effectors and/or ERK1/2 activation might be 
occurring even faster than STAT3, as observed elsewhere [59].  
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B1.4.4. APP modulation of late Gαo-induced neuritic elongation 
After confirming that APP and Gαo cooperate in a fast signaling mechanism that induces 
neuritogenesis, we further analyzed if this effect was maintained for a longer time period. SH‐SY5Y 
cells were thus transfected for 24h with Gαo alone or co‐transfected with the different APP‐GFPs, 
and morphological changes were evaluated and compared to control conditions (cells co‐
transfected with empty vectors) and with the results obtained at 6h of transfection (Figure B1.4). 
Control cells increase their number of processes with time, until what appears to be a maximum 
steady level common to most conditions at 24h (~5 processes/cell), but do not alter their number 
of neurites (Figure B1.4A‐C ‘Vector’). Cells overexpressing wild‐type Gαo showed no alterations in 
the number of processes per cell between 6h and 24h, but presented a significant higher 
percentage of cells with at least one pre‐neurite (48±2% at 6h vs 65%±4% at 24h of transfection, 
p<0.05) (Figure B1.4C). For the Wt APP:Gαo co‐transfection, the number of processes decreased 
with time (from 7.6±0.5 at 6h to 4.7±0.5 at 24h, p<0.05), to values similar to control and Gαo alone 
conditions (Figure B1.4A‐B), and the percentage of cells with pre‐neurites only slightly increased 
(Figure B1.4C). SE APP co‐transfection with Gαo had a similar effect than Wt APP: it decreased the 
number of processes per cell to the lowest value (from 5.7±01 at 6h to 4.1±0.3 at 24h of 
transfection, p<0.01), and a slight not significant increase in the percentage of cells with pre‐
neurites (compared to Gαo alone values). On the other hand, co‐transfection of Gαo with SA APP 
resulted in a slight increase in the number of processes (to Vector control levels) and in a significant 
increase in the percentage of cells with pre‐neurites (45±2% at 6h vs 74±8% at 24h of transfection, 
p<0.05). A take‐away message from these results is that after the initial burst of processes 
formation, Gαo overexpressing cells stop this mechanism in favor of elongating at least one process. 
At this time, the elongation effect is more favored by Gαo co‐transfection with SA APP.  
Following, the activation state of the STAT3 and ERK1/2 signaling pathways was also analyzed, and 
revealed a shift in their activity after 24h of APP and Gαo overexpression. While there is an 
activation of the STAT3 pathway at 6h of transfection (Figure B1.3), at 24h no increased activity 
over control cells was detected on the conditions tested (Figure B1.4D). On the other hand, an 
increase in the pERK/ERK ratio was observed for Gαo alone but more significant when Gαo was co‐
transfected with Wt and SE APP (2.1±0.2‐fold change for Gαo:Wt APP, p<0.05; and 3.3±0.3‐fold 
change for Gαo:SE APP, p<0.01) (Figure B1.4E). These pERK1/2 results correlate well with the ability 
of these two forms of APP to bind and activate Gαo (Figure B1.1). 
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Figure B1.4. Gαo:APP morphological and signaling effects after 24h of transfection. A. Microphotographs of SH‐SY5Y 
cells transfected during 24h with either the empty vector, Gαo, Gαo:Wt APP, Gαo:SA APP or Gαo:SE APP cDNAs. Gαo: 
red; APP: green. Scale bar: 20 μm. Morphometric analyses were performed and compared to the results obtained at 6h 
of transfection: B. Number of processes arising from the cell body; C. Percentage of cells presenting at least one pre‐
neurite or neurite, termed ‘(pre‐)neurite’ (processes longer than 20μm). D. Western blot analyses of STAT3 and E. ERK1/2 
phosphorylation levels at 24h of transfection. The fold changes (FC) of the pSTAT3/STAT3 and pERK/ERK1/2 ratios were 
calculated, taking the ratios of the empty vector (“Vector”) as 1. Symbols ‘*’ and ‘#’ represent a statistical significance 
relative to the empty vector and to the 6h of transfection, respectively. */#, p<0.05; **/##, p<0.01; ***/###, p<0.001. 
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Combined, these data suggest that part of the later Gαo‐induced neuritic elongation is mediated 
by ERK1/2 activation. Arguing in favour of this idea is the fact that inhibition of the Epidermal 
Growth Factor Receptor (EGFR) by PD168393 decreased the percentage of cells with processes 
longer than 20 m (and the number of processes), in both Gαo alone and Gαo:SE APP conditions 
(Supplementary Figure B1.3). Nevertheless, ERK1/2 can not be the only mechanism by which Gαo 
induces neuritic elongation, since the conditions where there is a highest level of ERK1/2 activation 
(Gαo:Wt APP and Gαo:SE APP) are not the ones where there is the highest number of cells with 
pre‐neurites (Gαo:SA APP). These indicate that ERK1/2 activation might be necessary but not 
sufficient for the maximum efficiency in neuritic elongation, and that other molecules can be into 
play, whose action is favored by the presence of SA APP. Also, the increased ERK1/2 activation 
detected in Gαo:Wt APP and Gαo:SE APP conditions might be playing a role in other cellular 
functions not addressed in this work [60–62].   
 
B1.4.5. Gαo and APP interplay on neuronal differentiation 
After studying the neuritogenic role of the APP‐Gαo in SH‐SY5Y cells, the effect of this complex was 
analyzed in rat cortical neurons. Primary neuronal cultures, differentiated for 3 days in vitro (DIV), 
were transfected for 24h with the Gαo cDNA, alone or together with the Wt and SE APP‐GFPs (or 
V1:V2 vectors, for control). Noteworthy, GαoCA transfection for 24h was highly deadly to neurons 
(data not shown). The 3‐4 DIV period was chosen due to its ongoing axonal growth and onset of 
dendritic outgrowth [63, 64]. At this time period, the longest neurite is the axon, practically negative 
for the Microtubule‐Associated Protein 2 (MAP2), while the much shorter dendrites are MAP2‐
positive (Supplementary Figure B1.4) and easy to identify. Cells analyzed were positive for the 
neuronalβIII‐tubulin marker (Figure B1.5‐6). 
Gαo was found abundant not only at the neuronal soma, but also at both dendrites and axons; it 
highly colocalized with transfected APP‐GFP at the soma and dendrites, and at the axonal proximal 
region (Figure B1.5A). Gαo overexpression increased dendritic outgrowth by ~50% (226±18 µm in 
V1:V2 to 372±33 µm, p<0.05), at the expense of axonal elongation (Figure B1.5A‐B; zoom‐ins). The 
number of primary neurites is maintained (6.6±0.6 for V1:V2 and 6.5±0.2 for Gαo). Gαo:Wt APP co‐
transfection had similar effects that Gαo in total dendritic outgrowth but, notably, it had a lesser 
detrimental effect on axonal elongation than Gαo alone (Figure B1.5A zoom‐ins, 5B). Both Gαo and 
Gαo:Wt APP increased the total length per dendrite (Figure B1.5C and B1.5D), but Gαo:Wt APP (and 
Gαo:SE APP)  increase dendritic branching at a higher extent  than  Gαo  alone  (Figure B1.5D), while  
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Figure B1.5. Gαo:APP neuritogenic effects in primary neurons. A. Microphotographs of rat embryonic cortical neurons 
at 4 days in vitro (DIV), a time point when the axon is highly elongated and the dendrites have started to elongate. At 3 
DIV, neurons were transfected for 24h with the empty vectors (‘V1:V2’), Gαo alone, Gαo:Wt APP‐GFP or Gαo:SE APP‐GFP 
cDNAs. APP‐GFP (green), Gαo (red); βIII‐tubulin (blue) is shown to confirm the cells as neurons. Zoom‐ins are shown at 
right to highlight neuronal morphology aspects and the proteins co‐distribution. Bar: 50 µm. EndgGαo, Endogenous Gαo; 
TfGαo, Transfected Gαo. B. Total dendritic and axon lengths (including branches) C. Average primary dendritic length D. 
Number of branches per primary dendrite. Symbols ‘*’ and ‘#’ represent a statistical significance relative to the empty 
vectors and to the Gαo alone, respectively. */#, p<0.05. For each condition, at least 50 different neurons were analyzed, 
from 2 different experiments. 
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slightly decreasing the number of primary neurites (6.2±0.4 for Gαo:Wt APP and 6.0±0.4 for Gαo:SE 
APP). SE APP co‐expression with Gαo significantly protected the axon from the effects of Gαo alone 
(658±7 µm for Gαo:SE APP vs 587±17 µm for Gαo, p<0.05). This higher commitment to elongation 
of the longest neurite occurred at the expense of the elongation of the novel dendrites (Figure 
B1.5A and B1.5B).  
These results show that the formation of new processes induced by Gαo and Gαo:Wt APP in SH‐
SY5Y cells is translated to 4 DIV neurons as an increase in dendritic elongation and branching. A role 
for the STAT3 pathway in this dendritogenic effect is suggested by WB analyses, that reveal 
increased phospho and total STAT3 levels only for Gαo and Gαo:Wt APP neurons, in accordance 
with their dendritogenic profile (Figure B1.6A).  
Pharmacological inhibition of the Src‐STAT3 pathway confirmed the involvement of this cascade in 
basal and in Gαo‐induced neuronal differentiation (Figure B1.6B). Exposure for 18h to the Src 
inhibitor PP1 decreased dendritic outgrowth in control (V1:V2) and in Gαo expressing neurons. 
Surprisingly, co‐expression of Gαo with APP (Wt or SE) in neurons protected these from the PP1 
negative effects and allowed dendritic elongation (Figure B1.6B). Interestingly, pERK2 (lower band 
in the immunoblot) and total ERK levels also remarkably increased in Gαo and Gαo:APP expressing 
neurons (Figure B1.6C). Nevertheless, the EGFR inhibitor PD168393 only decreased dendritic length 
in Gαo overexpressing neurons (and not in basal cells), with APP co‐expression again protecting 
from the detrimental effect (Supplementary Figure B1.5).  
Therefore, Gαo has a major role in dendritic elongation, mainly via Src‐STAT3 but also via EGFR. 
Interestingly, APP (particularly SE APP) co‐overexpression with Gαo protected neurites from the 
detrimental effects of Src‐STAT3 and EGFR inhibition (Figure B1.6A and Supplementary Figure B1.5). 
Taken together, when alone neuronal Gαo primarily acts via Src‐STAT3 and the ERK pathway, but 
when in the presence of APP, the Gαo:APP complex  might be acting on alternative routes to Src 
and EGFR or acting on these cascades downstream of Src/EGFR.  
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Figure B1.6. STAT3 and ERK1/2 signaling on APP-Gαo effects in primary neurons. A. Levels of phospho and total STAT3 
were determined in WB of neuronal lysates. B. Morphometric analysis of total dendritic and axonal lengths (including 
branches) upon Src inhibition. Neuronal cultures were transfected with V1:V2, Gαo, Gαo:Wt APP‐GFP and Gαo:SE APP‐
GFP cDNAs at 3 DIV, and exposed to 10 μM of the Src inhibitor in the last 18h. PP1, Src inhibitor; Ctrl, control unexposed 
neurons. For each condition, at least 50 different neurons were analysed, from 2 different experiments. C. Levels of 
phospho and total ERK1/2 were determined in WB of neuronal lysates. Left: graphical analyses; right: ERK1/2 blots. 
Symbols ‘*’ and ‘+’ represent a statistical significance relative to the empty vectors (‘V1:V2’) and to control without Src 
inhibitor (‘Ctrl’), respectively. */+, p<0.05. 
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B1.5. Discussion  
 
In the 90’s an interaction between APP and Gαo, the major neuronal G‐alpha subunit, was first 
described [20]. APP was discovered not only to bind but also to activate Gαo in a GPCR‐like manner 
[21, 31, 35]. This opened new perspectives to understand how APP, a protein central to the 
Alzheimer’s pathology, functions in the brain. It also advanced knowledge on Gαo, a much more 
elusive protein with potential roles in brain plasticity and memory [65, 66]. However, albeit their 
relevance in the brain, the role for the APP‐Gαo protein‐protein complex is still not clear. With our 
work, we further characterized how APP and Gαo interact and uncovered a new role for this 
interaction on neuritogenesis, a process very important to the human brain during developmental 
and regenerating conditions. Further, we have demonstrated that APP and Gαo activate signaling 
pathways (STAT3 and ERK1/2) central to various cellular processes and that may underlie other 
APP‐Gαo functions in cell proliferation and neuronal plasticity, for example. 
We first characterized the APP and Gαo physical interaction. Since Serine 655 phosphorylation 
induces backbone conformational changes on the APP C‐terminal Gαo‐binding pocket [20, 36], we 
hypothesized that it interfered with Gαo‐APP binding strength. In fact, Gαo strongly binds to and is 
activated by the phosphomimetic SE APP (Figure B1.1). APP was described to effectively activate 
Gαo when bound to 22C11. This anti‐APP N‐terminal antibody was suggested to mimic ligand‐
mediated APP activation and induce APP C‐terminal conformational changes that facilitated Gαo 
activation [21, 31]. We postulate that APP S655 phosphorylation has a similar conformational effect 
as 22C11 does, and that pAPP (APP S655 phosphorylated) is an “activated” form, mediating 
extracellular signaling to Gαo.  
Following, we investigated a role for the APP‐Gαo complex in neuritogenesis, a biological process 
to which both proteins had been previously associated in separate. Wt Gαo and Gαo CA constructs 
were used in an attempt to differentiate between active and non‐active Gαo effects. Nevertheless, 
in various neuritogenic parameters analyzed, there were no significant differences between Gαo 
and Gαo CA conditions. This was previously observed in F11 cells [28], and might result from both 
a higher amount of Gαo being available to be activated by its upstream interactors, and from the 
higher levels of Gαo compared to its endogenous negative regulators. These regulators belong to a 
class of proteins called Regulators of G‐protein Signaling (RGS) that accelerate the GTPase activity 
of Gα subunits, resulting in the conversion of GTP to GDP and G protein signaling termination [67–
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70]. Thus, a deficit in RGS control upon the overabundant Gαo could result in Gαo remaining in its 
GTP‐bound form for longer periods of time, behaving similarly to Gαo CA. 
Neuritogenesis involves both the formation and extension of cellular processes that eventually 
elongate into neurites. These two mechanisms appear to be competitive, and are regulated by 
different signaling cascades that share common molecular players [14]. Our results support this 
idea, showing that Gαo (and APP) plays a part on both phases of neuritogenesis.  
Phase I, the formation of new processes, occurs earlier and is promoted by Gαo and activation of 
the Src‐STAT3 signaling (Figure B1.2‐3). APP cooperates with Gαo in this function; however, its role 
does not seem to be restricted to activating Gαo since our results show that overexpressing both 
APP and Gαo increases the number of processes beyond the effect of overexpressing a 
constitutively active mutant of Gαo. One possibility relates to the cyclic nature of Gαo activity. In a 
case that Gαo is in a continuous cycle of activation/deactivation (such as when it is co‐expressed 
with Wt APP), this might maintain the formation of new processes for longer periods of time 
without eliciting a negative feedback response. Contrarily, a constant activation of Gαo (as in 
transfection with Gαo CA) might result in a faster/stronger feedback inactivation of the mechanism. 
A similar hypothesis has been raised by other authors regarding the function of some small 
GTPases; for example, the constitutively activation of Rac1 and Cdc42 gave opposite results to the 
established roles of these proteins in neurite outgrowth [71, 72].  A different study even showed 
that a GTP‐GDP cycle was essential for Cdc42 to induce neuronal polarity [73]. This hypothesis is 
corroborated by our results regarding STAT3 signaling, where Gαo overexpression leads to an 
apparent cyclic activation of Gαo that results in a cyclic activation of STAT3, while a constant 
activation of Gαo (Gαo CA) results in a longer period of STAT3 inactivity after an initial earlier 
activation (Figure B1.3). Alternatively, APP might be acting by targeting Gαo to zones of neurite 
formation and/or by potentiating Gαo binding to the Rap1GAP protein by bridging means, since 
binding of Gαo to Rap1GAP prevents this last from inhibiting Rap1 and leads to Src‐STAT3 activation 
[23, 24]. Indeed, our results corroborate the already published data that Gαo is able to activate the 
STAT3 pathway [23, 44], and adds that this signaling is primarily involved in the formation of new 
processes rather than in their elongation, with APP being able to modulate this event. APP may also 
function by bringing to the mix other neuritogenic molecules, such as GAP43, Reelin, and Rit. These 
proteins are known functional interactors of either Gαo or APP, and have all already been 
implicated in neuritogenesis [29, 53, 74–77], so APP and Gαo overexpression might act by bringing 
together a complex involving these proteins. 
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Phase II, the elongation phase, occurs after the formation of new processes, with the cell shifting 
its machinery to the elongation of at least one process. This mechanism occurs when Gαo is 
overexpressed and correlates with an increase in ERK1/2 activity (Figure B1.4).  These results are in 
continuity with previous studies showing that Gαo is not only capable of activating the ERK1/2 
pathway [56, 58] but that this pathway can translate Gαo neuritogenic effects [29]. This delayed 
activation of ERK1/2 signaling (no activitation detected at 6h of transfection, data not shown) has 
also been observed in mevastatin‐differentiated Neuro2a cells [78]. Moreover, ERK1/2 has already 
been associated with neurite elongation instead of neurite formation [79]. In this study, light‐
stimulation of the Raf/MEK/ERK signaling in PC12 cells resulted in a significant increase on neurite 
length accompanied by a decrease in the number of neurites formed. Hynds et al [80] also 
demonstrated that neurite initiation and elongation are two events regulated by separate signaling 
pathways. However, contrary to ours and to Zheng et al results [79], Hynds et al observed that 
inhibition of MEK blocked Rit‐induced ERK1/2 phosphorylation and consequent neurite initiation, 
but not elongation nor branching. Rit is a G protein that can function in neuritogeneis downstream 
NGF or Gαo [29, 81]. One explanation for these differences could arise from differences in ERK1 
and ERK2 functions. While our results show a preferentially increase in ERK2 phosphorylation (42 
kDa protein), Hynds et al paper show an equal increase in both ERK1 (44kDa protein) and ERK2 
phosphorylation. Either way, further analyses are required to fully comprehend the role of Gαo‐
ERK1/2 signaling in neurite outgrowth.  
APP role on this phase of neuritogenesis is not completely clear. Our results show that initially, APP 
co‐expression with Gαo can increase processes’ length, in a S655 phosphorylation dependent 
manner (Figure B1.2). However, this early effect did not correlate with an increase in either STAT3 
or ERK1/2 activation (Figure B1.3). Moreover, after 24h, SE APP further increased Gαo‐induced 
ERK1/2 activation but this did not result in a significant increase in neuritic elongation (Figure B1.4). 
This could mean that the initial increase in neuritic elongation could be occurring by either a faster 
activation of the ERK1/2 pathway not detected in our experiments, or by the participation of other 
neuritogenic molecules, similar to what might be happening during neurite formation. Of the 
aforementioned proteins that could play a role in this, GAP‐43 is a suitable candidate since it is able 
to activate Gαo in neuronal cells, leading to neurite outgrowth [75, 77], and it co‐localizes with APP 
in growing neurites during brain development, as well as in pathological conditions [82, 83]. 
Moreover, it has been shown that GAP‐43 can modulate GPCRs signal transduction [84]. This 
strengthens the hypothesis that GAP‐43 could do the same in an APP‐Gαo signaling pathway.  
GRIN1 is also a potential candidate for a role in this mechanism. Gαo is able to interact with GRIN1 
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in a pathway that leads to Cdc42 activation and culminates in neurite extension [22]. More recently, 
both GRIN1 and GAP‐43 were associated with a Gαo complex present in PC12 cells and rat cortical 
neurons [54]. This complex acted downstream of the α7 nicotinic receptor on the regulation of 
neural differentiation. While this model is still incomplete, with the signaling pathways acting 
downstream of Gαo remaining unknown, the existence of a complex between Gαo/GRIN1/GAP‐43 
in our model could also be possible, since both GRIN1 and GAP‐43 are expressed in SH‐SY5Y cells 
[85].  This does not exclude future research of other proteins involved in the APP‐Gαo signaling 
pathway, such as Rit [29] and Necdin [86], as well as the importance of APP proteolytic fragments, 
sAPP[18, 87] and AICD[88, 89], in APP‐Gαo induced neuritogenesis.  Nevertheless, one conclusion 
that we can take from our results is that APP can indeed cooperate with Gαo in the activation of 
the ERK1/2 pathway, with phosphorylation of S655 enhancing this effect. ERK1/2 activation seems 
directly involved in neuritogenesis since the use of an EGFR inhibitor decreased the proccesses’ 
length (Supplementary Figure B1.3). This has still to be further explored by using a MEK inhibitor, 
but Gαo has already been described to activate ERK1/2 by modulation of the Epidermal Growth 
Factor Receptor (EGFR) pathway [56], and a relationship between APP neuritogenic role, ERK1/2 
activation and EGFR activation state in SH‐SY5Y cells is being established in our lab  (data not 
published). Nevertheless, the ERK1/2 pathway is only part of the elongation mechanism, since SA 
APP was able to further elongate cells at 24h of co‐transfection with Gαo, and did not  increase 
pERK activation over Gαo (Figure B1.4). In our lab, we are also observing that SA APP is more 
associated to actin cytoskeleton remodeling in late neuritogenic phases (unpublished data). Per se, 
SA APP cannot elongate neurites over Wt or SE APP, but it might be favoring elongation in a Gαo 
overexpression background.  
Our data corroborate previous reports stating that the formation and elongation of processes are 
two competitive mechanisms. The ERK pathway would be primarily involved in the elongation of 
neurites [79], while other pathways as the Src‐STAT3 cascade are required for their genesis. Final 
evidence supporting this hypothesis of Gαo‐STAT3 signaling being involved in neurite 
formation/initiation and Gαo‐ERK1/2 signaling being involved in neurite elongation comes from the 
results with the JAK2 inhibitor. Inhibition of this kinase led to a slight decrease in the number of 
processes per cell while increasing the percentage of cells with at least one pre‐neurite (Figure 
B1.3), an effect that was Gαo‐dependent since there was no increase in control cells. Increased 
concentrations of the inhibitor enhanced this effect and was accompanied by an increase in ERK1/2 
phosphorylation (Supplementary Figure B1.2). While it is not clear what is the exact mechanism 
beyond JAK2 inhibition that leads to increased ERK1/2 activation, this gives strength to the dual role 
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of Gαo in neurite initiation and neurite elongation, and to the STAT3 and ERK1/2 signaling 
involvement in these neuritogenic phases.  
Finally, in differentiating neurons, Gαo main role seems to be in dendritogenesis, with its 
overexpression significantly increasing dendritic length, and having a negative effect on axonal 
elongation (Figure B1.5). This is in accordance with our (and other groups) data on neuritogenesis 
sharing molecular players both involved in neuritic initiation, elongation, branching, and thus 
competing. Wt APP maintains this Gαo dendritogenic effect, although partial shifting the focus from 
dendritic elongation to dendritic branching (Figure B1.5). STAT3 and ERK1/2 pathways are altered 
in Gαo and Gαo‐Wt APP conditions (Figure B1.6). However, while Src‐STAT3 and EGFR‐ERK1/2 are 
indeed involved in Gαo‐induced dendritogenic effects, as confirmed by their pharmacological 
inhibition, surprisingly APP co‐expression protected from the detrimental effects of these pathways 
inhibition (Figure B1.6). Hence, in neurons, APP might be either activating STAT3 and ERK1/2 via 
other means than Src and EGFR, or modulating other signaling pathways. Importantly, SE APP 
appears to be also very involved in elongation of longer or more stable neurites, as it was much less 
detrimental to axonal elongation (at the expense of decreasing its effect on dendritic arborization). 
In conclusion, we have demonstrated that Gαo and APP physically and functionally interact in an 
APP S655 phosphorylation mode. The APP‐Gαo complex has roles in both neuritic formation and 
elongation. Additionally, APP phosphorylation state and the orchestrated activation of the STAT3 
and ERK1/2 signaling pathways helps to determine the outcome of APP‐Gαo interaction [90, 91]. 
Importantly, the disruption of these signaling pathways could potential play a role on the 
involvement of the APP and Gαo proteins in Alzheimer’s Disease [92, 93]. Therefore, the 
characterization of the dual neuritogenic effects and signaling activation of Gαo, and the role of 
APP role on its modulation, not only sheds new light on the mechanisms of neuronal differentiation 
and physiology, but might also provide new groundwork to advance the knowledge on AD 
pathogenesis. 
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B1.7. Supplementary Material 
 
 
 
 
 
 
 
Supplementary Figure B1.1. Morphometric analysis of SH-SY5Y cells transfected with the different APP-GFPs for 6h. 
Number of processes arising from the cell body (left graph) and the percentage of cells presenting at least one pre‐neurite 
or neurite, termed ‘(pre‐)neurites’ (right graph) (processes longer than 20μm). ‘*’ represents a statistical significance 
relative to the empty vector. *, p<0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure B1.2. JAK2-STAT3 inhibition. A) Percentage of cells presenting at least one pre‐neurite or neurite, 
termed ‘(pre‐)neurites’ (processes longer than 20μm). Cells were treated with 10 µM of AG490 (“JAK2 inhibitor”) or left 
untreated (“Control”). B) and C) Effects of increasing concentrations of AG490 on Gαo‐induced neuritogenic effects. The 
percentage of cells with at least one pre‐neurite was accounted for (B) and the longest process of each cell was measured 
(C).  ‘*’ represents a statistical significance relative to the untreated cells (“control”). *, p<0.05; **, p<0.01; ***, p<0.001. 
D. Immunoblot of pERK levels in cells transfected with Gαo and treated with increasing concentrations of AG490. 
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Supplementary Figure B1. 3. EGFR inhibition in SH-SY5Y cells. SH‐SY5Y cells were transfected with the Gαo cDNA alone 
or both Gαo and SE APP cDNAs, and exposed to 10 M PD168393, an EGFR inhibitor. Morphometric analysis revealed 
that, in Gαo transfected cells, EGFR inhibition significantly reduced the percentage of cells with at least one (pre)‐neurite 
(processes longer than 20 m, including pre‐neurites and neurites) from 48±2% to 32±5%. In Gαo:SE APP‐expressing cells 
EGFR inhibition reduced it from 53±4% to 37±2% (p<0.05). The EGFR‐ERK1/2 pathway is thus important in Gαo and Gαo:SE 
APP‐induced neuritic elongation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure B1.4. Confirmation of the neuritic nature in 4 DIV neurons. 3DIV rat embryonic cortical neurons 
were transfected with empty vector (V2‐GFP) for 24h. At 4DIV, cells were fixed and immunolabeled for MAP2 (blue), a 
dendritic marker. Scale bar = 20 µm. Dendrites can be identified by a strong MAP2 signal (arrowheads), while the axon 
exhibits little to no MAP2 labelling (arrows).  
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Supplementary Figure B1.5. Impact of EGFR inhibition on APP-Gαo effects in primary neurons. B. Morphometric analysis 
of total dendritic and axonal lengths (including branches) upon EGFR inhibition. Neuronal cultures were transfected with 
V1:V2, Gαo, Gαo:Wt APP‐GFP and Gαo:SE APP‐GFP cDNAs at 3 DIV, and exposed to 10 μM of the EGFR inhibitor in the 
last 18h. PD168393, EGFR inhibitor; Ctrl, control unexposed neurons. For each condition, at least 50 different neurons 
were analysed, from 2 different experiments. Symbol ‘+’ represents statistical significance relative to control without 
inhibtor. +, p<0.05; ++, p<0.01. B. Representative microphotographs of the neuritogenic effects of EGFR inhibition. Gαo 
(red); APP and βIII‐tubulin (green); arrows, axon; arrowheads, dendrites. EndgGαo, Endogenous Gαo; TfGαo, Transfected 
Gαo. Scale bar = 50 µm.  
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B2.1. Abstract 
 
One of the mechanisms that cells use to control signaling responses is by regulating protein levels. 
This can be achieved either by modulation of gene expression or by modulation of protein 
degradation. Interaction between APP and Gαo has been under study for the last decades. Some 
potential crucial functions that have been attributed to this interaction include the (co)‐activation 
of signaling pathways involved in cell migration and neuronal differentiation. Nevertheless, it is not 
known how APP‐Gαo signaling is terminated. By using SH‐SY5Y neuroblastoma cells transfected 
with either APP or Gαo, we show that APP downregulates Gαo protein levels, and that this effect is 
dependent on APP phosphorylation at S655. Moreover, this downregulation occurs primarily via 
lysosomal degradation, in a mechanism that appears to involve chaperone‐mediated autophagy 
(CMA). Treatment of cells with pertussis toxin (PTX), a known inhibitor of Gαo, triggers Gαo 
proteasomal degradation under basal conditions, while also affecting APP protein levels, further 
indicating that control of APP and Gαo is interconnected. APP overexpression, in its turn, targets 
PTX‐inactive Gαo to a degradation pathway other than the proteasome, potentially CMA. The work 
here presented uncovers new mechanisms by which APP and Gαo protein levels are controlled, 
thus broadening our understanding of APP/Gαo signaling.  
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B2.2. Introduction 
 
Inside human cells, G protein signaling is widely used for many important cellular processes and is 
maintained under tight control. One of the mechanisms by which cells implement this control is by 
direct termination of their signaling. G proteins are mainly negatively modulated by a family of 
proteins called Regulators of G Protein Signaling (RGS) [1–3]. RGS bind to the α subunit of G proteins 
and increase their GTPase activity. This leads to the conversion of GTP to GDP, and subsequent 
recoupling of the Gα subunit with the βγ complex, thus terminating their intracellular signaling. 
Nevertheless, the targeting of G proteins to degradation is also a control mechanism used by cells 
[4]. Another mechanism by which cells implement this control is by modulating the protein levels 
of G proteins and their G‐Protein Coupled Receptors (GPCRs). Several GPCRs have already been 
described to suffer ubiquitination after their activation [1, 5]. For instance, both the β2‐Adrenergic 
receptor [6–8] and the chemokine receptor CXCR4 [9] are ubiquitinated upon activation, leading to 
the receptor’s internalization and trafficking to lysosomal degradation. GPCRs can also be subjected 
to proteasomal degradation, in a general mechanism by which cells eliminate misfolded receptors, 
that is not dependent on the receptor activation [10, 11]. Several lines of evidence show that 
various α‐subunits of heterotrimeric G proteins also suffer ubiquitination [12–14]. In rats, 
polyubiquitination of Gαi2 occurs after intense exercise, resulting in the α‐subunit being targeted 
to proteasomal degradation, a mechanism that is dependent on receptor activation [15]. G protein 
degradation also occurs as an effect of certain toxins. For instance, prolonged treatment with 
cholera toxin, a known activator of Gαs, leads to the down‐regulation of this α‐subunit [16, 17].   
The Gαo protein is the most expressed Gα subunit in neurons, though its main function in the brain 
it is still not clear. Several studies have indicated possible roles in neuronal differentiation and 
migration [18–23]. Some RGS proteins that act upon Gαo to control its activity have already been 
described [24–26], however, few is known regarding the regulation of Gαo protein levels. One study 
has shown that the protein levels of Gαo are controlled by its interaction with the heat shock 
protein 90 (hsp90) [27]. The authors demonstrated that the disruption of the Gαo‐hsp90 complex 
by incubating cells with Geldanamycin, a ligand of hsp90, led to a decrease of Gαo levels. 
Furthermore, this decrease occurred via degradation of Gαo by the proteasome [27].  As with other 
G proteins, certain toxins also affect the levels of Gαo. The Pertussis toxin (PTX) is known to inhibit 
Gαo by ADP‐ribosylating its C‐terminal [28], and treatment of LA‐N‐5 neuroblastoma cells with PTX 
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leads to reduced Gαo levels [29].  The consequence of this response, however, was not addressed 
in a Gαo signaling context.  
Our group has been studying Gαo signaling pathways, with a particular focus on Gαo neuritogenic 
functions and on Gαo cooperation with one of its interactors, APP (Amyloid Precursor Protein). APP 
is a type 1 transmembrane protein, mostly known for its role in the Alzheimer’s Disease (AD) [30–
32], but that also plays a part in neuronal differentiation and migration, as well as in cell survival 
[18–20, 33–37]. The interaction between APP and Gαo has been well documented, with APP being 
described to bind and activate Gαo, acting as a GPCR‐like protein [18, 38–40]. The outcome of this 
interaction, however, is still not completely clear. Initial studies showed that a mutated form of 
APP, present in Familial Alzheimer’s Disease, is able to increase Gαo activation when compared to 
Wild‐type APP, resulting in increased cell death [41, 42]. Further studies have shown that the APP‐
Gαo interaction could also have a role in Aβ‐induced toxicity [43, 44], thus complementing the idea 
that Gαo might have a central role in AD. A physiological role in cell migration has been implied to 
this interaction. Using an insect homolog of APP, APPL, researchers showed that inhibition of either 
APPL or Gαo resulted in erratic neuronal migration of enteric neurons in a Manduca sexta model 
[18]. They also demonstrated that APP acts upstream Gαo, similarly to a GPCR. In our studies on 
the nature of this interaction we have observed that APP interaction with Gαo leads to the 
activation of the STAT3 and ERK1/2 signaling pathways in neuroblastoma SH‐SY5Y cells, resulting in 
increased neuritogenesis (Chapter B1). Furthermore, we showed that this interaction is modulated 
by APP phosphorylation at Serine 655 (S655, APP695 isoform numbering), a residue of the YTSI 
sorting domain. Upon S655 phosphorylation, the YTSI domain changes its conformation, as well as 
the conformation of the downstream hydrophobic pocket, where Gαo binds [38, 45]. 
Phosphorylation of this residue was already associated by us with the control of APP trafficking. By 
using phosphomimicking mutants of APP (SA APP and SE APP) we have shown that phosphorylation 
of S655 directs APP trafficking to the secretory pathway, increasing the rate of APP cleavage to 
soluble APP (sAPP) [46].  Further, in the endo‐lysosomal pathway, APP S655 phosphorylation 
rescues APP from degradation by redirecting it to the trans‐Golgi network [47].  On the other hand, 
APP internalization from the plasma membrane in a unphosphorylated state targets it for lysosomal 
degradation [47, 48]. 
Since APP is able to activate Gαo in a GPCR‐like manner, while also being subjected to similar 
mechanisms of protein level’s control as GPCRs, this raises the hypothesis that the cell could be 
modulating APP‐Gαo interaction and signaling by tightly regulating their protein levels. The work 
presented here addresses the possible role of APP and its phosphorylation on the regulation of Gαo 
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levels, and investigates the potential for Gαo activity acting as a feedback mechanism affecting APP 
degradation. Finally, the degradation mechanisms involved in the modulation of the APP‐Gαo 
complex that might play an important role on the control of their functions are identified. 
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B2.3. Materials and Methods 
 
B2.3.1. Antibodies  
Primary antibodies used in Western Blot (WB) and Immunocytochemistry (ICC) assays: mouse 
22C11 monoclonal anti‐APP N‐terminus (Chemicon; WB‐1:250; ICC‐1:50); rabbit anti‐Gαo/GNAO1 
polyclonal (Upstate; WB‐1:5000; ICC‐1:250; Thermo; WB‐1:2000; ICC‐1:200); mouse anti‐LAMP2 
(abcam; ICC‐1:50); rat anti‐Hsc70 (kindly provided by Dr. Paulo Pereira; WB‐1:2000; ICC‐1:200). 
Secondary antibodies used: horseradish peroxidase‐labeled goat antibodies (GE Healthcare) for 
enhanced chemiluminescence (ECL) detection; Alexa Fluor 405, 488, 568 or 594‐conjugated goat 
antibodies (Molecular Probes) for ICC analysis. Antibodies were prepared in 3% BSA in phosphate 
buffer saline (PBS) for ICC, and in either 3‐5% milk or BSA for WB, per the manufacturers’ 
instructions.  
 
B2.3.2. Chemicals 
Chloroquine (CQ) (N4‐(7‐Chloro‐4‐quinolinyl)‐N1,N1‐dimethyl‐1,4‐pentanediamine diphosphate 
salt; Sigma) was used at a concentration of 50 μM to inhibit lysosomal degradation [47]. 
Proteasomal degradation was inhibited by using Lactacystin (Lac; Millipore) and Proteasome 
Inhibitor I (PSI; Millipore), each at 10 µM [27, 49]. Cells were incubated with either a proteasomal 
or a lysosomal inhibitor for 18h before being subjected to ICC, or collected for WB analyses. 
Pertussis toxin (PTX; Calbiochem) was used at a concentration of 100 ng/mL to inhibit Gαo [50].  
 
B2.3.3. Gαo and APP cDNA constructs 
Wild‐type and constitutively active cDNAs of human G‐protein alpha o, isoform A, (Gαo and GαoCA, 
respectively), cloned into a pcDNA3.1+ vector, were obtained from Missouri S&T cDNA Resource 
Center. The GαoCA cDNA has a Q205L mutation that hinders its GTPase activity [51]. The empty 
pcDNA3 vector (Invitrogen) was used to control Gαo transfections. APP cDNAs (human isoform 
695), Wt and Serine 655 (S655) point mutated to Alanine (SA) or to Glutamate (SE), already N‐
terminally fused to GFP (Green Fluorescent Protein) were previously constructed . Due to the amino 
acids characteristics, S655E and S655A mimic a constitutively phosphorylated and 
B2. Regulation of Gαo and APP 
University of Aveiro  131 
dephosphorylated S655 state, respectively. The pEGFP‐N1 empty vector (Clontech) was used to 
control the APP‐GFP cDNAs transfections [47, 52–54]. 
 
B2.3.4. SH-SY5Y cells culture and transfection 
Human neuroblastoma SH‐SY5Y cells (ATCC CRL‐2266) were grown in Minimal Essential Medium 
(MEM) supplemented with F‐12, 10% FBS, 0.5 mM L‐glutamine, 100 U/ml penicillin and 100 mg/ml 
streptomycin (Gibco, Invitrogen). Cells were maintained at 37°C/5% CO2. APP‐GFP (Wt, SA, and SE) 
and Gαo (Wt, CA) cDNAs were transiently transfected using TurboFect (Fermentas), according to 
the manufacturer. After 24h of transfection, cells were either harvested with 1% SDS for WB 
analyses, or fixed with 4% paraformaldehyde for ICC.  
 
B2.3.5. Immunocytochemistry, microscopy and image software 
Fixed cells were permeabilized (0.2% Triton), washed with PBS, blocked (3% BSA/PBS), and 
incubated with primary antibodies for 2h. Following 3 washes with PBS, cells were incubated with 
secondary antibodies for 1h, washed with PBS and deionised water, and mounted onto glass slides 
(Vectashield mounting medium with or without DAPI; Vector Labs). Microphotographs were 
acquired on a LSM 510 META confocal microscope (Zeiss), as before [47], and image analysis was 
carried out using ImageJ Fiji [55]. For the co‐localization analysis, z‐stacks of individual cells were 
acquired by confocal microscopy, and analyzed with the JaCoP plugin [56] to obtain the percentage 
of proteins co‐localization, using the Manders’ method.  
 
B2.3.6. SDS-PAGE and Western Blot  
Total protein mass‐normalized (BCA protein assay; Pierce) cell aliquots were subjected to SDS‐PAGE 
and WB. Ponceau‐S staining of the transferred proteins was used as loading control, as an 
alternative to actin or tubulin, since these proteins vary with our experimental conditions [19, 57]. 
For this, nitrocellulose membranes were immersed in Ponceau‐S solution (Sigma‐Aldrich; 0.1 % 
[w/v] in 5% acetic acid), further washed with distilled water, and scanned (GS‐800 calibrated 
densitometer, Bio‐Rad). Following their wash with TBS‐T, membranes were subject to WB analysis. 
Briefly, membranes were blocked with 5% milk or BSA in TBS‐T, incubated with primary antibodies 
for 2h or overnight, and with horseradish peroxidase‐linked secondary antibodies for 2h, and 
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subject to ECL detection. X‐ray films (Amersham) were scanned and protein bands quantified with 
the Quantity One 1‐D Analysis Software (Bio‐Rad).  
 
B2.3.7. Statistical analysis 
Data is expressed as mean ± SEM (standard error of the mean) of at least three different 
experiments. Statistical analysis was conducted by one‐way ANOVA followed by the Tukey test, or 
by one‐sample t‐test, using the GraphPad Prism® software. Three levels of significance were used, 
depending if the p‐value was under 0.05, 0.01 or 0.001.  
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B2.4. Results 
 
B2.4.1. APP and Gαo regulation of each other’s protein levels depends on the APP 
phosphorylation and Gαo activation states 
Our previous work has focused on characterizing the APP‐Gαo interaction, as well as characterizing 
the neuritogenic role of this complex (Chapter B1). When analyzing the distribution of these two 
proteins in neuroblastoma SH‐SY5Y cells, we detected a distinct contrast between APP and Gαo 
labeling. In cells where APP was present in high quantities Gαo protein levels were low, and cells 
with high levels of Gαo had low levels of APP (Figure B2.1). While some cells presented low levels 
of both proteins, there was an almost complete absence of cells whit high levels of both proteins. 
 
Figure B2.1. APP and Gαo distribution in SH-SY5Y cells. Endogenous Gαo (red) and APP (green) immunolabelled in SH‐
SY5Y cells. Nuclei were labelled with DAPI (blue). The population includes cells expressing high levels of APP and low levels 
of Gαo (arrows) and cells expressing high levels of Gαo and low levels of APP (arrowheads). Scale bar = 20µm. 
 
Since APP has been described has a GPCR‐like protein [58], we hypothesized that its interaction 
with Gαo could be subjected to similar regulatory mechanisms that control GPCR signaling, mainly 
the regulation of the signaling protein’s levels. To test this hypothesis, we first transfected SH‐SY5Y 
cells for 24h with increasing amounts of either Gαo or APP‐GFP cDNAs (Figure B2.2). Since our 
previous work had already described a role of Serine 655 (S655) phosphorylation on APP‐Gαo 
interaction, cells were also transfected with two phosphomutants mimicking either S655 
phosphorylation (SE APP‐GFP) or S655 dephosphorylation (SA APP‐GFP). Transfection of low and 
medium amounts of Gαo cDNA had no effect on APP protein levels, as the transfection of a high 
amount of Gαo cDNA led to a slight increase in APP levels, although not significant (1.16±0.13‐fold 
change over the empty vector at the maximum 2 g cDNA/10 cm2 dose) (Figure B2.2A – left blots 
and light gray graph). A Gαo cDNA mutant that expresses a constitutively active form of Gαo (Gαo 
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CA) was also transfected. Interestingly, while transfection of a low amount of Gαo CA resulted in a 
non‐significant increase in APP protein levels (1.13±0.24‐fold change over the empty vector), 
transfecting higher concentrations led to a decrease in APP levels (0.80±0.14‐fold change over the 
empty vector at the maximum 2 g cDNA/10 cm2 dose) (Figure B2.2A – right blots and black graph). 
In both cases there was a high variability between experiments.  
Figure B2.2. Effects of APP and Gαo on each other’s protein levels. A. Effects of Gαo overexpression on endogenous APP 
protein levels, by transfection of SH‐SY5Y cells for 24h with increasing amounts of Gαo or GαoCA (constitutively active 
Gαo Q205L mutant). Transfection of 2 µg of pcDNA3, the Gαo empty vector, was used as control. N=5. B. Effects of APP 
overexpression on endogenous Gαo protein levels, by transfection of SH‐SY5Y cells for 24h with increasing amounts of 
APP‐GFP cDNAs: wild‐type APP (Wt APP) or APP phosphomutants mimicking S655 dephospho‐ or phosphorylation state 
(SA APP and SE APP, respectively). Transfection of 2 µg of pEGFP‐N1, the APP empty vector, was used as control. N=5. 
Symbol ‘*’ represents statistical significance relative to the transfection of the empty vector. *, p<0.05. 
 
On the other hand, overexpressing increasing amounts of SA APP‐GFP did produce a consistent 
effect on endogenous Gαo (Figure B2.2B). Overexpression of a high concentration of SA APP (2 µg 
cDNA) led to a significant decrease in Gαo protein levels (0.77±0.06‐fold change over transfection 
of empty vector, p<0.05), while neither Wt nor SE APP had a significant impact on Gαo levels. This 
is an interesting result, since our previous data showed that S655 phosphorylation is important for 
APP interaction with Gαo, and its activation. Indeed, while every form of APP‐GFP can bind Gαo, 
the dephosphomimicking mutant SA APP is the least efficient in binding and activating Gαo (Chapter 
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B1). These results show a correlation between high amounts of an ‘inactive’ APP form (in terms of 
inefficiency to bind/activate Gαo) and a decrease in Gαo protein levels.   
 
B2.4.2. Proteasomal and lysosomal Gαo degradation 
Degradation of Gαo seems to be an important mechanism in regulating its activity in neuronal cells. 
After observing the above effect of SA APP on Gαo levels, we decided to focus on the mechanisms 
by which APP constitutive dephosphorylation was decreasing Gαo protein levels.  
Gαo high neuronal levels have been reported as a result of not only increased synthesis of the 
protein but also due to a significant increase in its half‐life (from 28h to 58h) during differentiation 
of N1E‐115 neuroblastoma cells [59]. Notwithstanding its low degradation rate, Gαo has already 
been described as a substrate of proteasomal degradation [27], and SA APP could be targeting Gαo 
to proteasomal degradation. We transfected cells with SA APP and treated them with two different 
proteasome inhibitors, Proteasome Inhibitor I (PSI) and Lactacystin (Lac) (Figure B2.3). 
Unexpectedly, treatment with both proteasome inhibitors led to a decrease in Gαo protein levels, 
instead of the expected increase (Figure B2.3B). This decrease was especially pronounced for cells 
expressing the empty vector (control cells), with Gαo in SA APP cells being less affected by PSI and 
Lac due to their already decreased Gαo protein levels.  
 
Figure B2.3. Effects of proteasome inhibition on Gαo protein levels. SH‐SY5Y cells were transfected with SA APP or its 
empty vector (pGFP, as control), and treated with two different proteasome inhibitors, Proteasome Inhibitor I (PSI) and 
Lactacystin (Lac), at 10 µM each. A. Immunoblots of Gαo and APP, and Ponceau staining as the loading control. B. 
Variations in Gαo protein levels were evaluated by assessing Gαo signal in each condition and comparing it to the signal 
in cells transfected with the empty vector and left untreated (“Vector – Ctrl”; dashed line). The ‘*’ symbol represents 
statistical significance of cells treated with PTX relative to the untreated condition (dashed line). *, p<0.05. N=4. 
 
These results suggest that either 1) mass‐normalized WB is not able to detect differences in protein 
levels of proteins with low degradation rates such as Gαo, under proteasome inhibition conditions, 
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2) that Gαo is degraded by the proteasome in altered conditions but not in basal cellular conditions, 
or 3) Gαo is being downregulated by other mechanisms. To gather some clues we analyzed Gαo co‐
localization with endogenous APP and the different APP forms (Figure B2.4).  Both Gαo and Gαo CA 
forms colocalized with endogenous APP at the Golgi region, where APP is abundant, and at the 
plasma membrane (PM). Gαo also co‐localized with APP at small cytoplasmic vesicles, more than 
Gαo CA, which is more enriched at the PM and the Golgi (Figure B2.4A). In APP‐GFP transfected 
cells (Figure B2.4B), endogenous Gαo co‐localizes with SA APP mainly in the cytoplasm (Golgi area 
and cytoplasmic vesicles), while its co‐localization with SE APP occurs almost exclusively in cellular 
processes, with less Gαo being present in the cytoplasm. Co‐localization with Wt APP is 
intermediate to these two, occurring at all these subcellular regions.  
Figure B2.4. Gαo and APP colocalization in SH-SY5Y cells. A. Cells were transfected with Gαo or Gαo CA (red) and 
endogenous APP (‘endg APP’) was detected by immunocytochemistry (ICC) means (22C11 antibody, green). B. Cells were 
transfected with the Wt, SA or SE APP‐GFP cDNAs (green) and endogenous Gαo (‘endg Gαo’) was detected by ICC means 
(red). DAPI was used to counterstain the nuclei (blue). Scale bar: 10 µm. PM, plasma membrane; Golgi R.. Golgi region, 
where APP is concentrated; Process, cellular projection, including its plasma membrane where both proteins co‐localize. 
 
Taken together, these results and the ones above on Figure B2.2 on higher effects of active Gαo on 
APP levels, and SA APP on Gαo levels, suggest a degradation route where phosphorylated APP 
activates Gαo, potentially near the PM, and that upon APP dephosphorylation both proteins are 
targeted to degradation. Given that SA APP endocytosed from the PM is preferentially degraded by 
the lysosome (while SE APP is not) [47, 48], we subsequently investigated if Gαo could be degraded 
by the lysosome. To test if the SA APP trafficking could also be leading Gαo to degradation, we 
inhibited the lysosome with Chloroquine (CQ) in cells overexpressing the three APP‐GFP species 
and monitored Gαo protein levels through western blot (WB) (Figure B2.5).  Confirming our 
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hypothesis, a small amount of Gαo (≈20%, as in Figure B2.3) was recovered in SA APP expressing 
cells (1.22±0.07‐fold change, p<0.05) when lysosomal degradation was inhibited with CQ (Figure 
B2.5A). This did not occur for the other conditions (Vector, Wt and SE APP). Indeed, similar to the 
results of the proteasomal inhibition, there was even a slight (although not significant) decrease in 
Gαo levels when the lysosome was inhibited in Wt and SE APP overexpressing cells. Co‐localization 
of Gαo with LAMP2, a lysosomal marker, in basal conditions, also corroborates the CQ results 
(Figure B2.5B). Gαo co‐localization with LAMP2 is generally low but significantly higher in SA APP 
transfected cells when compared to Wt and S655E APP (5.6±0.8%, p<0.05 vs ~3.3% for Wt and SE 
APP). In the same cells, SA APP also co‐localized more with LAMP2 than Wt and SE APP, confirming, 
as expected, that S655 dephosphorylation increases APP targeting to the lysosome.  
Figure B2.5. APP and Gαo degradation in lysosomes. A. Western blot and quantitative analysis of Gαo protein levels 
when in SH‐SY5Y cells transfected with empty vector, Wt, SA, or SE APP (APP‐GFP constructs), and treated with 50 µM of 
chloroquine (CQ). Ponceau‐S staining was used as loading control. Variations in protein content were evaluated by 
assessing Gαo signal in each V/APP condition treated with CQ (“+”) and comparing it to the respective condition without 
CQ (“‐”). ‘*’ represents statistical significance relative to the untreated condition (dashed line), and “#” represents 
statistical significance relatively to Wt APP.  */#, p<0,05. N=3. B. Maximum intensity projections of Z‐stacks from SH‐SY5Y 
cells transfected with pEGFP‐N1 vector (“Vector”) and APP‐GFP (Wt, SA, SE), and immunolabeled for Gαo (red) and the 
lysosomal marker LAMP2 (blue). Scale bar = 2 μm. Graph: percentage of co‐localization of endogenous Gαo and APP 
proteins with LAMP2 (‘Gαo:LAMP2’ and ‘GFP:LAMP2’, respectively), quantified using the Manders’ method.  A minimum 
of 30 z‐stacks from SH‐SY5Y cells were analyzed for each condition. Symbols * and # represent a statistical significance 
relative to the empty vector and Wt APP, respectively. */#, p<0.05; **/##, p<0.01; ***/###, p<0.001.  
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B2.4.3. Chaperone-mediated autophagy as a potential mechanism of Gαo control 
Taking together the above results suggest that SA APP decreases Gαo levels in a mechanism 
involving Gαo targeting to lysosomes, alone or combined with SA APP. Besides Serine 655, APP 
targeting to the lysosome is also regulated by an APP “KFERQ” targeting motif. This motif is an 
essential component of chaperone‐mediated autophagy (CMA), also being called CMA‐targeting 
motif [60, 61], and it has already been reported that deletion of the APP’s KFERQ‐like motif results 
in a decrease of APP co‐localization with the lysosome [62]. Since no data exists linking Gαo and 
lysosomal degradation, we first tried to identify possible KFERQ motifs in the Gαo amino acid 
sequence. Considering the properties that a sequence must comply to be considered a potential 
KFERQ motif [60, 61], we have identified the 173QDILR177 sequence has a KFERQ‐like motif (Figure 
B2.6).  
Figure B2.6. Presence of lysosomal-targeting motifs in the Gαo sequence. The 173QDILR177 sequence (green) was 
identified as a potential KFERQ‐like motif. A “KFERQ” motif is a pentapeptide consisting of a glutamine in either side of 
the motif, a positively and a negatively charged amino acid, a hydrophobic amino acid, and a fifth amino acid that can 
either be positively charged of hydrophobic [60, 61]. By using the ELM resource [63], we also identified the 33DVKLL37 
sequence (blue) as a putative Endosome‐Lysosome‐Basolateral sorting signal, and the 231YDQV234 sequence (gray) as a 
putative tyrosine‐based sorting signal. 
 
By using the ELM resource [63], the 33DVKLL37 sequence was identified as a putative Endosome‐
Lysosome‐Basolateral sorting signal. This motif, however, is mostly associated with the sorting and 
trafficking of transmembrane receptors to the endosome and lysosome and so its presence in a G 
protein might not be relevant [64]. The 231YDQV234 sequence was also identified as a putative 
tyrosine‐based sorting signal, which mediates intracellular trafficking through the binding to 
Adaptor Proteins (AP) [65, 66]. Interestingly, a version of this motif is also present on APP, the 
653YTSI656 sequence, which includes Serine 655 [46, 67]. 
The targeting of KFERQ‐containing proteins to the lysosome occurs through their interaction with 
the Hsc70 protein (Heat shock cognate protein 70). Cytosolic Hsc70 recognizes and binds to 
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cytosolic KFERQ‐containing target proteins, and mediates their lysosomal uptake via a lysosomal 
hsc70 counterpart and LAMP2 [61, 68]. To further validate a possible role of CMA in Gαo control, 
Gαo co‐localization with Hsc70 in SH‐SY5Y cells was investigated (Figure B2.7A).  
 
Figure B2.7. Gαo and Hsc70 co-localize in SH-SY5Y cells. SH‐SY5Y cells were transfected for 24h with pEGFP‐N1 empty 
vector (‘Vector’), Wt APP‐GFP (‘Wt APP’) and SA APP‐GFP (‘SA APP’) (green). A. Maximum intensity projections of Z‐stacks 
from SH‐SY5Y cells immunolabelled for Gαo (blue) and Hsc70 (red). For each condition, a region of interest (ROI) was 
digitally amplified, showing either the combination of Gαo and Hsc70 labeling (upper ROI) or a combination of Gαo, Hsc70, 
and APP (lower ROI). Scale bar = 5 µm. B. Percentage of co‐localization of Gαo and Hsc70 signals, quantified using the 
Manders’ method. A minimum of 25 z‐stacks from SH‐SY5Y cells were analyzed for each condition. “#” represents a 
statistical significance relative to Wt APP. #, p<0.05 
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Gαo had a very interesting juxtaposed co‐localization with Hsc70 in small vesicles/puncta 
throughout the cytosol, including near the membrane (Figure B2.7A). As expected, co‐localization 
between both proteins increased when SA APP was overexpressed; microphotographs reveal what 
appears to be a higher merge of the Hsc70/Gαo signals in these cells (Figure B2.7A ROIs and B2.7B). 
Nevertheless, even though the co‐localization between Gαo and Hsc70 changed with APP 
expression, the three proteins were rarely detected together (Figure B2.7A, arrows).  
The correlation between Gαo increased degradation in SA APP‐overexpressing cells and its 
increased localization with Hsc70 points to CMA as a possible regulatory mechanism of Gαo levels. 
Still, further tests need to be conducted in order to verify if Gαo interacts directly with Hsc70, and 
if this potential interaction is required for the SA APP‐induced Gαo degradation.  
 
B2.4.4. Effect of Gαo inhibition on Gαo and APP protein levels 
As aforementioned, the effect of APP on Gαo levels seems to be dependent on its ability to first 
bind and activate Gαo. To test this hypothesis, we treated cells overexpressing the different APP‐
GFPs with Pertussis Toxin (PTX), a known inhibitor of Gαo/i proteins. ADP‐ribosylation by pertussis 
toxin blocks G protein interaction with GPCRs [28], and it has already been described to hinder Gαo 
activation by APP [33, 38]. SH‐SY5Y cells were transfected with 2 µg of each APP construct or with 
an empty vector and, after 6h of transfection, PTX was added to the cell media for additional 18 
hours. Gαo successful inhibition can be confirmed by observing its slower migration through the 
SDS‐PAGE (Figure B2.8A, arrows), a phenomenon previously described as a consequence of ADP‐
ribosylation [69].  
Analysis of Gαo protein levels after PTX treatment showed a significant decrease when compared 
to cells left untreated, both in cells overexpressing the empty vector as well as in cells 
overexpressing APP (Figure B2.8A). Moreover, there were no significant differences in Gαo 
reduction levels between the different forms of APP (0.60±0.04‐fold change for Wt APP, 0.62±0.06‐
fold change for SA APP, and 0.57±0.03‐fold change for SE APP). A similar reduction had already been 
reported in other type of neuroblastoma cells, LA‐N‐5 cells; however, no specific mechanism has 
been described to explain this downregulating effect [29].  
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Figure B2.8. Impact of PTX treatment on Gαo and APP protein levels. SH‐SY5Y cells were transfected with 2 µg of either 
pEGFP‐N1 empty vector or the Wt, SA or SE APP‐GFP cDNAs. After 6h of transfection, PTX was added to the cell media to 
a final concentration of 100 ng/mL, for additional 18 hours. Variations in protein content were evaluated by assessing A. 
Gαo and B. APP protein levels in PTX treated cells (“+”) compared to the respective condition without PTX (“‐”). The ‘*’ 
symbol represents statistical significance relative to the untreated condition (dashed line). *, p<0,05; **, p<0,01; ***, 
p<0,001. N=6. Of note, ADP‐ribosylation by PTX results in a slower migration of the Gαo protein through the SDS‐PAGE 
gel (arrows in the immunoblot).  
 
The APP protein levels were also analyzed after PTX treatment (Figure B2.8B). While endogenous 
APP did not seem to be affected by PTX (1.03±0.13‐fold change for Vector), both exogenous Wt and 
SE APP suffered significant decreases with PTX treatment (0.66±0.08‐fold change for Wt APP, 
p<0.01; 0.84±0.05 for SE APP, p<0.05). SA APP also decreased with PTX treatment, although not 
significantly (0.89±0.11‐fold change). It is important to notice that in most experiments performed 
Wt APP transfection efficiency was lower than SA and SE APP (Figure B2.8B, APP immunoblot). 
These differences of transfection could be a factor playing in APP response to PTX treatment, and 
thus explain why Wt APP is more affected than the APP phosphomutants. Nevertheless, the data 
indicates a correlation between S655 phosphorylation and PTX effect on APP levels.  
Taking together, these results offer two new pieces of information regarding the manner APP and 
Gαo are regulated: a) inhibition of Gαo causes a reduction in its protein levels that is independent 
of APP expression and/or phosphorylation state; and b) inhibition of Gαo triggers a concomitant 
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downregulation of APP protein levels, a process more dependent on the APP S655 phosphorylation 
status. In turn, it also opens several questions, such as which mechanisms are behind these 
alterations in protein levels.  
To try and answer this question, the role that proteasomal degradation could be playing in Gαo and 
APP decrease in response to PTX treatment was addressed. SH‐SY5Y cells transfected with the 
different APPs were treated with PTX in combination with the proteasome inhibitor Lactacystin 
(Lac), and compared to cells treated with PTX alone (Figure B2.9). Evaluation of Gαo levels revealed 
that the Gαo decrease in PTX control cells (transfected with empty vector) was partly reversed by 
the proteasome inhibition (Figure B2.9A‐B and Supplementary Figure B2.1A). However, this effect 
was lost in cells overexpressing APP. Regarding APP, Lac treatment significantly increased 
transfected APP levels, even past control levels (Figure B2.9A and B2.9C, and Supplementary Figure 
B2.1B). This pronounced effect indicates that proteasomal inhibition leads to the accumulation of 
overexpressed APP (mainly immature APP) which would otherwise be targeted to proteasomal 
degradation to control APP cellular levels [70]. Based on this result, however, we cannot determine 
if PTX effect on Wt and SE APP protein levels is a result of increased proteasomal degradation of 
these proteins. 
This data indicates that, under basal conditions, Gαo inhibition by PTX triggers its degradation 
through the proteasome. Under an APP overexpression background, however, inhibited Gαo 
molecules are also downregulated by other routes. Further testing will be necessary to comprehend 
APP role in this effect. Since we have detected a link between APP overexpression and Gαo 
CMA/lysosomal degradation (Figure B2.5‐7), this pathway is a potential promising candidate.  
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Figure B2.9. Effect of proteasome inhibition on PTX treatment. SH‐SY5Y cells were transfected with 2 µg of either pEGFP‐
N1 empty vector or the Wt, SA or SE APP‐GFP cDNAs. After 6h of transfection, PTX was added to the cell media to a final 
concentration of 100 ng/mL, for additional 18 hours. To test the role of the proteasome on PTX‐induced degradation, the 
proteasome inhibitor Lactacystin (Lac) was added to cells in combination with PTX. A. Immublots of Gαo and APP; 
Ponceau staining was used as loading control. B-C. Variations in Gαo and APP protein content were evaluated by 
comparing cells treated with PTX (“PTX”), or PTX in combination with Lac (“PTX+Lac”), to the respective control condition 
without PTX (dashed line). The ‘*’ symbol represents statistical significance of cells treated with PTX relative to the 
untreated condition (dashed line). The “#” symbol represents statistical significance of cells treated with PTX+Lac relative 
to PTX alone. */#, p<0.05; **/##, p<0.01; ***/###, p<0.001. N=3.  
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B2.5. Discussion 
 
The interaction between Gαo and APP has been a challenging subject. It is known that APP is able 
to bind and activate Gαo [38, 40], however, the physiological role that this interaction plays in the 
human brain is still unclear [71]. Moreover, the mechanisms that regulate this interaction inside 
the cell have remained unexplored. The work presented here revealed that APP and Gαo protein 
levels can be controlled reciprocally. 
Previous work conducted by us (Chapter B1) showed that the APP’s ability to bind and activate Gαo 
is enhanced by APP phosphorylation at Serine 655. Our results presented here show that APP 
(de)phosphorylation also has an impact on Gαo protein levels. Overexpression of an APP mutant 
mimicking S655 constitutive dephosphorylation led to the reduction of Gαo protein levels through 
lysosomal degradation (Figure B2.2 and Figure B2.5), while inhibition of proteasomal degradation 
did not recover Gαo levels (Figure B2.3). This is surprising, since the only report of Gαo degradation 
explores Gαo proteasomal cleavage [27]. Although unexpected, there have been reports of other 
G proteins being degraded through the lysosome [72, 73], making it more plausible that APP could 
be targeting Gαo to this degradation pathway.   
Even though our experiments showed no Gαo recovery upon proteasomal inhibition, this pathway 
should not be completely ruled out in the control of APP/Gαo signaling. The further decrease in 
Gαo levels detected upon proteasomal inhibition could be an artifact from the mass‐normalized 
Western Blot samples. Since proteasomal inhibition might lead to the accumulation of mainly 
proteins with a fast turnover [74], proteins with a slow turnover, such as Gαo, might have reduced 
relative abundance in the loaded sample, even if being affected by the proteasome. Other works 
have found Western blot unreliable in the study of proteins changes after proteasomal inhibition 
[75]. One way of overcoming this issue might be to normalize the Western Blot samples to the 
number of cells rather than to the total protein, or to use immunofluorescence to evaluate protein 
expression in each condition [76].  
The decrease of Gαo protein levels upon proteasome inhibition could also be a result of increased 
protein degradation by other pathways. As described by us, Gαo is subjected to lysosomal 
degradation when SA APP is overexpressed. Since SA APP levels greatly increase upon proteasomal 
inhibition (Figure B2.3), this could result in an increased Gαo targeting to the lysosome. This could 
also explain why APP overexpression blocks Gαo recovery upon treatment with PTX and Lactacystin 
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(Figure B2.9). However, since Gαo levels are also downregulated when cells are transfected with 
the empty vector and treated with Lactacystin (Figure B2.3), or endogenous APP also highly 
increases, or a different/additional mechanism by which Gαo is being led to degradation is probably 
in play. There are reports that proteasome inhibition might lead to activation of autophagy 
mechanisms [77, 78], so a closer look into this process might help explain Gαo decreased 
expression. 
Our work unraveled a new potential way by which Gαo can be targeted to degradation, the 
chaperone‐mediated autophagy (CMA) pathway. Contrary to the more classical view of autophagy, 
where organelles and other membranar compartments containing different types of proteins are 
fused to lysosomes, resulting in the degradation of their contents [79], CMA consists on the 
targeting of specific cytosolic proteins to the lysosomes. Proteins with KFERQ motifs, also known as 
CMA‐targeting motifs, are recognized by Hsc70 and then targeted for lysosomal degradation [61]. 
Our findings show that not only does Gαo possess a KFERQ‐like motif (Figure B2.6), but also that SA 
APP overexpression increases Gαo co‐localization with Hsc70 (Figure B2.7), giving strength to the 
hypothesis that Gαo can be degraded through CMA. Nevertheless, further testing is needed to 
demonstrate this pathway. The presence of a KFERQ motif does not necessarily implies that Hsc70 
can recognize it, it also needs to be exposed to the protein exterior. A look into Gαo’s 3D structure 
might answer this question, while binding assays, such as co‐immunoprecipitation, will also verify 
if Gαo and Hsc70 can bind each other, and if phosphorylation of APP at its S655 residue affects this 
binding. 
The complete mechanism by which APP influences Gαo levels is still not completely clear. We have 
shown that APP S655 dephosphorylation increases Gαo lysosomal degradation, which is 
accompanied by an increase in Gαo co‐localization with the chaperone Hsc70. Also, APP 
dephosphorylated at S655 (SA APP mutant) decreases APP interaction with Gαo (Chapter B1) and 
also increases APP targeting to the lysosome [47, 48]. By combining these findings one possible 
mechanism emerges: the decreased binding of Gαo to APP results in the unmasking of the Gαo’s 
KFERQ motif [61]. This in turns leads to the recognition of the motif by Hsc70, thus activating 
chaperone‐mediated autophagy and Gαo lysosomal degradation. In this hypothesis, APP would 
serve has a hub to bring together certain factors, such as Hsc70, that can also bind APP  [62, 80], to 
bind and target Gαo to degradation.  
The fact that SA APP, Gαo, and Hsc70 are rarely co‐localized in SH‐SY5Y cells argues that these 
proteins are being targeted for degradation separately. Nevertheless, since Gαo CA also affects APP 
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levels (Figure B2.2A), and appears to be even more degraded than Gαo itself by SA APP (data not 
shown), both proteins might be co‐targeted for degradation. Hence, another potential mechanism 
could be occuring: APP could bind and activate Gαo, upon APP phosphorylation, targeting it to the 
PM; upon APP dephosphorylation, APP would be endocytosed with Gαo still bound to it, and Hsc70 
would bind to both APP and Gαo; since the dephospho APP avidity to Gαo is small, the Gαo‐Hsc70 
dimer could free itself and bind to LAMP2 for Gαo to be uptake to the lysosome. Indeed, Gαo 
activation produces a negative feedback upon APP protein levels; however, this effect seems to be 
highly dependent on the levels of Gαo activity (Figure B2.2). While high levels of transfection of the 
constitutively active Gαo decreased APP levels, low levels of transfection of the constitutively active 
Gαo increased APP levels. Since expression of wild‐type Gαo also causes a slight increase in APP 
levels, this could mean that expression of Gαo might act as a stimulus to increase APP expression, 
or decrease its degradation, and thus initiate a signaling pathway. Gαo increased activation would 
then cause a feedback mechanism, triggering downregulation of APP in order to shut down the 
signaling event. However, due to the high variability between experiments, it is unclear what it is 
occurring. Overactivation of Gαo using other method other than transfection of a constitutively 
active mutant, such as treatment with Mastoparan [81], will help us understand the effect of Gαo 
activation on APP.  
Further, the effect of Gαo activity was also assessed by inhibiting it with Pertussis Toxin (PTX).  As 
previously described, Gαo inhibition after treatment with PTX leads to the downregulation of its 
protein levels [29]. Our results corroborate this and show that this decrease is at least partially 
caused by proteasomal degradation under basal conditions (Figure B2.8 and Figure B2.9). We have 
also detected that APP presence apparently did not change the PTX effect; however, it did block 
Gαo recovery upon proteasomal inhibition. Although this could be expected for SA APP, since we 
now know that it is targeting Gαo to the lysosome, it also occurs for both Wt and SE APP. Moreover, 
these two forms are also downregulated when PTX is presence. These effects could somehow be 
connected to how APP and Gαo interact and how PTX affects this interaction. PTX mechanism of 
action consists on the ADP‐ribosylation of the cysteine present in 4th residue of the Gαo C‐terminal, 
the region where GPCRs and APP bind [28]. While ADP‐ribosylation is described to cause the 
disruption of the interaction between GPCRs and Gαo, a study has described that PTX treatment in 
Manduca sexta increases Gαo binding to the APP‐like protein [18]. If a similar effect occurs with 
mammalian APP and Gαo, it might result in the strengthening of the Gαo interaction with Wt and 
SE APP, the two forms to which Gαo preferentially binds. This could lead to both proteins being 
downregulated together. However, the exact mechanisms by which this occurs are still not clear. 
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Further testing with inhibition of both the proteasome and the lysosome, under PTX treatment, 
might shed some light on these questions. Interaction assays of APP and Gαo after PTX treatment 
are also required to determine the exact impact of ADP‐ribosylation on this interaction. 
The data presented here uncovers new mechanisms by which APP and Gαo are controlled and help 
understand how APP/Gαo signaling is regulated. This work focused mainly on the degradation 
pathways of Gαo and APP. Future work should also evaluate possible alterations in the gene 
expression levels of these proteins, as well as look into alterations on the APP processing, especially 
the formation of soluble APP, due to its important role on brain function and its reported action 
with Gαo in cell survival [33, 82]. 
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B2.7. Supplementary Material  
 
Supplementary Figure B2.1. Effect of proteasome inhibition on PTX treatment. SH‐SY5Y cells were transfected with 2 
µg of either pEGFP‐N1 empty vector, Wt APP‐GFP, SA APP‐GFP or SE APP‐GFP. After 6h of transfection, PTX was added to 
the cell media to a final concentration of 100 ng/mL, for an additional 18 hours. To test the role of the proteasome on 
PTX treatment, the proteasome inhibitor Lactacystin (Lac) was added to cells in combination with PTX. The effect of 
proteasome inhibition on A. Gαo and B. APP protein levels was evaluated by calculating the ratio between cells treated 
with PTX+Lac and cells treated just with PTX, and the results are presented as fold changes between both conditions (+/‐ 
Lac). The ‘*’ symbol represents statistical significance of cells treated with PTX+Lac relative to PTX alone (dashed line). *, 
p<0.05; **, p<0.0
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B3.1. Abstract  
 
Neurons are specialized cells of the Central Nervous System whose function is intricately related to 
the neuritic network they develop to transmit information. Morphological evaluation of this 
network and other neuronal structures is required to establish relationships between neuronal 
morphology and function, and may allow monitoring physiological and pathophysiologic 
alterations. Fluorescence‐based microphotographs are the most widely used in cellular bioimaging, 
but phase contrast (PhC) microphotographs are easier to obtain, more affordable, and do not 
require invasive, complicated and disruptive techniques. Despite the various freeware tools 
available for fluorescence‐based images analysis, few exist that can tackle the more elusive and 
harder‐to‐analyze PhC images. To surpass this, an interactive semi‐automated image processing 
workflow was developed to easily extract relevant information (e.g. total neuritic length, average 
cell body area) from both PhC and fluorescence neuronal images. This workflow, named 
‘NeuronRead’, was developed in the form of an ImageJ macro. Its robustness and adaptability were 
tested and validated on rat cortical primary neurons under control and differentiation inhibitory 
conditions. Validation included a comparison to manual determinations and to a golden standard 
freeware tool for fluorescence image analysis. NeuronRead was subsequently applied to PhC 
images of SH‐SY5Y neuroblastoma cells differentiated with retinoic acid and brain‐derived 
neurotrophic factor, which were maintained in normal differentiating conditions, or treated with 
Pertussis Toxin, a known Gαo/i inhibitor. Data obtained allowed the correlation of morphological 
alterations occurring during differentiation with changes in Gαo protein levels. It also further 
validated NeuronRead as a time‐ and cost‐effective useful tool for monitoring differentiation of 
both primary neurons and neuronal‐like cells.  
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B3.2. Introduction 
The highly specialized neuronal morphology is intimately interconnected with its role, and the 
function of neuronal networks depends on their complex connections at both regional and single 
cell level [1–3]. Morphometric analyses are thus applied to neuronal images to study correlations 
between neuronal structure and function. Neuronal morphometric analyses help to assess network 
distortions associated with neurological disorders and injury, and can assist high throughput 
screens of neuronal differentiation and regeneration [4–6]. However, neuronal images typically 
acquired from primary cultures [7] can be difficult to image and analyze. Even when grown in a 2D 
environment, neurons present significant morphological variations throughout the culture resulting 
in highly heterogeneous images. Problems as uneven illumination are relatively common and derive 
from e.g. unevenly distributed neurons, out‐of‐focus neurites, and the lower height of neuronal 
cells [8]. Other imaging problems may occur when working with living cells, such as artifacts arising 
from dead cells and debris. Although still having to deal with some of these noisy features, 
fluorescence imaging against a dark background has resolved some of the problems and led to a 
scarcer use of phase contrast (PhC) images. Processing tools freely available for neuronal cultures 
analysis are thus usually devoted to fluorescence and not PhC microphotographs [8–10]. PhC 
images are nevertheless easier to obtain, almost cost‐free (just requiring a properly equipped 
imaging equipment), and may be easily used to image live cells, besides fixed ones. This brightfield 
microscopy technique explores alterations in the cells’ refraction index and circumvents the need 
for staining reagents, being used to improve the contrast of unlabeled and unprocessed biological 
samples, such as live cells [11]. PhC microscopy is thus a cost‐effective solution that can 
simultaneously assure imaging of entire populations and live cells. This optical contrast technique 
is widely used in cellular migration and morphology studies [12, 13], including studies in neuronal 
differentiation [14–16]. It has been used to create solutions in cell biology for cell tracking and 
automation of cell counting (via deep learning methodologies and newly developed segmentation 
algorithms) [17, 18]. 
Nevertheless, and although they are useful, almost no freeware tools dedicated to the automatic 
or semi‐automatic analysis of PhC neuronal images are available. Currently, NeuronGrowth [19] 
and NEMO [20] were the only tools retrieved by our survey. NeuronGrowth is a program that 
automatically quantifies the extension and retraction of neurites and filopodia in time‐lapse 
sequences of two‐dimensional images. NeuronGrowth was implemented as a free ImageJ plug‐in, 
in Java language, being an independent multi‐platform system that contains entire digital image 
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pre‐processing and processing modules [19]. In PhC images this program can be used to track and 
measure neurites, and in fluorescence images, it can be used to track filopodia. Unfortunately, 
NeuronGrowth can only be applied to images obtained from time‐lapse experiments where the 
same sample field is imaged through time. NEMO [20] is also designed to handle and process large 
quantities of data on single neuronal cells as they evolve over time. This freeware is written in 
MATLAB code, can handle fluorescence and brightfield images of neuronal 2D cultures and 
organotypic slices, and uses 3‐way principal component analysis (PCA) for variables analysis. NEMO 
performs morphological analysis using local and global variables; local variables are related to the 
dendritic tree, while global variables are related to the whole cell structure and include features as 
radial extension, soma area and cone angle [20]. This program is more dedicated to the automated 
analysis of images in batch, which has the benefit of time but may result in less accurate measures. 
When used in a semi‐automated manner NEMO can be very efficient; the downside it that images 
must be correctly labeled before analysis and the tool is relatively complex.  
The work here described addresses the need for a simple and straightforward tool that could work 
in the widely‐used ImageJ platform, which could handle not only PhC but also fluorescence images, 
in a semi‐automated manner in order to minimize error in cell segmentation and improve accuracy 
in morphological features’ extraction. We have therefore developed NeuronRead, an ImageJ macro 
that is capable of analyzing both types of images. PhC/fluorescence pair images of primary neurons 
at 4 days in vitro (DIV) were used to validate NeuronRead by comparison to manual determinations 
and to a recognized golden standard for neuronal images, NeuriteQuant [21]. NeuronRead was 
subsequently applied to a scientific question in order to assess its applicability. SH‐SY5Y 
neuroblastoma cells were differentiated with a combination of retinoic acid (RA) and brain‐derived 
neurotrophic factor (BDNF) [22], and the morphological changes occurring during differentiation 
were evaluated with NeuronRead. Moreover, changes in morphology were correlated with 
alteration in the protein levels of two neuronal markers, GAP‐43 and βIII‐tubulin [23], and of two 
proteins highly associated with neurite outgrowth, Gαo and APP [24, 25]. Cells were further treated 
with Pertussis Toxin (PTX), a known inhibitor of Gαo/i proteins, and its effect on SH‐SY5Y 
differentiation was also assessed with NeuronRead. This experiment further demonstrated the 
usefulness and reliability of NeuronRead in the analysis of the differentiation of both primary 
neuronal cultures and neuronal‐like cells, such as SH‐SY5Y neuroblastoma cells.   
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B3.3. Materials and Methods  
B3.3.1. Antibodies  
Primary antibodies used in Western Blot (WB) and Immunocytochemistry (ICC) assays: mouse 
22C11 monoclonal anti‐APP N‐terminus (Chemicon; WB‐1:250); rabbit anti‐Gαo/GNAO1 polyclonal 
(Thermo; WB‐1:2000; ICC‐1:200); rabbit anti‐βIII‐tubulin (abcam; WB‐ 1:10000; ICC‐1:250), rabbit 
anti‐GAP‐43 (Millipore; WB‐1:1000). Secondary antibodies used: horseradish peroxidase‐labeled 
goat antibodies (GE Healthcare) for enhanced chemiluminescence (ECL) detection; Alexa Fluor 594‐
conjugated goat antibody (Molecular Probes) for ICC analysis. Antibodies were prepared in 3% BSA 
in phosphate buffer saline (PBS) for ICC, and in either 3‐5% milk or BSA for WB, per the 
manufacturers’ instructions.  
 
B3.3.2. Rat cortical neuronal and SH-SY5Y neuroblastoma cell cultures 
Rat cortical primary neurons were established by dissociation of E18 embryonic cortices, as 
described in [26]. Briefly, upon euthanize the mothers, the embryo cortices were dissociated for 5–
10 min/37°C with 0.23 mg/mL trypsin/0.15 mg/mL deoxyribonuclease I‐supplemented Hank’s 
balanced salt solution. Dissociated cells were plated at 1.0x105 cells/cm2 onto poly‐D‐lysine‐coated 
dishes in B27/0.5 mM glutamine/60 µg/mL gentamicin‐supplemented Neurobasal medium (GIBCO, 
Invitrogen), and maintained at 5% CO2/37ºC for 4 days before being imaged. A minimum number 
of pregnant female Wistar rats (9‐12 weeks; Harlan Interfaune Ibérica, SL) was used, and all steps 
were taken to ameliorate animal suffering. All experimental procedures complied the ARRIVE 
guidelines, observed the European legislation for animal experimentation (EU Directive 
2010/63/EU) and were approved and supervised by our Institutional Animal Care and Use 
Committee: Comissão Responsável pela Experimentação e Bem‐Estar Animal, CREBEA).  
Primary neuronal cultures were treated for 18h (from 3 to 4 DIV) with 10 M of PD168393 (Sigma‐
Aldrich), a drug inhibitor of the known neuritic promotor epidermal growth factor receptor (EGFR) 
[27, 28]. After treatment, neurons were fixed with 4% paraformaldehyde (PFA) in PBS for ICC.  
Human neuroblastoma SH‐SY5Y cells (ATCC CRL‐2266) were grown in Minimal Essential Medium 
supplemented with F‐12, 10% FBS, 0.5 mM L‐glutamine, 100 U/ml penicillin and 100 mg/ml 
streptomycin (Gibco, Invitrogen) at 37°C/5% CO2.  
SH‐SY5Y cells were differentiated using a protocol adapted from Encinas et al, 2000 [22]. Briefly, 
cells were seeded at an initial density of 1x105 cells per 35mm plate. After 24h (day 0), retinoic acid 
(RA, Sigma‐Aldrich) was added to the cells to a final concentration of 10 M. Cells were maintained 
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in RA for 5 days, after which RA was removed and brain‐derived neurotrophic factor (BDNF) was 
added in serum‐free medium, to a final concentration of 10 ng/mL. Cells were then maintained for 
further 7 days (to day 12); medium was changed every 2‐3 days. Differentiating cells were also 
treated with 100 ng/mL Pertussis Toxin (PTX) from either day 0 or day 5 of differentiation to day 
12. Undifferentiated cells were maintained as control throughout the 12 days. Cells were collected 
at day 3, 5, 6, 9 and 12 with 1% SDS. 
 
B3.3.3. Immunocytochemistry and Image acquisition 
Fixed rat 4 DIV cortical neurons were permeabilized with 0.2% Triton/in PBS, washed with PBS, and 
blocked with 3% BSA/in PBS for 1h. Neurons were incubated for 2h with a primary antibody  (1:200) 
against Gαo, a protein highly abundant in the inner side of the neuronal plasma membrane [29], 
allowing for the visualization of the complete neuronal network. Following washing with PBS, cells 
were incubated with an anti‐rabbit secondary antibody for 1h, washed with PBS and deionised 
water, and mounted onto glass slides using a Vectashield mounting medium (Vector Labs).  
Digitized images (n = 30 images) of fixed cortical primary neurons at 4 DIV were acquired by PhC 
illumination using a LCPlanFl20x/0.40 objective in an Olympus IX‐81 widefield epifluorescence 
inverted microscope equipped with a 12 bit CCD monochromatic 1376 x 1032 pixel digital camera, 
binning 1x (F‐view II, Soft Imaging System) [12, 13, 15]. Paired fluorescence images of the same 
areas, labeled with an anti‐Gαo antibody, were also acquired [filtersets: DAPI (BP 330‐385/FT 
400/LP 420); GFP/FITC (BP 450‐480/FT 500/LP 515); TexasRed/TRICT (BP 510‐550/FT 570/LP 590); 
exposure time for Gαo: around 100‐200 ms]. Live differentiated SH‐SY5Y neuroblastoma cells were 
also imaged under the Olympus IX microscope using PhC techniques, at 3, 5, 6, 9 and 12 days of 
differentiation. Image acquisition was performed in the LiM facility of iBiMED, a node of PPBI 
(Portuguese Platform of BioImaging).  
 
B3.3.4. SDS-PAGE and Western Blot  
Mass‐normalized (BCA protein assay; Pierce) cell aliquots were subjected to SDS‐PAGE and WB. 
Ponceau‐S staining of the transferred proteins was used as loading control, as an alternative to actin 
or tubulin, since these proteins vary with our experimental conditions [15, 30]. For this, 
nitrocellulose membranes were immersed in Ponceau‐S solution (Sigma‐Aldrich; 0.1 % [w/v] in 5% 
acetic acid), further washed with distilled water, and scanned (GS‐800 calibrated densitometer, Bio‐
Rad). Following their wash with TBS‐T, membranes were subject to WB analysis. Briefly, membranes 
were blocked with 5% milk or BSA in TBS‐T, incubated with primary antibodies (2h or overnight), 
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and with horseradish peroxidase‐linked secondary antibodies (2h), and subject to ECL detection 
using the ChemiDocTM Imaging System (Bio‐Rad). 
 
B3.3.5. The NeuronRead algorithmic workflow 
NeuronRead is a macro script designed to use image processing techniques and to run within the 
ImageJ environment, which supports semi‐automated quantitative analysis of bioimages [31, 32]. 
A tutorial explaining how to install the macro can be found as a supplementary data at the end of 
this chapter. Also, the NeuronRead macro can be downloaded from 
http://www.sciencedirect.com/science/article/pii/S1044743117300866. It was developed focusing 
on PhC images but can also process fluorescence images. The processing workflow and the major 
settings are described below (Figures B3.1 and B3.2). The whole computational procedure 
integrates image enhancement, segmentation and feature extraction steps that provide robust 
quantitative descriptors of the neuronal images. The algorithm first deals with cell body 
segmentation, which subsequently drives the neuritic network recognition steps. The algorithm 
implementation relies both on native ImageJ functionalities and on companion plugins such as 
MorphoLibJ v1.2.0 [33], Skeletonize3D and AnalyzeSkeleton [34]. A great majority of the operations 
are automated, and the interactive steps are clearly indicated.  
Figure B3.1. Processing workflow of the NeuronRead macro. Schematic flowchart detailing each step of the 
NeuronRead Macro taken during neuronal soma segmentation (upper part) and neurite segmentation (lower part). 
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1. Cell body segmentation. Generally, PhC (and Fluorescence) raw images are not compatible with 
straightforward automated image analysis approaches, impairing the estimation of reliable 
quantitative features. Our cell‐body segmentation strategy assumes that cell bodies and neuritic 
structures may be considered as tiny objects of interest within a large background comprising mid‐
range gray level values that clearly dominate the global or regional intensity‐based statistics. Noise, 
intrinsic artifacts and the need to handle rather thin objects were the immediate driving factors 
determining the chain of pre‐segmentation steps that provide thresholding “friendly” images as 
shown in Figure B3.2B from the input raw images shown in Figure B3.2A.  
 
Figure B3. 2. Details of the NeuronRead 
workflow, applied to Phase Contrast 
Images. A-D: Cell body segmentation. 
A. Raw PhC neuronal image. Mid‐range 
values of background gray levels clearly 
dominate (yellow line), as suggested by 
the example intensity profile shown 
below. B. Resulting image after grey‐
level ‘bottom‐hat’ filtering. As shown in 
the intensity profile, the background is 
almost removed. Only objects with 
shape and size fitting the structuring 
element (SE) stand out more clearly 
(yellow line). C. Automatic threshold 
(upper image) and subsequent 
morphological opening (image below). 
D. The original shape of cell bodies, as 
recovered after morphological 
reconstruction (upper image). Final 
result with refinements obtained with 
watershed segmentation (image 
below). E-F: Neuritic segmentation. E. 
The difference of Gaussians image 
masked with cell body areas. F. 
Skeletonized neuritic pathways 
superimposed on the original image. 
Structures attached to the image 
boundaries are not measured. Scale bar 
= 50 μm. 
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The main idea is to make our target objects stand out relative to the background and other objects 
whose shape and size do not qualify them as cell bodies. Given the very nature of neuronal images, 
our choice to obtain an appropriate tradeoff between noise and contrast enhancement relied upon 
grey‐scale morphological operators [35, 36]. Mathematical morphology provides the conceptual 
basis for these operators. The basic idea is to express formally how well a small probing object fits 
the appearance of the target objects. The probing object, normally called the structuring element 
(SE), may assume any shape but often regular shapes such as disks, squares or lines are used.  
Binary erosion and dilation operators that are straightforwardly perceived using set‐theoretic 
definitions are the fundamental building blocks of more complex morphological operations 
recurrently applied in this work. Most of the binary morphological operators are fully extensible to 
grey‐level image analysis tasks. Erosion and dilation operators applied to grey‐scale images can be 
looked at as regional minimum and maximum filters, respectively, considering the regions 
restricted by the chosen SE. The opening operator is defined as an erosion followed by a dilation, 
and the closing operator is defined as a dilation followed by an erosion. For a thorough overview of 
mathematical morphology techniques and their applications in image analysis please refer to [35, 
36]. 
Our approach to obtain contrast enhanced images for reliable cell body segmentation, consisted of 
a bottom‐hat operation preceded by median filtering. This preliminary step removes the effect of 
the corpuscular spots. The bottom‐hat operation (or ‘black top‐hat’) is formally defined as the 
difference image of the closed and original versions of the image. Since the closing operation 
emphasizes the darker valleys, most of them matching our target cell bodies, the result of the 
bottom‐hat clearly promotes the conspicuousness of the cell bodies. This filtering approach 
practically removes the background clutter and leaves out, for further processing, only the cell body 
candidate regions. For the sake of visibility Figure B3.2B shows the complement of the bottom‐hat 
image. Notice that the neuritic networks are almost faded and the effect of the white halo 
surrounding the cell bodies is practically negligible. The image is now ready for proper cell body 
segmentation. The size and shape of the SE are critical parameters for successful segmentation. 
Given the acquisition setup, heuristic arguments suggest that the best performance is achieved with 
disk‐shaped SE with a radius of 5 to 10 pixels. 
Cell body segmentation consists of thresholding the bottom‐hat filtered image and its subsequent 
binary morphological filtering. Most of the time, the automatically computed threshold level is 
acceptable. However, the user can optimize the results with minimal manual adjustments. The 
binary images still undergo morphological opening to remove the tiny regions whose size prevents 
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them to be considered as live cell bodies. The opening filters with the above‐mentioned SE's impose 
considerable damage to the original body shapes (Figure B3.2C). In this phase, border objects that 
are only partially visible are also removed. A morphological reconstruction is then used to recover 
the original body shapes, as shown in Figure B3.2D (upper). An extra refinement in cell body 
delineation is provided by watershed techniques [37] that often succeed in separating visually 
overlapped cell bodies. The binary processing phase in body segmentation concludes as shown in 
Figure B3.2D (lower). 
The user may still mark for removal the few miss‐segmented cell body components, or add any cell 
body that was left unrecognized by the macro, by visual inspecting the superposition of the 
candidate masks to the raw grey‐scale image. The end result of this process is a body cell mask 
image that is ready to be labeled and measured using native ImageJ functionalities. Each cell body 
(binary object) in each image will thus be numerically labeled, making it possible to measure its 
morphological features, such as area or perimeter. 
2. Neuritic segmentation. To emphasize the tiny neuritic structures, contrast enhancement and 
differential filtering were applied. Contrast‐limited adaptive histogram equalization (CLAHE) and 
Difference of Gaussians (DoG) filtering provide a good compromise between structural emphasis 
and noise impact in the subsequent thresholding phase. DoG parameters were matched to the 
neurite expected width range. We empirically determined that standard deviations for each 
Gaussian of 1 and 3‐pixels were appropriate choices. As shown in Figure B3.2E, this intermediate 
image is then automatically masked with a dilated version of the cell bodies’ image, making then a 
band‐pass interactive threshold to easily identify the neuritic components. Again, image labeling 
enabled the identification and removal of disconnected structures with an area smaller than 200 
pixels. This threshold was previously experimentally determined, with smaller areas leading to the 
recognition of image artifacts as neurites. 
The last step consisted of user‐supervised skeletonizing, branch identification and length 
estimation, by using the AnalyzeSkeleton plugin. To visually validate the neuritic skeleton composed 
by the segmented neuritic components, the skeleton was automatically superimposed on the 
original image as shown, resulting in Figure B3.2F. 
The NeuronRead macro was developed on images taken under a 20X/0.4 objective (3.1 pixels/µm 
scale), but can work on different amplification settings (such as a 10X objective ‐ 1.55 pixels/µm) 
with little user intervention, showing NeuronRead robustness in dealing with images with different 
scales. To work with other scales/magnifications, some parameters might require user attention, 
including 1) the radius of different morphological filters that are applied during the macro; as well 
B3. NeuronRead 
University of Aveiro  167 
as 2) the areas used during “Analyze Particles” to remove unwanted objects from the image. As a 
rule, higher magnifications used during image acquisition will require higher values for these 
parameters, while lower magnifications will require lower values. Further, the macro is easily 
customizable, and some features such as the SE radius and the image scale are asked and can be 
altered while the macro is running. Noteworthy, the macro alters the scale at two different time 
points: 1) at the beginning, it removes any previous scale associated with the image or software, so 
that it does not impair any of the morphological operations the macro performs; 2) near the end, 
the macro asks for the image scale (number of pixels per micrometer) and applies it to the image 
being analyzed, so that every extracted feature comes at the desirable unit, normally μm, instead 
of pixels.  
3. Extracted Morphological Features. The quantitative features of the population become available 
in the “Log” window at the end of the macro. These include Neuritic Parameters (Total Neuritic 
Length) and Cell Body Parameters (Cell body count, Average Area, Circularity, Roundness, and 
Perimeter). Individual shape features are also available under the windows “Cell bodies” and 
“Branch information”. They can be saved as column based “.txt” files for further analysis in a 
software of choice. The macro does not retrieve neuritic length per cell, but this is easily obtained 
by dividing the total neuritic length by the number of cells scored in that image. A tutorial explaining 
how to install and run the NeuronRead macro can be found as supplementary data, at the end of 
the chapter. 
 
B3.3.6. Data analysis and Statistics 
All data is expressed as mean ± standard error of the mean of at least three independent 
experiments. For NeuronRead validation, statistical significance analysis was conducted by the 
Bland‐Altman method (comparison between NeuronRead and NeuriteQuant) and by the unpaired 
Student’s t‐test (control versus EGFR‐inhibitor cultures). In the differentiation assay, statistical 
analysis was conducted using the one‐sample t‐test (Control conditions defined as 1). 
All tests were performed on the GraphPad Prism® software. Three levels of significance were used, 
depending if the p‐value was under 0.05, 0.01 or 0.001.  
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B3.4. Results 
B3.4.1. The NeuronRead workflow and Cell Body recognition 
The image processing workflow based on the ImageJ environment was applied to PhC and 
fluorescence neuronal 2D‐images, with the intent of extracting quantitative morphological details. 
This workflow (Figure B3.1 and B3.2), named NeuronRead, was first developed and optimized using 
PhC images taken at living primary cultured neurons. Images of cultures at various differentiation 
days (days in vitro, DIV) were used to assure that NeuronRead could efficiently extract information 
from increasingly complex neuritic networks (in Dias and Gonçalves et al., accepted). The developed 
macro returns several primary parameters, such as cell number; cell body area, perimeter, 
circularity, roundness, and total neuritic length. Secondary parameters such as ‘neuritic length per 
cell’ can be obtained by dividing primary parameters by the number of cells. NeuronRead runs in a 
semi‐automatic manner, requiring user‐interaction on 4 occasions: first to input if the image to be 
analyzed is a PhC or fluorescence image; second, to improve cell body recognition (if necessary); 
third, to improve neuritic detection; and fourth, to input the scale. If wanted, this last step can be 
surpassed and the conversion from pixels to micrometers only performed by the user in another 
software of choice after gathering all information from all the images. 
A comparison between the raw NeuronRead output and a manual evaluation of the number of cell 
bodies showed a percentage difference of 5.8%, and the values obtained were not significantly 
different (paired t‐test analysis). This error mainly arises from the presence of large cell clusters 
(resulting in false negatives), or from the presence of debris in the live cells preparation (resulting 
in false positives). However, since the macro allows the user to add cell bodies or remove false 
positives (2nd user interaction step), this minor error can be easily corrected. At this step 
NeuronRead also allows the user to alter the automatic threshold set for the cell body, further 
improving cell body recognition and optimizing the “cell body area” value retrieved with 
NeuronRead. This parameter is nevertheless greatly optimized, with no significant differences 
between the macro and manual analysis (Figure B3.3). Naturally, close attention must be paid to 
threshold values. A low threshold value may increase the number of false positives, while high 
threshold values can lead to missed cell bodies. The same is particularly true for the neuritic 
detection threshold. While a lower threshold allows a more sensitive neuritic detection, in 
preparations with a high amount of debris this can lead to an overestimated neuritic length. Our 
macro was tested in both fixed and live neuronal cultures that did not have their culture media 
changed, and was able to deal with both types of cultures.  
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Figure B3.3.NeuronRead versus manual detection of neuronal cell bodies areas. A. Neuronal cell body recognition with 
NeuronRead in PhC microphotographs of neuronal cultures at 4 days in vitro. Raw data on the left, automatic cell body 
recognition on the right (halos surrounding cell bodies, in yellow). Scale bar = 50 µm. B. Graphical comparison of the 
average neuronal cell body areas determined by NeuronRead and by manual analysis of the PhC images. There were no 
statistical differences (ns) between both measurements. n= 10 images, in a total of ca. 300 cell bodies.  
 
B3.4.2. Validation of NeuronRead neuritic segmentation 
Our macro is able to extract morphometric data not only from PhC but also from neuronal 
fluorescence images. Its efficacy was first demonstrated by comparison to an established freeware 
tool, NeuriteQuant. This golden standard was chosen by its accuracy in neuritic network evaluation 
of fluorescence images [21]. To validate NeuronRead efficacy, the macro was applied to the same 
fluorescence images analyzed with NeuriteQuant. These were images of 4 DIV neuronal cultures 
immunolabeled against Go, a highly abundant neuronal protein that clearly stains and delineates 
the neuritic network [29] (Figure B3.4A upper panel). Results show that NeuronRead is as efficient 
in analyzing fluorescence images as NeuriteQuant, with 95% of the results having a difference less 
than 5% (Figure B3.4B, Bland‐Altman Plot). NeuronRead also performed as NeuriteQuant in 4 DIV 
neurons fluorescently immunolabeled against the cytoskeleton marker acetylated beta‐tubulin 
(data not shown). Afterward, using paired neuronal PhC/fluorescence images (Figure B3.4A), the 
data extracted with NeuronRead from PhC images was compared to the data extracted with 
NeuriteQuant from paired fluorescence images. The Bland‐Altman plot of Figure B3.4C shows that 
quantitative data extracted from PhC images with NeuronRead was on average 27% lower than the 
ones obtained from fluorescence with NeuriteQuant.  
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Figure B3.4. NeuronRead validation in PhC and fluorescence neuronal images. A. A set of 30 pairs of fluorescence 
(‘Fluor.’)‐phase contrast (‘PhC’) microphotographs of neurons at 4 days in vitro (raw images at the left) were analyzed 
with the NeuronRead macro (middle images) leading to the neuritic tracing in NeuronRead‐Fluor images (in green) and 
NeuronRead‐PhC images (in orange). The fluorescence images were additionally analyzed with the NeuriteQuant plugin, 
resulting in the NeuriteQuant‐Fluor tracing (right image, in blue). Scale bar = 100 µm. B. Bland‐Altman plot of the 
comparison between NeuronRead and NeuriteQuant analyses of fluorescence images. The plot shows an average 
difference between both methods of almost 0%, with 95% of the results differing less than 5%. C. Bland‐Altman plot of 
the comparison between phase contrast image analysis with NeuronRead and fluorescence image analysis with 
NeuriteQuant. The plot shows an average difference between NeuronRead and NeuriteQuant of ‐27.01%, demonstrating 
that there is less information available in PhC images than in fluorescence images.  
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The same was observed when comparing NeuronRead analysis of PhC images with NeuronRead 
analysis of fluorescence images (Supplementary Figure B3.1). Overlay of the resulting neuritic 
skeleton onto the original PhC image (Figure B3.4A, lower panel) shows that the macro is running 
as expected: generally detecting the entire neuritic network present in the image. Together with 
the previous results on fluorescence images (Figure B3.4B), this indicates that the main reason for 
the difference in the neuritic length found in fluorescence versus PhC images is the poorer signal‐
to‐noise ratio of raw PhC images, and the higher contrast of the fluorescence ones. These results 
demonstrate that 1) NeuronRead can be used as a reliable alternative to NeuriteQuant to analyze 
fluorescence images, while 2) also being able to analyze neuronal PhC images. However, results 
also highlight the fact that PhC images normally exhibit less detail than fluorescence images 
regarding the neuritic network and should not be used for ‘absolute’ determinations. When aiming 
for absolute values, one should use fluorescence images where the neuronal cytoskeleton or 
cytosol has been thoroughly labeled to highlight the maximum morphological details, as occurs by 
immunolabelling the highly abundant Go protein, or other neuronal markers such as βIII‐tubulin. 
We have also tested NeuronRead efficacy in the analysis of neuronal cultures at 12DIV, a time point 
at which the neuritic network has reached a high density. Comparison of the results obtained with 
NeuronRead and NeuriteQuant showed a difference of around 1% between both analyses, meaning 
that NeuronRead is efficient in analyzing both low (4DIV) and high (12DIV) density neuronal cultures 
(Supplementary Figure B3.2). 
NeuronRead robustness and sensitivity were also evaluated by using a similar approach as the one 
described in [38]. Briefly, by using the ImageJ “Noise” function, two different types of noise (Salt 
and Pepper, and Gaussian noises) were incrementally added to both PhC and Fluorescence images 
(Supplementary Figure B3.4). Quantitative analyses of these images showed that NeuronRead’s 
ability to extract cell bodies morphometric data is extremely resistant to noise levels, with no 
significant changes detected, even when noise was visually noticeable. NeuronRead ability of 
extracting neuritic data was also resistant to the addition of Salt and Pepper noise to PhC images, 
while only a high noise level affected its neuritic analysis of fluorescence images (Supplementary 
Figure B3.3A). Moreover, NeuronRead also effectively extracted neuritic data in the presence of 
low‐to‐medium levels of Gaussian noise (Supplementary Figure B3.3B).  
The next step was to evaluate if neuronal PhC images, analyzed with NeuronRead, could be used to 
detect relative alterations in the neuritic network. For that, we tested if the macro could accurately 
quantify alterations in the neuritic network in PhC images of neurons exposed to an inhibitor of the 
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epidermal growth factor receptor (EGFR). EGFR translates signals from the pro‐survival and pro‐
neuritogenic EGF and is involved in neuritic outgrowth [27, 28]. Differentiating neurons that were 
under 18h of EGFR inhibition should thus yield a decrease in their total neuritic length per cell, when 
compared to control conditions (Figure B3.5A). The analysis of neuronal PhC images using 
NeuronRead showed a significant reduction of 13.0% in neuritic length per cell when compared to 
control neurons, virtually identical to the difference obtained when analyzing fluorescence images 
(13.2%) (Figure B3.5B). These results thus show that both types of images can be analyzed and used 
to evaluate differences in neuritic length between experimental conditions.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Regarding some of the performance characteristics of both methods, in a standard PC (eg.  Intel® 
CoreTM i5‐5200 Dual Core 2.2 GHz, 8GB RAM, 500GB Hard Drive and Intel® HD Graphics 5500) 
NeuriteQuant took considerably more time analyzing each image (1‐2 minutes with NeuronRead vs 
8‐10 minutes with NeuriteQuant). Another advantage in using NeuronRead was its accurate 
detection of cell bodies in PhC images, which we did not find as reliable when using NeuriteQuant. 
Figure B3.5. Neuritic length analysis of 
neuronal cultures treated with the EGFR 
inhibitor. A. Neuronal cultures at 4 days in 
vitro under control conditions (left image) 
and treated with 10 μM of the EGFR 
inhibitor PD168393 (right image) to stall 
the neuritic outgrowth. Scale bar = 100 
μm. B. Images were analyzed with 
NeuronRead (PhC and Fluor. images) and 
NeuriteQuant (only Fluor. images). All
three methods were able to detect the 
same effect of the EGFR inhibitor 
treatment. n = 20 images. *, p<0.05 using 
Student’s t‐test. 
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The type of images analyzed also contributes for this difference, most probably due to how the 
fluorescent probe used stains the cellular body. Indeed, NeuronRead applied to fluorescence 
images also lost some accuracy in automated detecting the cell bodies, although this was easily 
corrected manually. Also, while both software programs require some user intervention, 
NeuronRead allows this while the macro is running, whereas NeuriteQuant requires a more 
laborious set up before the plugin starts the analysis [39]. NeuronRead is thus highly versatile and 
robust, and can be applied to neuronal PhC and fluorescence images, and also to PhC images of 
neuronal‐like cell models, such as differentiated SH‐SY5Y neuroblastoma cells (Supplementary 
Figure B3.4).  
 
B3.4.3. Monitoring SH-SY5Y differentiation upon modulation of Gαo activity 
As previously described, NeuronRead was successful in analyzing images of both neuronal and 
neuronal‐like cells. NeuronRead was thus used as a tool to monitor neuritogenesis in SH‐SY5Y cells, 
in a study aiming to evaluate Gαo protein levels during BDNF‐induced neuronal differentiation, and 
to assess the effect of modulating Gαo activity during this period.  
SH‐SY5Y cells were differentiated using a protocol adapted from Encinas et al, 2000 [22]. This 
protocol uses a sequential treatment of 10 µM RA for 5 days, followed by 10 ng/mL BDNF for 
additional 7 days (total of 12 days of differentiation), to obtain a culture of fully differentiated cells 
expressing several neuronal markers, such as GAP‐43 and MAP2. Cells differentiated with this 
protocol were live‐imaged at 3, 5, 6, 9 and 12 days (“D3, D5, D6, D9, and D12”), and the images 
were analyzed with NeuronRead (Figure B3.6A‐B). As expected, results show an increase in neuritic 
length per cell with time when compared to undifferentiated cells. Interestingly, while an increase 
in neuritic length was already detected at day 3, it only became significantly different after adding 
BDNF to the medium (51±8 µm at D6‐Diff vs 11±2 µm at D6‐Ctrl, p‐value<0.05). From D6 to D9 there 
was a burst in neuritic outgrowth (51±8 µm to 94±19 µm at D9‐Diff), which then stabilized in the 
last 3 days of differentiation (94±19 µm to 100±18 µm at D12‐Diff).  We also checked the expression 
of two differentiation markers, βIII‐tubulin and GAP‐43, by western blot (Figure B3.6C). The levels 
of each protein in the differentiated condition, at a given day, were compared to its levels in the 
undifferentiated condition at the same day. The differences were plotted with time (Figure B3.6C 
graphs). This type of analysis excludes possible changes in protein levels that were caused by time‐
in‐culture rather than by the differentiation itself. 
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Figure B3.6. Differentiation of SH-SY5Y cells with RA and BDNF. A. Microphotographs acquired of live SH‐SY5Y cells at 3, 
5, 6, 9 and 12 days in culture, in an undifferentiated state (“Control”), or undergoing the differentiation treatment 
(“Differentiation”). Differentiation was achieved by treating cells with 10µM RA for 5 days and 10 ng/mL BDNF for 
additional 7 days. Scale bar: 50 µm B. Quantification of the neuritic length per cell during differentiation. Ctrl, 
undifferentiated cells; Diff, differentiated cells. The neuritic length of each day was compared between Ctrl and Diff with 
the two‐way ANOVA test. C. Upper: Immunoblots with the alterations in βIII‐tubulin, GAP‐43, Gαo, and APP protein levels 
during differentiation. Of note, all the lanes are from the same blot, but were rearranged to the presented order. Lower: 
Differences between Diff and Ctrl conditions were plotted with time. At each day, protein levels of the differentiation 
condition (“Diff”) were compared to the ones in control condition (“Ctrl”), and the results presented as fold changes. N=5. 
The ‘*’ symbol represents statistical significance relative to control (1.0). *, p<0,05; **, p<0,01; ***, p<0,001.  
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βIII‐tubulin is already expressed in undifferentiated SH‐SY5Y cells, but its protein levels started to 
slightly increase when BDNF was added to the culture medium (at D6). A significant increase could 
be observed at D12 (1.76±0.18‐fold change over undifferentiated cells, p‐value<0.05). GAP‐43 was 
almost absent from control and RA plus conditions, and increased at 6 and 9 days of differentiation 
(D6, D9), returning to values close to the control at D12. A similar pattern had been described in 
the original work by Encinas et al, with GAP‐43 levels increasing with the addition of BDNF and then 
returning to control levels in the subsequent days [22]. The expression of βIII‐tubulin and GAP‐43, 
together with the morphological analysis, shows that SH‐SY5Y cells were successfully differentiated.  
We further evaluated the expression profile of Gαo, a protein highly enriched in neuronal cells that 
has been strongly associated with neuronal differentiation [24, 40]. In our experimental conditions 
(Figure B3.6C), we observed that Gαo levels remained close to the control levels during the first 5 
days of differentiation (1.07±0.12 at D3 and 1.08±0.08 at D5). However, when BDNF was added to 
the cells, a significant increase in Gαo levels was detected (1.46±0.16, p‐value<0.05). Gαo levels 
remained high in the subsequent days, but the difference lowered, as undifferentiated control 
levels slightly increased with time in culture. The protein levels of APP, a known interactor and 
activator of Gαo [41, 42], and also strongly associated with neuronal differentiation [25, 43] 
(Chapter B1), were also monitored. The protein levels of APP followed a pattern similar to Gαo, 
with APP levels (and their difference to control) peaking at D6 of differentiation (1.73±0.24, p‐
value<0.05), although a significant increase could already be detected at D5 of differentiation 
(1.30±0.04, p‐value<0.01) (Figure B3.6C). APP levels remain higher thereafter, but the difference to 
the control also decreases, since APP increases with time in culture (Figure B3.6C immunoblot, D9‐
D12).   
Since the peak in Gαo levels at day 6 correlated with a significant increase in neuritic outgrowth, as 
well as an increase in both GAP‐43 and APP, we further evaluated the role of Gαo effect in BDNF‐
induced SH‐SY5Y differentiation by modulating Gαo activity. Cells were exposed to RA for 5 days, 
after which cells were either allowed to differentiate in the presence of BDNF alone (Figure B3.7A 
‐ “Differentiation”), or treated with both BDNF and Pertussis toxin (PTX), a known inhibitor of Gαo 
and Gαi proteins (Figure B3.7A – “Differentiation + PTX”). 
Evaluation of neuritic length showed that from D6 to D9, neuritic growth was roughly the same in 
untreated cells (“Diff”) and cells treated with PTX (“Diff+PTX”) (Figure B3. 7B). At day 12, cells 
treated with PTX presented a higher neuritic length than untreated cells, although this difference 
was not significant (136±18 µm in Diff+PTX vs 107±23µm in Diff). PTX treatment also affected the 
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protein levels of neuronal markers, βIII‐tubulin and GAP‐43. βIII‐tubulin levels remained lower in 
cells treated with PTX for the entire duration of the treatment (0.71, 0.78, and 0.80 at D6, D9, and 
D12, respectively), when compared to the control differentiating cells. Alternatively, GAP‐43 
protein levels increased with PTX treatment, especially at D6 and D12.  
Analysis of Gαo itself also showed a reduction in its protein levels with PTX treatment, at all time 
points. Further, inhibition of Gαo via ADP‐ribosylation by PTX can be visually confirmed, as the Gαo 
protein migrates slowly through the SDS‐PAGE gel (asterisk in Figure B3.7C immunoblot). A PTX‐
induced reduction in Gαo levels, and the migration shifts, have already been described during 
differentiation of LA‐N‐5 neuroblastoma cells [44]. Finally, APP protein levels were only affected by 
PTX at D12 of differentiation, showing an increase in comparison to untreated cells. 
Figure B3.7. Treatment of differentiating SH-SY5Y cells with Pertussis Toxin (PTX). A. Microphotographs acquired of live 
SH‐SY5Y cells at 6, 9 and 12 days of differentiation, with or without PTX treatment. Differentiation was achieved by 
treating cells with 10 µM RA for 5 days and 10 ng/mL BDNF for additional 7 days. PTX was added at 5 days of 
differentiation, at a concentration of 100 ng/mL, and it was maintained until the end of the differentiation. Scale bar: 50 
µm B. Quantification of the neuritic length per cell during differentiation, with or without PTX treatment. Diff, 
differentiated cells without PTX treatment; Diff+PTX, differentiated cells with PTX treatment. No statistical differences 
were found between conditions. C. Immunoblots of βIII‐tubulin, GAP‐43, Gαo, and APP protein levels during 
differentiation in the presence of PTX. At each day, protein levels of cells treated with PTX were compared to the 
untreated differentiating cells; results were graphically presented as fold changes (+PTX/‐ PTX). Of note, all the lanes are 
from the same blot, but were rearranged into the presented order. ADP‐ribosylation by PTX results in a slower migration 
of the Gαo protein through the SDS‐PAGE gel (* in the immunoblot). N=2.      
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B3.5. Discussion 
Quantitative analyses of neuronal morphologic characteristics are widely used to study correlations 
between morphology and function for various applications, including therapeutic drug 
development for neuroregeneration [6]. Neuronal features more relevant for quantitative 
assessment include cell body area and roundness, and neuritic‐related parameters such as neuritic 
length and branching [4, 5, 45]. Although fluorescence microphotographs are nowadays more 
widely used in cellular imaging, partially due to the high number of freeware tools dedicated to 
them, PhC images are easier to obtain and more affordable. For example, these PhC images of 
neuronal cultures can provide valuable and easy‐to‐obtain morphological data regarding 
alterations induced by drugs to neuronal cells and their network. Since PhC images are potentially 
inexpensive in terms of imaging reagents (antibodies or dyes), sample preparation or staining, they 
are less time‐consuming. Another advantage of this technique is its non‐invasiveness so that 
neurons can be imaged alive. As downsize, these images have intrinsic lower contrast, resulting in 
less absolute information and in a higher difficulty in their analysis. Technical difficulties of PhC 
images include the low contrast between objects and background (low signal‐to‐noise ratio), 
uneven illumination resulting from shining light on 2D‐objects, vignetting (darkening of the image 
corners), and shade‐off and halo patterns characteristic of the PhC optical system [11]. However, 
these last two are considered minor obstacles, and the halo effect can emphasize contrast 
differences in the less contrasting negative PhC images. 
Despite these issues and the potential of PhC images, there are few freeware tools capable of 
analyzing PhC neuronal images in an automatic or semi‐automatic manner [7]. Our search for 
freeware tools for automatic or semi‐automatic analysis of PhC neuronal images only retrieved 
NeuronGrowth [19] and NEMO [20]. NeuronGrowth cannot be applied to images as the ones herein 
presented since these were not obtained from time‐lapse experiments; it would thus be necessary 
to mark all the neurites manually if this program was to be used. NEMO [20] performs various 
morphological analyses and, although very efficient, it is more dedicated to the automated analysis 
of single cells in images in batch, as time‐lapse images, and is more time consuming (e.g. the images 
need to be correctly labeled before analysis).  
In our institute, we perform multiple analyses of neuronal differentiation and regeneration 
processes in 2D‐cultures. This requires a customized image processing workflow that can handle 
very specific imaging contexts and is able to tackle the processing problems of both types of 
neuronal images. A sequence of processes and analyzing steps using the ImageJ platform was thus 
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established and optimized, and termed ‘NeuronRead’. The workflow developed is able to quantify 
parameters such as the cell number, cell body area, and total neuritic length, in a semi‐automatic 
manner. It requires little user‐interaction, in order to supervise cell body identification and to 
reduce noise before neuritic detection. Further, similar to NeuronGrowth and NEMO, NeuronRead 
can be applied to both PhC and fluorescence images. Validation of our macro was based on various 
comparative experiments. The robustness of NeuronRead in detecting cell somas and correctly 
extracting their area was tested by comparison with manual determinations. Indeed, the average 
cell body areas of 4 DIV neurons retrieved by NeuronRead were not significantly different to our 
manual evaluation performed with the help of ImageJ tools (Figure B3.3). The macro’s ability to 
extract and quantify the neuritic network in PhC and fluorescence images was compared to the 
widely used tool NeuriteQuant, applied to fluorescent images (Figure B3.4 and Figure B3.5). There 
was no statistical significance between the results obtained with both methods (NeuronRead and 
NeuriteQuant) when these were applied to fluorescence images, either in basal conditions or in 
conditions of neuritic growth inhibition (Figure B3.4 and Figure B3.5). The macro could also 
accurately detect the neuritic network of PhC images, but the absolute values taken from PhC 
images were always below the ones obtained using the paired fluorescence ones (around 25% 
lower). This results from the fact that PhC images possess a poorly differentiated background where 
thick and thin, bright and dim neurites coexist, while good fluorescent probes can increase the 
signal‐to‐noise ratio and enhance smaller or thinner structures that are almost invisible in PhC 
images. Nevertheless, although PhC images render less absolute neuritic information, they are very 
useful to compare experimental conditions, and can be used to accurately detect alterations 
imposed to the neuritic network by variables external or internal to the culture.  
In line with this idea, NeuronRead was successfully applied to track morphological changes 
occurring during the differentiation of SH‐SY5Y neuroblastoma cells (Figure B3.6). As demonstrated 
in previous work by Encinas et al [22], the treatment of SH‐SY5Y cells with RA followed by treatment 
with BDNF resulted in cells presenting a morphological appearance close to mature neurons (Figure 
B3.6A‐B). Moreover, this was accompanied by the increased expression of two neuronal markers, 
GAP‐43 and βIII‐tubulin (Figure B3.6C). The expression of these markers confirm this method of 
differentiating SH‐SY5Y cells as a reliable tool to evaluate the role of certain proteins or drugs in 
neuronal differentiation. Other protocols for the differentiation of SH‐SY5Y cells, such as the 
treatment with only RA, while being able to induce neurite outgrowth in these cells, do not 
significantly alter the expression of neuronal markers [23]. These biochemical differences between 
methods could explain why we detected an increase in Gαo levels with BDNF differentiation, while 
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other works using SH‐SY5Y cells only differentiated with RA did not detect any increase [46, 47]. 
Indeed, Gαo protein levels were observed to augment during rat’s brain development [48], and 
during the in vitro differentiation of other cell lines, such as N1E‐115 and PC12 cells [49, 50]. It is 
interesting to observe that Gαo levels increase after the addition of BDNF, and that it correlates 
with the increase of both GAP‐43 and APP expression, two proteins that are known interactors and 
activators of Gαo. Moreover, APP increased expression during SH‐SY5Y differentiation had already 
been described in multiple settings, either it be differentiation with RA‐only or in combination with 
BDNF [15, 51, 52]. Some of the GAP‐43 and APP roles in the brain have been linked to their 
association with Gαo. GAP‐43 and Gαo are highly enriched in neuronal growth cones, and activation 
of Gαo by GAP‐43 has been shown to modulate neurite outgrowth [53, 54]. Regarding APP, 
although initial work on its interaction with Gαo focused on its relevance for the Alzheimer’s 
Disease [55, 56], APP‐Gαo interaction also seems to have a physiological role in the brain, such as 
in the control of neuronal migration [57, 58] and in the regulation of neuronal differentiation 
(Chapter B1). The paralleled increase of Gαo with APP and GAP‐43 at D6 could indicate a possible 
interplay between these proteins at this stage of neuronal differentiation, during which a burst of 
neurite outgrowth is occurring [22].  
To our knowledge, no previous association between BDNF action and Gαo has been reported. Our 
results showing an increase in Gαo levels after the addition of BDNF points to a possible role for 
Gαo in the mediation of BDNF neuritogenic functions. Indeed, some of the main pathways activated 
by BDNF during neuronal differentiation are also known to be modulated by Gαo. BDNF‐induced 
neuritogenesis in SH‐SY5Y cells is accompanied by an increase in ERK1/2 activation, which if 
inhibited leads to a significant decrease in neurite outgrowth and GAP‐43 expression [59]. 
Moreover, BDNF‐ERK1/2 activation has also been reported in differentiation of neural stem cells 
[60, 61]. Different studies, including our own research (Chapter B1), have identified a correlation 
between Gαo‐induced neuritogenesis and ERK1/2 activation [62, 63]. To further understand the 
meaning of the Gαo role in SH‐SY5Y differentiation, cells were treated with PTX, a Gαo/i inhibitor, 
at the same time BDNF was added to the cells (Figure B3.7). This treatment completely inhibited 
Gαo, confirmed by the slower migration of Gαo through the SDS‐PAGE, a consequence of its ADP‐
ribosylation (Figure B3.7C) [44]. Gαo inhibition did not produce significant effects on the average 
neuritic length per cell, only slightly increasing it at later time points, but it significantly altered the 
protein levels of GAP‐43 and βIII‐tubulin (Figure B3.7). This shows that Gαo might not be essential 
for some of the morphological alterations occurring during neuronal differentiation, but that it 
plays a significant role in the biochemical maturation of neuronal cells. It is not clear how inhibiting 
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Gαo leads to the alterations in GAP‐43 and βIII‐tubulin. Since GAP‐43 is thought to act upstream 
Gαo, its increased expression could be a cellular feedback response to try to overcome Gαo 
inhibition. The same could be thought of APP, although its protein levels were not so affected by 
PTX, only increasing at D12. Increased GAP‐43 could also be a sign of deregulation of proper 
neuronal differentiation and function [64, 65], thus explaining the reduction in βIII‐tubulin levels. 
An evaluation of the phosphorylation status of GAP‐43 will be important to help us understand if 
this increased expression is also accompanied by an increased activation [66]. Further studies could 
also monitor potential differences in the subcellular distribution of these proteins, as well as look 
to other neuronal markers, such as MAP2, tau, and PSD95. It is also imperative to check signaling 
pathways that might be affected by Gαo inhibition, specially the MAPK/ERK signaling. Finally, 
although this study shows promising results concerning the role of Gαo in BDNF‐induced neuronal 
differentiation, since PTX is not a specific inhibitor of Gαo, it is important to also evaluate the role 
of Gαi in this process. Specific targeting of Gαo during BDNF treatment, either by its downregulation 
or overexpression, will improve our understanding of Gαo role on neuronal differentiation. 
In conclusion, NeuronRead proved to be a flexible, practical and useful tool in bioimaging analysis 
of PhC and fluorescence microphotographs of primary neurons in neuronal cultures. It does not 
need manual tracing of the neurites as in other neuronal analysis software programs, it requires 
minor user‐interaction to increase its accuracy in morphological detection, and the errors 
associated with its automated detection are minor, particularly for comparative analyses. The 
macro is also easily customizable, with the user being able fit the macro to its needs (e.g. batch 
processing and analysis). In synthesis, this ImageJ Macro is reliable, fast, easy to apply, and 
considerably robust in extracting morphometric data from the easier, faster and affordable PhC 
images, with the plus of also being applicable to the neuritic analysis of fluorescence images. It can 
thus be easily used in routine operations involving morphometric analyses of neuronal cultures. 
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B3.7. Supplementary Material 
 
Supplementary Figure B3.1. Comparison between NeuronRead analyses of phase contrast images and fluorescence 
images. A set of 30 pairs of fluorescence (‘Fluor.’)‐PhC microphotographs of neurons at 4 days in vitro were analyzed with 
the NeuronRead macro. Data extracted from both types of images were compared via the Bland‐Altman plot, which 
shows an average difference between both methods of almost ‐27.02%, again indicating that neuronal PhC images have 
lower amount of neuritic information. 
 
Supplementary Figure B3.2. Analysis of rat cortical primary neuronal cultures. Upper: Fluorescence images of 12DIV 
(days in vitro) neuronal cultures, labeled with an antibody against β‐III tubulin, were analyzed with NeuronRead and 
NeuriteQuant. Bar: 50 µm. Bellow: Bland‐Altman plot of the comparison between NeuronRead and NeuriteQuant show 
an average difference between both methods of around 1%. n = 10. 
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Supplementary Figure B3.3. Testing NeuronRead robustness and sensitivity to noises. Salt and Pepper (A.), and Gaussian 
noises (B.) were incrementally added to PhC and Fluorescence images, using the ImageJ. NeuronRead’s ability of extract 
the number of cell bodies and total neuritic length was tested in these conditions. n = 5. Bar = 50 µm. S&P, Salt and 
Pepper; SD, Standard Deviation. 
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Supplementary Figure B3.4. Differentiated SH-SY5Y cells analyzed with NeuronRead. SH‐SY5Y cells were differentiated 
for 12 days in vitro (DIV) using a protocol adapted from Encinas et al (2000) using 10 M retinoic acid (first 5 days) and 
10 ng/mL of brain‐derived neurotrophic factor (BDNF; in the further 7 days). Photos were taken to living cells at 12 DIV 
(raw image at the left), and cells’ neuritic network was analyzed with NeuronRead (right image, tracing in orange). Scale 
bar = 100 μm.  
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NeuronRead Tutorial 
  
Setup 
The NeuronRead macro runs on ImageJ software and is supported by three main plugins: 
MorphoLibJ, Skeletonize3D and Analyze Skeleton. For the smoothest and fastest application of the 
macro we recommend installing the most recent FIJI package, an ImageJ bundle that already 
includes the Skeletonize3D and Analyze Skeleton plugin (https://imagej.net/Fiji/Downloads). After 
installing FIJI, the MorphoLibJ must be added manually. Detailed instructions on how to install this 
plugin can be found on http://imagej.net/MorphoLibJ. NeuronRead was built around version 1.3.2 
of MorphoLibJ, which means that compatibility problems may arise when using older versions.  
There are 3 ways to install and run NeuronRead on ImageJ:  
1. Open ImageJ, select Plugin  Macro  Install, and then select NeuronRead. This way 
each time the user wants to run the macro he only needs to go to the Plugin  Macro 
and select NeuronRead at the bottom of the tab. This install is not permanent, so the user 
has to repeat these steps each time ImageJ is opened.  
2. Open ImageJ, go to Edit  Options  Startup… and add the following code: 
run("Install...", "install = /FullPath/macroname.ijm"); where "FullPath/macroname.ijm" 
must be replaced by the user actual path to the macro. This way, each time ImageJ is 
opened NeuronRead is installed automatically. 
3. Open ImageJ, select Plugin  Macro  Run and then select NeuronRead, which will start 
immediately.  
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Running NeuronRead 
1. Run NeuronRead. This step assumes the user performed the installation of NeuronRead as 
described in steps 1) or 2) of the previous section. 
 
 
2. A new window opens. Search for the folder where the images are saved and select the image to 
be analyzed.  
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3. The analysis starts. The first stop (user dialog box) is for defining if the image being analyzed is 
a phase contrast image. If so, leave the checkbox ticked. If you are analyzing a fluorescence image 
untick the checkbox.  
 
 
 
4. On the same box, the user can change some segmentation parameters to improve cell body 
recognition. These parameters are dependent on the magnification used for the images acquisition. 
Higher magnifications will require the application of filters with larger radius, while lower 
magnifications will require smaller radius. A filter of 5 is set as default; it was applied for images 
taken with a 20x objective, but it may change with the resolution of the camera. 
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5. The next step asks for defining the appropriate threshold for cell body recognition. Increasing 
the threshold will remove small debris present in the image, but it can also remove some cell 
bodies. Apply the threshold and, if you find it to be correctly adjusted, then click OK the “Soma 
Thresholding” box. 
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6. If any cell body is missing you can add it by using the selection tools of ImageJ and pressing “T” 
afterwards. You can also remove misidentified cell bodies by selecting them in the “ROI manager” 
and deleting them. 
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7. Proceed with neurite thresholding. The same principle that was mentioned before applies here 
to the threshold. Higher threshold limits will eliminate debris, but will also obscure neurites, while 
lower threshold limits can insert artifacts into neurite recognition. 
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8. The final user interaction stop is “Set scale”. For the data to be retrieved in µm, the user must 
input the image scale according to the acquisition settings used. This step can be ignored, in which 
case the results will be presented as pixels. Image scale can be obtained from the images’ 
information or from the scale bar, if available.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9. The macro ends by presenting the “Log” window with the morphological data extracted from 
the analysis.
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C. General Discussion 
University of Aveiro  199 
C1. Main findings and future work 
The Gαo protein is the most expressed Gα subunit in the brain. Discovered over 3 decades ago, Gαo 
specific function in neurophysiology has remained unclear so far. Several studies point to neuronal 
differentiation as one of the main mechanisms in which Gαo is involved: Gαo expression increases 
during rat brain development, as well as during the neuronal‐like differentiation of different cell 
lines, such as PC12 and N1E‐115 [1–3]; several signaling pathways activated by Gαo lead to 
neuritogenic alterations, such as the Src‐STAT3, ERK1/2, and GRIN1‐cdc42 pathways [4–8]; and 
activation of  Gαo promotes synaptogenesis [9–11], a mechanism not only necessary during brain 
development but also extremely important during adulthood, especially for memory and learning.  
The main goal of this work was to further characterize the role of Gαo during neuronal 
differentiation by focusing on Gαo interaction with the Amyloid Precursor Protein (APP). APP, like 
Gαo, has been strongly associated with neuronal differentiation. Its expression suffers critical 
changes during neuritogenesis [12–14], and it has also been described as a modulator of at least 
two of the signaling pathways that Gαo is involved, such as STAT3 and ERK1/2 [15–17]. The 
combined knowledge that APP binds and activates Gαo [18, 19], and that these two proteins share 
similar neuritogenic functions, led us to hypothesize that the APP‐Gαo interaction could play a role 
in neuritogenesis.   
Our work started by evaluating if APP phosphorylation affected the APP‐Gαo binding (Chapter B1). 
Phosphorylation of Serine 655 is known to induce conformational changes in the APP’s C‐terminal 
region to which Gαo binds [20]. By using APP phosphomutants mimicking constitutive 
dephospho/phosphorylation of S655 (SA APP and SE APP, respectively), we demonstrated that Gαo 
bound preferentially to wild‐type (Wt) APP and SE APP. Moreover, phosphorylation of APP also 
increased Gαo activation. This is the first time that it was described a connection between APP 
phosphorylation and its binding to Gαo. Furthermore, APP phosphorylation is an important 
modification that induces crucial alterations on APP interactome and functions [21, 22]. 
Phosphorylation of Thr668 increases with differentiation of PC12 cells and expression of an APP 
mutant mimicking Thr668 phosphorylation affects NGF‐induced differentiation of these cells [23]. 
However, it is still not known what is the profile of S655 phosphorylation with neuronal 
differentiation. It will be important to study this profile, and to see how it relates to the alterations 
we have detected on Gαo expression during BDNF‐induced differentiation of SH‐SY5Y cells, and in 
differentiating cells upon Gαo inhibition (Chapter B3). It is also important to keep in mind that the 
Gαo activation induced by SE APP might not mimic exactly what happens in vivo. On one hand, SE 
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APP phosphomutant is mimicking a state of constant phosphorylation, while in vivo APP 
phosphorylation exists in a cyclic state due to the combined action of kinases and phosphatases 
[24]. On the other hand, the substitution of an amino acid to mimic phosphorylation (in this case 
substituting serine by a glutamate to mimic a phosphorylated serine) is not able to completely 
mimic the phosphorylated residue. In the case of glutamate, this residue only possesses one 
negative charge in its side‐chain, while the addition of a phosphate group adds two negative 
charges to the phosphorylated residue, which can then lead to subtle but important variations of 
the protein conformation [25]. These differences in conformation might account for some of the 
differences detected in SE APP activation of Gαo. Activation of G proteins can induce a shift on the 
localization of the Gα subunit from the plasma membrane, where it normally rests and is activated, 
to the cytosol, where it binds to various effector proteins [26, 27]. However, when we transfected 
SH‐SY5Y cells with SE APP‐GFP we observed an increase of Gαo localization on the plasma 
membrane compared to the cytosol. This could indicate that SE APP, due to its different 
conformation, is “locking” Gαo with it in the plasma membrane of the cell body and cell processes, 
where these proteins interact. The APP‐Gαo complex at the plasma membrane might thus interact 
with a smaller and specific subset of Gαo effectors related to neuritic elongation. This could then 
explain some of the morphological features we detected, such as the increased in neurite 
elongation already at 6h after transfection. Still, these observations are based on a qualitative 
analysis of SE APP‐GFP transfected cells. More detailed experiments, such as colocalization studies 
with a plasma membrane marker and fractionation assays, will demonstrate if SE APP is indeed 
increasing Gαo membrane localization.   
We then tried to decipher the morphological consequences of this interaction and possible 
signaling pathways that would underlie these alterations and would be modulated by the APP‐Gαo 
complex. We detected a sequential activation of STAT3 and the ERK1/2 pathway by Gαo, with 
STAT3 being involved in the formation of new processes, while ERK1/2 increased activation 
correlated more with an increase in neuritic elongation. Another study has reported an involvement 
of ERK1/2 in neuritic elongation rather than neurite formation [28], while an interplay between 
STAT3 and ERK1/2 activation in neurite outgrowth is also known (discussed in more detail further 
ahead). However, some questions remain regarding this biphasic mechanism. One is if STAT3 initial 
activation is required for ERK1/2 activation. This does not seem the case since co‐transfection of SE 
APP with Gαo was able to activate ERK1/2 without a previous phase of STAT3 activity. However, 
since we only evaluated specific time‐points, and phosphorylation events can occur in a matter of 
minutes or even seconds, SE APP‐Gαo activation of STAT3 might have occurred without we being 
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able to detect it. So, to answer this question time‐courses with shorter time‐points should be 
performed, or STAT3 phosphorylation could be inhibited for longer periods of time (up to 24h) and 
ERK1/2 activation monitored during that time. It will also be important to confirm if ERK1/2 
activation is indeed necessary for the neuritic elongation by directly modulating ERK1/2 activity 
with MEK1/2 inhibitors. 
APP effect on Gαo‐induced neuritogenesis also seemed to develop throughout two phases. At 6h 
of transfection, Wt APP augmented Gαo‐induced STAT3 activation, which resulted in the highest 
increase in the number of processes formed. This increase must thus result not only from cycles of 
Wt APP‐induced Gαo activation, but Wt APP must also serve as bridge to an important Gαo effector 
in the STAT3 pathway (such as Rap1GAP) or other involved in generation of new processes (such as 
GRIN1, activator of Cdc42 and its subsequent filopodia formation).  Also at 6h of transfection, SE 
APP‐Gαo expression promoted the elongation of pre‐existing neurites, with no visible early 
alterations on STAT3 and ERK1/2 signaling.  
At 24h of transfection, APP potentiator effects on Gαo‐induced neurite formation and elongation 
seem to be lost, with Gαo alone being able to elongate neurites to the same extent than Gαo‐Wt 
and SE APP co‐transfected conditions. At this time point, Gαo alone is more efficient in neuritic 
elongation than when co‐overexpressed with the Wt APP. This suggests that the potential Wt APP 
effect of activating and bridging Gαo to an effector more involved in new processes formation is 1) 
sequestering part of the Gαo pool from being involved in elongation and/or 2) per se not sufficient 
to induce/maintain novel processes formation in a period of major neuritic elongation and no STAT3 
activation. It could also mean that the overexpression of these two proteins might induce 
pathological effects due to excessive Gαo activation. We detected a significant increase in ERK1/2 
activation when SE APP‐Gαo were co‐transfected with no increase in neuritic elongation over Gαo 
alone. EGFR‐ERK1/2 activation is important for neuritic elongation, as observed in the EGFR 
inhibitor assays but overactivation of ERK1/2 by APP has already been associated with Alzheimer’s 
Disease [29], and Gαo overactivation induced by mutant APP has also been reported in cases of 
Familial Alzheimer’s Disease [30, 31]. Thus, one has to consider that overactivation of Gαo by SE 
APP might also lead to cell damage in the long run. An evaluation of cell viability should provide us 
some answers regarding these effects. Surprisingly, SA APP co‐expression with Gαo was able to 
further increase the number of cells with pre‐neurites, without alterations in the Gαo‐induced 
ERK1/2 signaling. One can speculate that this increased neuritogenesis might be related to the 
increased Gαo degradation detected in the second part of this thesis (Chapter B2). Protein 
overexpression can have detrimental effects on normal cell function, even by the simple fact that 
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when a transfected protein exists in overabundance when compared to physiological conditions, it 
can be mistargeted to the wrong subcellular compartments, and can be improperly folded [32]. 
Furthermore, as we are talking about a signaling protein, it is important to properly control its 
periodic signaling. Since we have detected that SA APP was able to control Gαo by targeting it to 
lysosomal degradation, this could be a mechanism by which APP is controlling Gαo function with 
time and thus promote a more efficient neuritogenesis. Nevertheless, this could be a short‐term 
effect in these in vitro conditions, since SA APP transfection results in a higher production of Aβ 
[33], one of the main elements of Alzheimer’s Disease. Differences between the effects of the 
different APP forms on Gαo‐induced neuritogenesis might also be explained by alterations of the 
Gαo interactome. In our lab we have evaluated the differential phospho S655 (pAPP) interactome, 
and observed that while SE APP binds more to signaling‐related moelcules, SA APP binds (among 
other) to a group of proteins that relate to actin remodeling (data not published). A study evaluating 
the Gαo interactome in the presence or absence of APP overexpression might thus provide us with 
new molecular players involved in APP‐Gαo signaling at this stage of neuritic elongation. 
Our results on rat primary neurons showed that Gαo and APP promote dendritogenesis in 
detriment of axonal growth at 4 days in vitro. After 24h of (co‐)transfection no significant increase 
in the STAT3 and ERK1/2 ratios was detected, although the levels of both phospho and total STAT3 
and ERK1/2 were increased over control conditions. Further, Src and EGFR inhibitors hindered Gαo 
positive effects on dendritogenesis. This means that these two pathways are connected to Gαo 
dendritogenic function on rat primary neurons, directly or not. Interestingly, APP transfection 
overcomed Src and EGFR inhibitory effects on dendritogenesis. This seems to indicate that, in 
neurons, APP is able to activate mechanisms that are independent of these two proteins (Src and 
EGFR). However, it is not clear if Gαo participates on such mechanisms. Future experiments should 
evaluate the effect of APP single transfections on this time‐point, and inhibit Gαo on these 
conditions. Moreover, APP‐Gαo effects should also be evaluated at earlier time‐points (0‐2 DIV), 
where the formation of new neurites is more pronounced [34, 35].  
The second part of this work focused on the effects that APP and Gαo have on each other’s protein 
levels (Chapter B2). We identified two degradation mechanisms by which Gαo can be eliminated: 
Lysosomal degradation in response to SA APP overexpression; and proteasomal degradation after 
Gαo inhibition with PTX treatment.  
As mentioned above, lysosomal degradation could be a mechanism activated to control APP‐Gαo 
signaling. One hypothetical signaling event would thus be initiated by APP phosphorylation. Gαo 
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binds to the phosphorylated APP, is activated and initiates downstream signaling (potentially 
through STAT3 and ERK1/2, and other effectors). If APP is maintained in a phosphorylated state, it 
can reactivate Gαo after GTP‐hydrolysis. Subsequent APP dephosphorylation, however, stops the 
signaling, not only by being unable to reactivate Gαo but also by enhancing its degradation. 
Lysosomal degradation would thus act as a feedback mechanism to stop APP‐Gαo signaling. This 
targeting to lysosomal degradation probably takes other factors into account: e.g. the localization 
of APP and Gαo inside the cell. It is unlikely that APP dephosphorylation would directly deliver Gαo 
for degradation. It might instead act has a hub for other molecular players that will be involved in 
this mechanism, such as Hsc70, and Adaptor Proteins [22, 33, 36, 37]. Indeed, we discovered that 
Gαo, like APP, possesses a KFERQ‐motif, a signaling sequence involved in chaperone‐mediated 
autophagy (CMA). We also observed an increased co‐localization of Gαo with Hsc70, one of the 
main players of CMA, in SA APP transfected cells. Further, in these cells Gαo also co‐localizes more 
with LAMP2, another CMA major player. Future work should focus on trying to understand if Gαo 
does interact with Hsc70 and if the co‐localization between both proteins is directly correlated with 
Gαo lysosomal degradation. 
Proteasomal degradation of Gαo as a result of PTX treatment could be a response of the cell to 
eliminate ADP‐ribosylated proteins, similar to the mechanism it uses to eliminate misfolded 
proteins. However, at this point, it is still unclear how ADP‐ribosylation of Gαo causes its 
degradation. One hypothesis is that ADP‐ribosylation causes a conformational change in Gαo that 
makes it recognizable by ubiquitin ligases, and thus prone to be ubiquitinated and targeted to the 
proteasome. Another hypothesis is that the ADP‐ribosyl group itself might be recognized by the 
proteasome. This seems to occur in cases of poly‐ADP‐ribosylation, however, it is unclear if it also 
occurs in mono‐ribosylated proteins [38, 39]. Also, the fact that APP also seems to be co‐degraded 
with Gαo in response to PTX treatment needs to be further investigated.  
During our experiments with primary neuronal cultures we felt the need to evaluate neuronal 
differentiation with time without having to fix and immunostain the neuronal cells. The easiest and 
fastest way to visualize a same live cell population is by phase contrast (PhC) imaging.  However, 
while several software exist to analyze fluorescence images of 2D neuronal cultures, such as 
NeuriteQuant and MorphoNeuroNet [40, 41], we could not find any reliable tool to analyze random 
fields of PhC images. So, the third and final part of this work focused on the development of 
NeuronRead, an ImageJ macro capable of analyzing both PhC and Fluorescence neuronal images 
(Chapter B3). NeuronRead is able to extract information regarding the cell body morphology 
(number of cells, average area, circularity) and neuritic network (total neuritic length, average 
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neuritic length per cell) with high accuracy, demonstrated by the comparison with manual analyses, 
as well as by using NeuriteQuant, a proved tool used to analyze neuritic networks in fluorescence 
images [40]. Also, NeuronRead proved to be reliable in the analysis of images acquired from primary 
neuronal cultures, as well as images from neuronal‐like cells, such as differentiated SH‐SY5Y 
neuroblastoma cells. 
Following, NeuronRead was used successfully to relate morphological alterations induced by RA‐
BDNF differentiation of SH‐SY5Y cells [42] with alterations in Gαo protein levels. Moreover, it also 
detected alterations in total neuritic net length caused by PTX treatment. Future work will also use 
secondary parameters obtained with Neuron Read (through “Skeletonize” and “Analyze Skeleton”, 
two plugins integrated into NeuronRead), such as the number of branches detected in each image, 
to further evaluate the role of Gαo activity in SH‐SY5Y differentiation.  
Our initial approach was already able to detect significant biochemical alterations as a result of Gαo 
inhibition, such as the decrease in βIII‐tubulin and the increase in GAP‐43 levels, two neuronal 
markers. While further work is required to determine the real meaning of these alterations, it does 
strengthen the idea that Gαo is a fundamental player in proper neuronal differentiation.  
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C2. Potential role of APP-Gαo signaling during brain 
development 
Most of the analysis and discussion of our results was performed in light of the applied 
methodology, such as the use of SH‐SY5Y cells as our main cell model, and the use of protein 
overexpression as a way to determine potential physiological effects. But can we now fit this data 
with the already described mechanisms involved in neuronal differentiation, as well with what is 
known about APP and Gαo functions?  
One of the main signaling pathways associated with neuronal differentiation is the MAPK/ERK 
signaling [43–46]. As mentioned above, Gαo is able to induce ERK1/2 activation, with APP 
potentiating this effect. Interestingly, this activation occurred after an initial phase of STAT3 
activity. An interplay between ERK1/2 and STAT3 during neuritogenesis has already been described. 
Neuronal differentiation of mice embryonic stem cells with retinoic acid is accompanied by an 
increase in ERK1/2 and STAT3 activity. Inhibiting ERK1/2 results in a decrease of STAT3 activity, and 
a decrease in the expression of neuronal markers [44]. Another study has shown that activation of 
the CB1 receptor (CB1R) and IL‐6 receptor (IL‐6R) act synergistically to promote neurite outgrowth 
via activation of STAT3 and ERK1/2 [47]. Interestingly, this study showed that a peek in ERK1/2 
activation occurred early (first 15 min of stimulation), while STAT3 activity peaked later (around 6h 
after initial treatment). In both these studies, ERK1/2 activation preceded STAT3, which seems to 
contradict our results. However, there are studies showing that ERK1/2 activation can occur in a 
biphasic mechanism. The first phase of ERK1/2 activation is reportedly extremely fast, between 1‐
15 min after stimulation, while the second phase seems to vary accordingly to the 
stimuli/environment, ranging from 15 min [48] to several hours [49, 50] after the initial phase. Even 
in the work regarding the cooperation between CB1R and IL‐6R signaling, results show that after 
the initial ERK1/2 activation there was a second activation phase around 4‐6 hours after treatment. 
Taking together, these results could mean that the Gαo‐ERK1/2‐STAT3 signaling described in our 
work could be following a similar pattern, but since the first phase of ERK activation occurs 
extremely fast we were unable to detect it. Future work following ERK activity immediately after 
transfection will be necessary to answer this question. ERK1/2 activation detected in our 
experiments could be an outcome of crosstalk with other signaling pathways that were meanwhile 
activated, or because of activation of gene transcription during the first phase of signaling. Thus, 
inhibiting the STAT3 for longer periods of time (24h) will allow us to check if this activation needs 
to occur prior to ERK1/2, or if both signaling pathways happen in parallel.  
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Interestingly, one of the studies describing the biphasic ERK1/2 activation demonstrated that 
activation of Gαi/o proteins was required for the second phase of the process [48]. Moreover, the 
overall ERK1/2 activation mechanism started with the stimulation of CB1R, a receptor that can 
induce neuritogenesis by activating Gαo‐Src‐STAT3 [5, 6]. This could mean that APP activates a 
signaling pathway similar to the one downstream of CB1R. It would also be interesting to explore 
the role of APP as a participant in the CB1R pathway. The first phase described by Asimaki and 
Mangoura [48] involves PKC, which is the main in vivo kinase able to phosphorylate APP at Serine 
655 [51, 52]. One could hypothesize that the signaling initiated by CB1R would lead to PKC 
activation that would consequently lead to the phosphorylation of APP. pAPP would then be one 
of the initiators of the second phase of ERK1/2 signaling, by prolonging the cycles of Gαo activation. 
However, one must take close consideration the model in which to study this kind of signaling. 
While CB1R has be seen to activate ERK1/2 by different studies, the exact upstream pathways 
involved are not clear, with certain kinases, such as PI3K and Src, being either required or 
unnecessary for ERK1/2 activation [53, 54]. Also, to our knowledge, no direct crosstalk between 
CB1R and APP signaling has been described so far.  
APP and Gαo neuritogenic actions have both been independently associated with Reelin [55, 56]. 
Reelin is an extracellular factor involved in neuronal polarization [46, 57]. Reelin interaction with 
the extracellular domain of APP was detected in vitro, and knockdown of endogenous APP in rat 
hippocampal neurons blocked Reelin neuritogenic effects on these cells [56]. Another study showed 
that Gαo inhibition with PTX or knockdown using siRNA also blocked Reelin neuritogenic effects on 
hippocampal neurons, in a Src‐dependent mechanism [55]. However, no receptor was identified in 
this mechanism. One could then speculate that APP might act as an unconventional receptor for 
Reelin, which upon binding stimulates a downstream pathway involving Gαo. APP functioning as a 
receptor has been for long proposed, however, the identity of natural ligands is not well 
established. Treatment of APP‐Gαo vesicles with the 22C11 antibody has shown that binding of the 
antibody to APP modulates Gαo activation [19, 58]. Authors hypothesized that 22C11 could be 
acting as a possible not yet identified extracellular ligand of APP, and Reelin could be such a ligand. 
Another of Reelin main biological roles is to control neuronal migration, and hence a possible link 
between Reelin action and APP‐Gαo known co‐function in neuronal migration should also be 
investigated [57, 59, 60]. 
Our work has also brought up a possible connection between BDNF and Gαo signaling in neuronal 
differentiation, with Gαo being important for the biochemical maturation of neuronal‐like cells in 
vitro. So far, Gαo has never been described as a possible downstream effector of BDNF. However, 
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there is some work showing that BDNF release is significantly inhibited in AtT‐20 cells upon 
treatment with PTX [61]. Combining both results, Gαo could potentially act in a positive feedback 
loop during in vivo neuronal polarization. BDNF release would stimulate neurite elongation and 
branching accompanied by an increase in Gαo activation, what, in turn, would promote BDNF 
release, further promoting neurite elongation and branching.  
This thesis' main focus was on the role of Gαo on neuritogenesis, and the modulation of this 
function by APP. However, the formation and growth of dendrites and axon are only part of 
neuronal differentiation, with synaptogenesis being a crucial step for the full maturation of 
neuronal cells. There are already a few studies implying Gαo on synapse formation. In Drosophila, 
Gαo translates the signal from Frizzled receptors to the microtubule cytoskeleton during the 
formation of the neuromuscular junction (NMJ) [9]. Insect APP, like Gαo, is also involved in the 
proper formation of NMJ [62]. In hippocampal rat neurons, Gαo acts downstream of Wnt5‐Frizzled9 
signaling to regulate the formation of dendritic spines, a mechanism that also involves the 
activation of CaMKII, JNK, and PKC [10, 11]. Since we detected an increase in dendritic elongation 
and branching when overexpressing both Gαo and APP, it is possible that this complex is also 
important for the formation of dendritic spines and synaptogenesis.  
Finally, the lysosomal and proteasomal degradation that Gαo is subjected to, and the fact that APP 
plays an important part on this control, could be important features of normal neuronal 
differentiation. The ubiquitin‐proteasome‐system plays several important functions during brain 
development and function, including the control of axonal growth and guidance, neuronal 
migration, dendritic morphogenesis, and synaptic plasticity [63–65]. Likewise, several reports exist 
showing that lysosomal degradation plays an essential role in the nervous system, especially in the 
regulation of synaptogenesis and synaptic plasticity [66–68]. Also, Gαo increased levels during 
neuronal development have been associated with both an increase in its synthesis and a decrease 
in its degradation [69]. Further studies focusing on the regulation of Gαo turnover might provide 
vital clues regarding its function in the human brain.   
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C3. Conclusion 
This work had as its main goal to investigate Gαo role in neuronal differentiation, and we achieved 
it by focusing on the study of Gαo interaction with one of its activator proteins, the amyloid 
precursor protein. By doing this, we defined a mechanism by which Gαo induces neurite outgrowth 
by the sequential activation of the STAT3 and ERK1/2 pathway, and demonstrated that APP 
modulates this mechanism in a phosphoAPP‐dependent manner; we identified proteasomal and 
lysosomal degradation as important mechanisms for the control of APP‐Gαo interaction; and we 
described Gαo as a potential important player in BDNF‐induced differentiation. Furthermore, we 
developed an ImageJ macro to analyze Phase Contrast and Fluorescence neuronal images, thus 
adding a tool that the scientific community can use freely to study neuronal cells.  
This work thus adds new data regarding the function of Gαo on the human brain and unravels new 
potential mechanisms involved in neuronal differentiation.  
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